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Abstract 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease of stem cell origin. It 
is characterised by the Philadelphia chromosome and Bcr-Abl oncoprotein which is a 
constitutively activated tyrosine kinase that is causative in CML. Treatment of CML 
was revolutionized by tyrosine kinase inhibitors (TKIs) in the last decade. TKIs target 
Bcr-Abl and block its tyrosine kinase activity. Despite the success of TKI in eliminating 
differentiated CML cells, primitive quiescent CML stem cells still resist or persist with 
TKI treatment. In this study, several strategies have been investigated towards 
elimination of TKI-insensitive primitive CML stem cells.  
 
At first, the effect of nuclear entrapment of Bcr-Abl protein in CML cells was studied. 
Although Bcr-Abl protein is located in the cytoplasm of CML cells, TKIs, such as 
imatinib mesylate (IM), can induce the nuclear translocation of Bcr-Abl. Nuclear Bcr-
Abl tyrosine kinase is capable of inducing apoptosis after drug washout, and 
leptomycin B (LMB) can trap translocated Bcr-Abl in the nucleus. Primary CML CD34+ 
cells were treated with IM and LMB either continuously or sequentially. It was found 
that neither regimen significantly increased the anti-proliferative effect of IM in primary 
CML CD34+ cells. It was also observed that the majority of Bcr-Abl was still retained 
in the cytoplasm of CML cells treated with IM and LMB, suggesting other mechanisms 
apart from its tyrosine kinase activity retained Bcr-Abl protein in the cytoplasm of CML 
cells. Next the subcellular distribution of Bcr-Abl was investigated in TKI-insensitive 
CML progenitors which survived 12-Day treatment of a potent TKI dasatinib (150nM). 
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It was demonstrated that about 50% of Bcr-Abl was still retained in the cytoplasm of 
TKI-insensitive primary CML progenitors, although there was a significant increase in 
nuclear Bcr-Abl level in these survived cells compared to the no drug control (NDC). It 
was hypothesised that the cytoplasmic retention of Bcr-Abl was caused by its 
cytoplasmic binding partners, and it was found that a proportion of Bcr-Abl protein 
was associated with 14-3-3 proteins in the surviving cells, indicating the cytoplasmic 
retention of Bcr-Abl might be due to its binding with 14-3-3 proteins.  
 
In addition, due to the rapid nature of kinase inhibition and nuclear transportation, 
studies are required to measure the earliest time-point of inhibition of Bcr-Abl tyrosine 
kinase by IM. The common method to do this is to employ p-CrkL which has been 
widely used as a surrogate marker of Bcr-Abl tyrosine kinase activity, but the 
accuracy of p-CrkL as an indicator of Bcr-Abl tyrosine kinase status at early time-
points during in vitro TKI treatment has not been examined. It was demonstrated that 
p-CrkL was not a reliable indicator of Bcr-Abl kinase activity within 24 hours of IM 
treatment in vitro and indicated that the early responses to IM and dasatinib were 
different. It was also observed that there was a rapid and active dephosphorylation of 
Bcr-Abl within 1 hour of TKI treatment, driven at least in part by protein tyrosine 
phosphatase activity.  
 
Furthermore, a farnesyltransferase inhibitor (FTI) BMS-214662 preferentially induces 
apoptosis in CML stem and progenitor cells compared to their normal counterparts, 
but another similar FTI BMS-225975 does not. However, the mechanism of action of 
Peixun Zhou, 2011                                                                                                                                    
 
 
4 
BMS-214662 in inducing apoptosis of CML cells is not clear. When BMS-214662 was 
used as a negative control in the p-CrkL study, it was unexpectedly observed that the 
drug accumulated Bcr-Abl protein in CML cells. Thus, it was hypothesised that BMS-
214662 may function as a proteasome inhibitor, which could result in accumulation of 
Bcr-Abl protein and further elevation of intracellular ROS level, leading to apoptosis of 
CML cells. Although BMS-214662 treatment induced accumulation of total 
ubiquitinated proteins and specifically Bcr-Abl protein in K562 cells, BMS-225975 had 
very similar effects, and this might result from the common mechanism of BMS-
214662 and BMS-225975, which is their FTI activity. On the other hand, BMS-214662 
induced significantly higher levels of intracellular ROS in both proliferating and non-
proliferating K562 cells with respect to BMS-225975, indicating the production of ROS 
may be involved in the non-FTI mechanism of action of BMS-214662. However it was 
concluded that BMS-214662 was not a proteasome inhibitor like bortezomib. 
 
Finally, the use of synthetic low density lipoprotein (sLDL) as a vehicle for drug 
delivery to overcome the insufficient intracellular drug concentration in CML stem 
cells was investigated. Uptake and internalization of unloaded sLDL particles by CML 
cell line K562 and for the first time by CML stem cells was observed, demonstrating 
the targeting potential of sLDL particles in CML when they are loaded with drugs.  
 
Overall, this study provides further understanding of CML treatment and identifies 
some alternative strategies to target CML stem cells that may be used in combination 
with TKI to enhance the eradication of this stem cell-driven disease. 
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LREC                      Local Research Ethics Committee 
LSC   Leukaemic stem cell 
LTC-IC              Long-Term Culture-Initiating Cell 
LT-HSC  long-term HSC 
MAPK   Mitogen activated protein kinase 
M-bcr    Major break point cluster region 
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m-bcr    minor break point cluster region  
MCgR   Major cytogenetic response 
mCgR   Minor cytogenetic response 
Mcl-1   Myeloid cell leukaemia-1  
MDM2  Murine double minute 2 
MEP   Megakaryocyte-erythroid progenitor 
MFI                          Mean fluorescence intensity 
MMR   Major molecular response 
MNC   Mononuclear cells 
MPP   Multipotent progenitor    
mRNA  messenger RNA  
NDC                        No drug control 
NES                         Nuclear export signal 
NHL   non-Hodgkin's Lymphoma 
NLS                          Nuclear localisation signal 
NOD/SCID   Nonobese diabetic/severe combined immunodeficient 
PBS                          Phosphate buffered saline 
PCgR   Partial cytogenetic response 
PCR                         Polymerase chain reaction 
p-CrkL  Phosphorylated CrkL 
PDGF-R  Platelet-derived growth factor receptors 
PGFs                       Physiological growth factors 
Ph                            Philadelphia  
PH domain  Pleckstrin homology domain 
PHR   Partial haematologic response 
PI                             Propidium iodine  
PI3K   Phosphatidylositol 3-kinase 
PKCβ                       Protein kinase Cβ 
PLCγ    Phospholipase Cγ  
PP2A   Protein phosphatase 2A 
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PTP1B  Protein tyrosine phosphatase 1B 
PTP                   Protein tyrosine phosphatase  
PTK   Protein tyrosine kinase 
p-Tyr                       Phosphorylated tyrosine 
p-Tyr Bcr-Abl           tyrosine phosphorylated Bcr-Abl 
PVDF                       Polyvinylidene fluoride 
qRT-PCR  quantitative reverse transcription PCR 
Ras   Rat sarcoma 
RNA                         Ribonucleic acid 
ROS                         Reactive oxygen species 
Rpm                         Revolutions per minute 
RT                            Reverse transcription 
RTK                        Receptor tyrosine kinase 
SCF                         Stem cell factor 
SCT   Stem cell transplantation  
SDS-PAGE            Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SFM                         Serum free medium 
SH                    Src homology 
Shc   Src homology-containing 
siRNA                       small interfering RNA 
sLDL                        synthetic low density lipoprotein 
SL-IC   SCID leukaemia-initiating cell 
SOS   Son of sevenless 
SRC   SCID-repopulating cell 
SSC                       Side scatter  
SSG                         Sodium Stibogluconate 
ST-HSC  Short-term HSC 
STAT   Signal transducers and activators of transcription 
Syp   Synaptophysin 
TK   Tyrosine kinase 
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TKI   Tyrosine kinase inhibitor 
Ub   Ubiquitin 
WB                           Western blotting 
WCL            Whole cell lysate 
WCC   white cell count 
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1 Introduction 
1.1 Haemopoiesis and haemopoietic stem cells 
Haemopoiesis is the production of blood cells as a result of differentiation of 
haemopoietic stem cells (HSCs) (1;2). HSCs are multipotent cells which are capable 
of both self-renewal and differentiation into all types of blood cells by a hierarchically 
progressive lineage commitment of haemopoietic stem and progenitor cells (Figure 
 1-1). In addition, HSCs reside in the bone marrow, and account for no more than 
0.05% of bone marrow cells (1). Since most mature blood cells are terminally 
differentiated and short-lived in blood circulation, it is essential to generate functional 
blood cells to maintain the haemopoietic system in a steady state through the 
proliferation and differentiation of haemopoietic stem and progenitor cells (2). 
Furthermore, about 1.5 x 106 blood cells are continuously generated every second in 
an adult human (3).  
 
The balance between self-renewal and differentiation is regulated to maintain the 
HSC pool while generating sufficient progeny, and this can be achieved by 
asymmetrical cell division where one HSC gives rise to an identical daughter cell and 
a differentiated progeny (4). In addition, HSC can also divide symmetrically to 
generate two identical daughter cells or two differentiated progeny (4). The fate of 
HSCs is thought to be regulated by factors in their bone marrow microenvironment, 
i.e. stem cell niche (5).  
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HSC function is usually assessed in vitro by colony-forming cell (CFC) and long-term 
culture initiating-cell (LTC-IC) assays or in vivo by bone marrow engraftment of non-
obese diabetic/severe combined immunodeficient (NOD/SCID) mice (6). CFC assays 
detect multipotent and committed progenitors, while LTC-IC assays detect more 
primitive progenitors which are able to form colonies after 5-8 weeks culture on a 
stromal feeder layer (7;8). SCID-repopulation cells (SRCs) are capable of 
reconstituting NOD/SCID mice with a singe cell and are more primitive than most 
CFC or LTC-IC (9).  
 
Based on their ability to reconstitute the haemopoietic system of lethally irradiated 
mice, HSCs can be separated into three distinct groups: long-term HSCs (LT-HSCs) 
which are able to generate all types of blood cells for the lifetime of the animals and 
reconstitute secondary hosts; short-term HSCs (ST-HSCs) which derive from LT-
HSCs but can only reconstitute myeloid and/or lymphoid lineages for a limited period 
of time; multipotent progenitors (MPPs), which are generated by ST-HSCs, have no 
detectable self-renewal capacity and only transiently reconstitute lethally irradiated 
mice (10;11). MPPs can differentiate into common myeloid progenitors (CMPs) or 
common lymphoid progenitors (CLPs) which then give rise to myeloid or lymphoid 
lineage, respectively (12;13).  
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Figure  1-1: The model of haemopoietic hierarchy.  
Long-term and short-term HSCs have self-renewal capacity, which is lost in MPPs. The 
multi-potent progenitors differentiate into CLPs or CMPs, which give rise to mature 
cells after several differentiation steps. MEP: megakaryocyte-erythroid progenitor, 
GMP: granulocyte-macrophage progenitor. Adapted from Passegue et al., 2003 (14) 
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There is evidence to suggest that the majority of HSCs are out of cell cycle and in a 
quiescent state (in G0 phase of the cell cycle), as illustrated by the resistance of  
murine primitive haemopoietic cells to a anti-mitotic drug, 5-fluorouracil (5-FU) (15). It 
was also found that primitive human haemopoietic progenitors could remain in culture 
as single cells for more than 14 days and only started to divide with stimulation of 
some growth factors (16). Furthermore, it was estimated by mathematical modelling 
that HSCs only divide once every year, and each HSC could divide about 70 times in 
its lifetime (17). Thus, it is thought that at steady state homeostasis only a small 
fraction of HSCs are in cell cycle and repopulate the haemopoietic system (18) to 
ensure the stem cell pool is not exhausted throughout life. In addition, cell cycle arrest 
in G0 also allows cells to repair any DNA damage and maintain genomic stability (19).   
 
Cell surface antigens can be used to distinguish HSCs from differentiated cells in a 
heterogeneous haemopoietic population. CD34 is a widely used cell surface marker 
to identify HSCs, since the most primitive haemopoietic cells are contained in the 
CD34+ population. The frequency of LTC-IC in an enriched CD34+ population is 200-
400 times higher than in total human bone marrow mononuclear cells (8). In addition, 
human bone marrow CD34+ compartment contains primitive HSCs which are capable 
of generating all haemopoietic lineages (20). Furthermore, purified mobilized 
peripheral blood CD34+ cells are capable of reconstituting the whole haemopoietic 
system after human allogeneic transplantation (21). CD34+ cells represent about 
1.5% of normal human bone marrow mononuclear cells (22), and the level of CD34 
expression decreases progressively along with increased differentiation of these cells 
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(23). CD34 is a 115 kiloDaltons (kDa) transmembrane glycoprotein which may be 
involved in cell localisation, adhesion and signal transduction of haemopoietic stem 
and progenitor cells, but the understanding of its precise function is limited (22;24). 
 
However, haemopoietic CD34+ population is heterogeneous, and it contains primitive 
and committed haemopoietic progenitors (25). Thus, other cell surface markers are 
used together with CD34 to identify more primitive progenitors (26). It was found that 
SRCs are exclusively CD34+CD38–, and the frequency was calculated as 1 SRC in 
617 CD34+CD38– cells by limiting dilution analysis (26). CD34+CD38– cells are 
capable of repopulating lethally irradiated mice in a continuous and multi-lineage 
manner (26;27), while CD34+CD38+ cord blood cells repopulate lethally irradiated 
mice rapidly but only transiently (27). CD38 is a transmembrane glycoprotein, and its 
expression on the cell surface is elevated in correlation with increased differentiation 
(28). CD38 is expressed in more than 90% of CD34+ cells, and CD34+CD38– cells 
represent about 0.05% of bone marrow or cord blood mononuclear cells (28). 
CD34+CD38– cells are mainly quiescent in the absence of cytokine stimulation 
(28;29). After transplantation into irradiated mice, human CD34+CD38– cells are 
located at the stem cell niche in a quiescent state, and these cells can engraft 
secondary recipient mice (30). Overall, the primitive HSCs are within the 
CD34+CD38– compartment.        
 
In addition, human CD34+CD38– cells can be further fractionated based on cell-
surface HLA-DR expression. Human bone marrow CD34+CD38– HLA-DR+ cells can 
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differentiate into all lineages of haemopoietic system, while the more primitive 
CD34+CD38– HLA-DR– cells can generate not only all haemopoietic lineages but also 
stromal cells which can support HSCs in the bone marrow microenvironment (20). In 
addition, CD133 (also known as AC133 or Prominin 1) is another cell surface marker 
to identify human HSCs (31). CD133 is a 5-transmembrane glycoprotein, and can be 
present on the cell surface of CD34 bright haemopoietic progenitors (31). Enriched 
human mobilized peripheral CD133+ cells effectively engraft NOD/SCID mice, as well 
as secondary recipient mice (32). Purified human CD133+ cells contain more primitive 
progenitors than CD34+ cells as demonstrated by LTC-IC assay (33). Human 
CD34+CD133+ haemopoietic cells have a higher engraftment capacity of NOD/SCID 
mice than CD34+CD133– cells (34), indicating CD34+CD133+ cells are more primitive 
than CD34+CD133– cells.  
1.1.1 Leukaemic stem cells 
The hypothesis of cancer stem cells (CSCs) describes the existence of a small subset 
of cancer cells which are likely responsible for tumourigenesis, metastasis and 
disease relapse (35). CSCs have characteristics of normal stem cells, especially 
extensive self-renewal capability (35).  
 
The leukaemic stem cell (LSC) is a paradigm of CSC model. Early studies suggested 
that only a small fraction of leukaemic cells was able to proliferate extensively in vitro 
and in vivo (14). Park et al. demonstrated that about 1 in 100-10,000 leukaemic cells 
form colonies in CFC assay in vitro (36), and only 1-4% of leukaemic cells formed 
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colonies in spleen after murine transplantation (37). These clonogenic leukaemic cells 
were thought to be LSCs (14). In 1997, Bonnet and Dick showed that a tiny proportion 
of human acute myeloid leukaemia (AML) blasts were capable of engrafting 
NOD/SCID mice, and producing a disease same as human AML (38). These cells 
were defined as SCID leukaemia-initiating cells (SL-ICs) and they were exclusively 
CD34+CD38– in every patient, which is very similar to the phenotype of normal SRCs 
(38). In addition, these SL-ICs have great self-renewal capacity as assessed by 
successful engraftment of secondary recipient mice (38). These observations suggest 
that leukaemic transformations occur in primitive normal haemopoietic cells, which 
then give rise to leukaemia through clonal expansion (38). On the other hand, the 
leukaemic transformation may also occur in committed normal progenitors which then 
regain self-renewal capability and initiate leukaemias (14) (Figure  1-2). 
   
    
Figure  1-2: Model of leukaemic stem cell transformation.  
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Leukaemogenesis can occur in HSCs which give rise to a LSC with self-renewal 
capability. Alternatively, it can happen in progenitor cells which then reacquire self-
renewal capacity. Adapted from Passegue et al., 2003 (14) 
1.2 Chronic myeloid leukaemia  
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disease of stem cell 
origin (39). The Bcr-Abl protein is present in multiple haemopoietic lineages including 
myeloid, erythroid, B-lymphoid and occasionally T-lymphoid cells in most CML 
patients, suggesting the Bcr-Abl oncogene is formed in HSCs (14). By studying 
female patients with X chromosome linked heterozygous alleles, CML was 
demonstrated to be a clonal disease with origin in a single multipotent stem cell 
(39;40).    
 
The incidence of CML each year is 1 to 2 cases per one hundred thousand of the 
population, and it affects all age groups with median age of onset about 45-55 years 
(2;41). It accounts for about 20% of leukaemias in adults (41). CML is characterised 
by the presence of the Philadelphia (Ph) chromosome and Bcr-Abl oncogene. The 
reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)-
(q34;q11), results in a shortened chromosome 22, which is termed the Philadelphia 
(Ph) chromosome (Figure  1-3)(42;43). It is found in 95% of CML patients, and in 5% 
of children and 15-30% of adults with acute lymphoid leukaemia (ALL) (41). In 
addition, it is also present in 2% of patients with recently diagnosed AML (41).  
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Figure  1-3: Formation of the Philadelphia chromosome and Bcr-Abl oncogene.  
The reciprocal translocation between long arms of chromosome 9 and 22 results in a 
fused oncogene Bcr-Abl and a shortened chromosome 22, the Philadelphia 
chromosome. Adapted from Smith et al., 2003 (2). 
 
The reciprocal translocation results in a fusion gene Bcr-Abl on the Ph chromosome 
(44). The fusion gene product, Bcr-Abl protein, significantly affects cell growth, 
turnover, differentiation, apoptosis and adhesion (44). The Abl (Abelson kinase) gene 
located on chromosome 9 has 11 exons and is 230 kilobase (kb). The breakpoint in 
Abl gene is usually upstream of exon 2 (41). In most cases, Abl gene exons 2 to 11 
are translocated to the major break point cluster region(M-bcr) of the Bcr gene on 
chromosome 22, forming a hybrid Bcr-Abl gene. It is then transcribed into an 8.5 kb 
chimeric messenger ribonucleic acid (mRNA) with an e14a2 or e13a2 (also known as 
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b3a2 or b2a2) junction, and then mRNA is translated into a p210Bcr-Abl fusion protein 
(41;44;45). In rare cases of CML and in common cases of Ph positive ALL, the 
breakpoint of chromosome 22 occurs in a minor break point cluster region (m-bcr), 
and results in a e1a2 junction mRNA and a 190 kDa Bcr-Abl fusion protein, which is 
termed as p190Bcr-Abl (41;44). In very rare cases of CML, a third breakpoint is detected 
downstream of the M-bcr between exons e19 and e20 of Bcr gene, it is termed µ-bcr. 
Its transcription product is a mRNA with e19a2 junction and its final product is a 230 
kDa Bcr-Abl protein which is termed p230Bcr-Abl (41;44) (Figure  1-4).  
 
 
Figure  1-4: Three forms of Bcr-Abl oncogene.   
Adapted from Franklin et al., 1999 (41).  
 
CML is characterized by a triphasic clinical course (45), comprising initial chronic 
phase (CP), secondary accelerated phase (AP) and terminal blast crisis (BC) (41). 
About 85% of CML patients are diagnosed in CP, with common symptoms at 
presentation being abdominal fullness, anaemia, bleeding, fatigue, leukocytosis, 
purpura, splenomegaly, thrombocytosis and weight loss (41;46). CP CML features 
abnormal elevation of the number of myeloid progenitor and mature cells in the blood 
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and bone marrow (4;46;47). Bcr-Abl+ CML is diagnosed and monitored by the 
presence of Ph chromosome with cytogenetics, visualization of Bcr-Abl oncogene by 
double-fusion fluorescent in situ hybridization (D-FISH), or detection of Bcr-Abl mRNA 
with quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (48;49).   
 
The diagnostic criteria for AP and BC CML defined by the World Health Organisation 
are listed in the following table (Table  1-1). If left untreated, CP CML progresses to 
AP and BC about 3-5 years after onset (50). However, transformation of AP into BC 
can happen in several weeks or months (2). In the later stages, differentiation is 
blocked and non-functional immature blast cells accumulate in the blood and bone 
marrow, resembling acute leukaemias (2;47). Most patients acquire additional 
cytogenetic abnormality while progressing into BC CML (51), and the BC 
transformation can be myeloid, lymphoid or both lineages with very poor prognosis 
(2). The median survival time for myeloid and lymphoid BC CML is 4-5 months and 12 
months, respectively (2).  
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AP CML (Diagnosed if one or more of the following present) 
 
● 10 to 19% of peripheral blood white cells or bone marrow cells are blasts 
● Peripheral blood basophils  ≥20% 
● Persistent thrombocytopenia (100 x 109/L) unrelated to therapy, or persistent 
thrombocytosis (1000 x 109/L) unresponsive to therapy 
● Increasing spleen size and increasing WC count unresponsive to therapy 
● Cytogenetic evidence of clonal evolution 
 
BC CML (Diagnosed if one or more of the following present) 
 
● ≥20% of peripheral blood white cells or bone marrow cells are blasts 
● Extramedullary blast proliferation 
● Large foci or clusters of blasts in BM biopsy 
 
 
Table  1-1: Criteria for the diagnosis of AP and BC CML.  
Adapted from Vardiman et al., 2002 (52) 
1.2.1 The causal relationship between Bcr-Abl and CML 
Bcr-Abl is thought to play an essential role in the leukaemic transformation of 
haemopoietic cells and in the pathogenesis of CML (44). Nowell and Hungerford 
described that an abnormally short chromosome in 1960, which was lately named Ph 
chromosome, was consistently present in seven patients with chronic granulocytic 
leukaemia but not in normal cells of those patients or cells of other leukaemias, 
suggesting there was a causal relationship between Ph chromosome and chronic 
granulocytic leukaemia (53). Then Rowley discovered in 1973 that the Ph 
chromosome was a hybrid of chromosome 9 and 22 (54), and the fusion gene Bcr-Abl 
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was revealed on the Ph chromosome in 1980s (55). In 1990, Elefanty et al. 
introduced Bcr-Abl bearing retrovirus into bone marrow cells, and reconstituted 
lethally irradiated mice with these cells, resulting in a mild CML-like syndrome among 
several haemopoietic neoplasms (56). In the same year, introduction of Bcr-Abl by 
retrovirus into murine haemopoietic stem cells was employed to reconstitute lethally 
irradiated mice, and a myeloproliferative syndrome similar to human CP CML was 
developed prominently among half of recipient mice (57). Several years later, an 
improved method produced a human CML-like myeloproliferative disease in all 
recipient mice after transplantation of bone marrow cells with virally transfected Bcr-
Abl, and it is transplantable to secondary recipients (58). In addition, Bcr-Abl is 
associated with emergence of additional genomic abnormality and progression of CP 
CML into BC (59;60). Therefore, the leukaemogenic nature of Bcr-Abl makes it a 
therapeutic target in treating CML (2).  
1.3 Structures and functions of Bcr, c-Abl and Bcr-Abl  
1.3.1 Bcr 
Bcr is a 160 kDa protein with several structural and functional domains (61). There is 
a coiled-coil oligomerization domain in the N-terminus of Bcr (62). This domain 
enables Bcr to form a homotetramer. Downstream of the coiled-coil domain, there is a 
Src homology (SH) 2 binding domain (63). This domain is able to interact with the 
SH2 domain on c-Abl in a phosphotyrosine independent manner (63). In addition, 
there is a serine/threonine kinase located in the N-terminus encoded by the first exon 
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of Bcr (64). Located in the C-terminal of Bcr is a GTPase activating domain, which 
can increase the guanosine triphosphate (GTP) hydrolysis rate of a p21Rac GTP 
binding protein (G protein) (65). Also in the C-terminal of Bcr, there is a domain 
homologous to guanine nucleotide exchange factors (GEFs) of p21Rho/Rac family of G 
proteins (66). There is also a pleckstrin homology domain (PH domain) and a calcium 
dependent lipid binding (CaLB) domain in the Bcr protein (61) (Figure  1-5A). Having 
different types of structural and functional properties, Bcr protein may be involved in 
different signalling pathways and serve as the cross point of these pathways, but the 
understanding of the biological function of Bcr protein is limited (49;61).     
1.3.2 Abl 
C-Abl protein is a 145 kDa non-receptor tyrosine kinase (41). There are two splice 
variants of c-Abl, encoding two proteins with their difference in the first exon (1a and 
1b). C-Abl 1b is slightly longer than 1a and contains a myristoyl group at its N-
terminus, and this myristoyl group links c-Abl 1b with lipid membrane (67). Located in 
the N-terminus of c-Abl are three SH domains: SH3, SH2 and SH1. The SH3 domain 
binds to proline-rich (PxxP) motifs (68;69), and negatively regulates c-Abl tyrosine 
kinase activity (41). C-Abl tyrosine kinase can be activated by deletion of the SH3 
domain (70). The SH2 domain binds to phosphotyrosine residues in a sequence 
specific manner (68;69). The phosphotyrosine binding ability and transforming 
potential of activated Abl is reduced by point mutations in the SH2 domain (71). The 
following SH1 domain carries a tyrosine kinase (68). Downstream there are three 
proline-rich sequences which can interact with SH3-containing proteins (69). Towards 
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the C-terminus of c-Abl are three nuclear localisation signals (NLSs) and a nuclear 
export signal (NES), enabling it to shuttle between cell nucleus and cytoplasm 
(49;72). Located in the C-terminus are DNA and actin binding domains (49;73) 
(Figure  1-5B).  
 
C-Abl is mainly located in the cytoplasm of human haemopoietic cells with a low-level 
presence in the nucleus (74), whereas it is largely present in the nucleus of fibroblasts 
(75). The tyrosine kinase activity of c-Abl is tightly regulated in vivo, and its activity is 
very low in normal context (76). C-Abl can be activated by cell cycle progression, 
DNA damage and integrin mediated adhesion (68). C-Abl tyrosine kinase is increased 
during cell cycle progression to S phase (68). Activated c-Abl phosphorylates C-
terminal domain of RNA polymerase II and enhances transcription (68;77). In 
addition, c-Abl is activated in response to DNA damage and induces cell cycle arrest 
or apoptosis (78). Furthermore, integrin mediated adhesion can induce transient 
cytoplasmic translocation and activation of c-Abl in fibroblasts, which then activates 
mitogen activated protein kinase (MAPK) cascade (79;80).        
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Figure  1-5: The structural and functional domains of Bcr, c-Abl and Bcr-Abl proteins.  
(A) In Bcr, the coiled-coil oligomerization domain resides at the N-terminus. This is 
followed by a SH2 binding domain. Then there is a serine/threonine kinase domain, a 
Rho guanine nucleotide exchange factor (Rho-GEF) domain, a pleckstrin homology 
domain (PH domain), a calcium dependent lipid binding (CaLB) domain and a Rac 
GTPase activating protein (Rac-GAP) domain. (B) In c-Abl, there is a myristoyl group 
(in c-Abl 1b but not 1a), a Src homology  3 (SH3) domain, a SH2 domain and a SH1 
tyrosine kinase (TK) domain at the N-terminus, followed by several proline-rich 
domains (P) and three nuclear localisation signals (NLSs). At the C-terminus there are 
DNA- and actin-binding domains and a nuclear export signal (NES). (C) Bcr-Abl 
contains the first five domains of Bcr and all the c-Abl domains except the N-terminus 
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encoded by its first exon. Adapted from Smith et al., 2003 (2) and Deininger et al., 2003 
(49). 
1.3.3 Bcr-Abl 
The p210 Bcr-Abl protein forms dimers or tetramers in vivo that autophosphorylate 
each other (81). Fusion of Bcr to c-Abl inhibits the latter’s SH3 kinase regulatory 
domain, resulting in constitutive activation of the Abl tyrosine kinase in Bcr-Abl (41). 
Two domains of Bcr are thought to be essential for Abl tyrosine kinase activation and 
transforming potential of the Bcr-Abl oncoprotein: amino acids 1-63 and 176-242 (62). 
The first domain is the coiled-coil oligomerization domain, and it is involved in the 
deregulation of Abl tyrosine kinase and enhancement of filament (F)-actin binding 
ability of Abl (82). Mutations in the oligomerization domain abolished the transforming 
activity of Bcr-Abl protein (62). Disruption of the Bcr-Abl tetramer by a competitive 
peptide of the coiled-coil oligomerization domain of Bcr efficiently inhibited tyrosine 
kinase activity and transforming function of Bcr-Abl protein (83). The second critical 
domain for kinase activation and transforming potential is the SH2 binding domain of 
Bcr (62), which deregulates tyrosine kinase by binding to Abl SH2 domain (63). On 
the other hand, Abl tyrosine kinase impairs Bcr serine/threonine kinase by 
phosphorylating Y360 residue on Bcr and Bcr-Abl (84). A deleted form of Bcr which 
cannot be tyrosine phosphorylated, inhibits tyrosine kinase activity of active c-Abl and 
Bcr-Abl, suggesting tyrosine phosphorylation of Bcr abolishes its inhibitory activity 
(85).  
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Bcr-Abl can interact and/or phosphorylate many proteins, making Bcr-Abl involved in 
diverse intracellular signalling pathways, including Ras-MAPK, PI3K-Akt, and JAK-
STAT pathways (44;86) (Figure  1-6 and Table  1-2). Bcr-Abl was found to bind several 
adaptor proteins, such as growth factor receptor bound protein 2 (Grb2), v-Crk avian 
sarcoma virus CT10 oncogene homologue-like (CrkL) protein and Src homology-
containing (Shc) protein (41). Grb2 is an SH2/3 domain-containing adaptor protein. 
The SH2 domain of Grb2 interacts with the phosphorylated Y177 residue located in 
the N-terminal part of Bcr-Abl (84). Y177F mutation impaired binding of Bcr-Abl with 
Grb2, and inhibited Ras signalling which can be activated by wild type Bcr-Abl (87). 
Interaction with Grb2 is essential for the transforming ability of Bcr-Abl. The Y177F 
Bcr-Abl mutant was not able to transform Rat1 fibroblasts and murine bone marrow 
cells (87).  
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Figure  1-6: Major signalling pathways activated by Bcr-Abl protein in CML cells.  
IL-3 activates these signalling pathways (PI3K-Akt, Ras-Raf-MEK-ERK and JAK-STAT) 
in Bcr-Abl– cells to promote growth, survival and differentiation. In CML cells, these 
pathways can be activated by Bcr-Abl in the absence of IL-3, leading to cell 
proliferation and survival. 
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Substrate Full Name Function Reference 
Akt Protein kinase B Serine/Threonine  kinase (88) 
Bad Bcl-2-associated death promoter Pro-apoptotic (89) 
Bap-1 Bcr-associated protein 1 14-3-3 protein (61) 
Bcl-XL B-cell lymphoma-extra large Anti-apoptotic (90) 
Cbl Casitas B-lineage lymphoma E3-ubiquitin ligase  (91) 
Crk Avian sarcoma virus CT10 
oncogene homologue Adaptor molecule (92) 
CrkL Crk-like protein Adaptor molecule (93) 
Fak Focal adhesion kinase Cytoskeleton (94) 
Grb2 Growth factor receptor bound protein 2 Adaptor molecule (87) 
PI3K Phosphatidylinositol 3-kinase Phospholipid kinase (95) 
PLCγ Phospholipase Cγ Phospholipase (96) 
Raf Ras-activated factor Serine/Threonine kinase (97) 
Ras Rat sarcoma Small G-protein (98) 
Ras-GAP Ras GTPase-activating protein 
Ras-GTPase 
activating (99) 
Shc Src homology containing protein Adaptor molecule (100) 
SOS Son of sevenless Guanine nucleotide 
exchange factor  (101) 
STAT1/5 Signal transducer and 
activator of transcription 
Transcriptional 
activator (102;103) 
Syp Synaptophysin Protein phosphatase (104) 
 
Table  1-2: Examples of an extensive group of Bcr-Abl tyrosine kinase substrates.  
Adapted from Raitano et al., 1997 (68) and Smith et al., 2003 (2). 
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Binding of Grb2 to Bcr-Abl links it with Rat sarcoma (Ras) cascade. Activation of Ras 
protein results in subsequent activation of Raf, MEK and ERK, leading to activation of 
gene transcription (105). Ras regulates cell proliferation and differentiation, and plays 
a central role in the pathogenesis of CML (41;106). Impairment of Ras signalling by 
dissociation of Grb2/SOS complex inhibits proliferation of primary CML cells and Bcr-
Abl+ cell lines (107). 
 
Bcr-Abl protects CML cells from apoptosis. Expression of Bcr-Abl in haemopoietic cell 
lines elevates anti-apoptotic signals, such as B-cell lymphoma-2 (Bcl-2), B-cell 
lymphoma-extra large (Bcl-xL) and myeloid cell leukaemia-1 (Mcl-1) (88;90;108). 
CML CD34+ cells are more resistant to a range of cytotoxic agents compared with 
their normal counterparts (109). Expression of Bcr-Abl in murine Bcr-Abl– cell lines 
confers significantly increased resistance to cytotoxic agents compared with their 
parental cell lines (109). HL60 is a human Bcr-Abl– promyelocytic cell line which is 
very sensitive to apoptosis inducing agents, while expression of Bcr-Abl in HL60 cells 
makes them very resistant to apoptosis induced by a range of cytotoxic agents (90).  
 
Furthermore, Bcr-Abl can activate Phosphoinositide 3-kinase (PI3K)-Akt and Janus 
kinase (JAK)-signal transducers and activators of transcription (STAT) pathways to 
inhibit apoptosis. PI3K is a heterodimer containing an 85 KDa regulatory subunit and 
a 110 KDa catalytic subunit (68). The regulatory subunit is tyrosine phosphorylated in 
Bcr-Abl+ cells, and PI3K activity is elevated in Bcr-Abl expressing fibroblasts and 
haemopoietic cells (68). Activation of PI3K by Bcr-Abl is mediated by adaptor proteins 
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CrkL, Crk and Cbl (2). Then a downstream serine/threonine kinase Akt (also known 
as protein kinase B) is activated which phosphorylates the pro-apoptotic protein Bcl-2 
associated death promoter (Bad), leading to dissociation of Bad from anti-apoptotic 
signals (such as Bcl-xL) and suppression of apoptosis (110). Activated Akt also inhibit 
the tumour suppressor p53 via activation of murine double minute 2 (MDM2) protein, 
leading to cell survival (111). In addition, there is constitutive activation of JAK and 
STAT in Bcr-Abl+ primary cells and cell lines (112;113). In the normal cellular context, 
cytokine stimulation activates JAKs which then phosphorylate and activate STATs. 
Activated STATs translocate to the nucleus and upregulate gene transcription (114). 
Activated STAT5 is involved in the malignant transformation of Bcr-Abl+ cells 
(112;115;116). Activation of STAT5 by Bcr-Abl upregulates anti-apoptotic protein Bcl-
xL, leading to suppression of apoptosis (117;118). However, activation of STAT5 is 
not always induced by activated JAKs in CML cells, as Bcr-Abl can phosphorylate 
STAT5 via haemopoietic cell kinase (Hck) (119).  
 
Bcr-Abl transforms haemopoietic cell lines into interleukin (IL)-3 independence in vitro 
(59;120). The proliferation of Bcr-Abl+ quiescent CML cells can be initiated without 
any added growth factor (121), but normal quiescent haemopoietic cells can not (16). 
Bcr-Abl also promotes IL-3 and granulocyte colony-stimulating factor (G-CSF) 
secretion and autocrine proliferation in CML stem and progenitor cells (122;123). IL-3 
and G-CSF are growth factors which regulate proliferation, differentiation and survival 
of haemopoietic cells by activating intracellular signalling pathways including Ras-
MAPK, PI3K-Akt, and JAK-STAT (86;124). Normal haemopoietic primitive cells are 
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dependent on growth factors to proliferate and survive (18). The aberrant autocrine 
production of IL-3 and G-CSF in CML stem and progenitor cells may confer them with 
a proliferative advantage compared with their normal counterparts (121;123).  
 
Furthermore, Bcr-Abl alters cellular adhesion of CML primitive cells within their bone 
marrow microenvironment. Normal haemopoietic progenitors interact with their bone 
marrow microenvironment via integrin mediated adhesion (125), which negatively 
regulates their proliferation (126). Abnormal circulation of immature CML progenitors 
in the peripheral blood and the proliferative advantage of CML progenitors may be 
explained by their altered adhesion with the bone marrow microenvironment 
(127;128). Primary CML progenitors have reduced adhesion with bone marrow 
stromal cells and the extracellular matrix glycoprotein fibronectin in vitro (129;130). 
However, this is controversial as Bcr-Abl transfected human and murine haemopoietic 
cell lines have increased adhesive interaction with stromal cells and fibronectin 
(131;132). In addition, it was suggested that restoration of normal haemopoiesis by 
interferon-alpha (IFN-α) in some CML patients may be due to recovery of adhesion of 
CML progenitors to the bone marrow stroma (133).  
 
In summary, the constitutively activated tyrosine kinase of Bcr-Abl promotes cell 
proliferation, inhibits apoptosis, transforms haemopoietic cells into growth factor 
independence and alters cellular adhesion, which is the driving force of 
leukaemogenesis of CML.    
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1.4 Treatment of CML  
1.4.1 Conventional therapies (pre-tyrosine kinase inhibitor era) 
Whole body or splenic radiation was the major treatment of CML until the 1950s, 
which was palliative and did not improve overall survival (45). Then busulfan was 
employed from the 1950s and it could maintain partial haematologic response (PHR, 
defined in Table  1-3) in most CML patients with serious side-effects (45;134). 
Hydroxyurea, an inhibitor of DNA synthesis and cell cycle, was introduced to treat 
CML in the 1970s (135). Hydroxyurea can rapidly control blood cell count and achieve 
complete haematologic response (CHR) in 50-80% of CML patients, but cytogenetic 
responses are rare (136;137). It is effective in CML patients resistant to busulfan 
treatment (135). However, both busulfan and hydroxyurea cannot block disease 
progression into BC where median survival remained to be 3 to 6 years (45).  
 
Allogeneic bone marrow transplantation (BMT) or stem cell transplantation (SCT) is 
the only curative therapy for CML in suitable patients (2). Allogeneic SCT with 
peripheral blood CD34+ progenitor cells can fully reconstitute the haemopoietic 
system of recipients (21). HLA matched donors receive G-CSF to mobilize their HSCs 
into peripheral blood. When 1-2% of blood cells are CD34+, and after leukapheresis, 
CD34+ cells are enriched by a CD34 specific monoclonal antibody for allogeneic 
transplantation (21). Haemopoietic engraftment by peripheral blood CD34+ cells is 
stable, faster to recover all haemopoietic lineages, and the stem cell collection 
procedure itself is more comfortable for the donor than bone marrow harvest under 
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general anaesthetic (21). Five-year survival after allogeneic BMT or SCT is up to 72% 
in low-risk CML patients but is associated with at least 20% transplantation–related 
mortality, while there is only around 20% survival in high-risk patients with 
transplantation–related mortality as high as 73% (138). The high mortality rate is 
usually caused by graft-versus-host disease and opportunistic infections (137). 30-
70% of CML patients achieved long-term disease-free survival after allogeneic SCT 
(45). However, only about 20% of CML patients are suitable for allogeneic 
transplantation due to limitations of age, fitness and matched donor availability (139).  
 
A human cytokine, IFN-α, became the first line therapy of CML patients who were not 
eligible for allogeneic SCT in the 1980s (140). IFN-α can achieve CHR in 46-80% of 
CML patients, partial cytogenetic response (PCgR) in 11-16% of patients and 
complete cytogenetic response (CCgR) in 13-32% of patients (45). IFN-α achieves 
durable CCgR in a subset of CML patients and is superior to busulfan and 
hydroxyurea in patient survival (140). However, IFN-α therapy results in a high 
possibility of neurotoxicity as well as some other intolerable side effects in older 
patients (45). Combination of IFN-α and cytarabine (or cytosine arabinoside, Ara-C) 
significantly improved cytogenetic response rates and survival time of CP CML 
patients compared with IFN-α alone (141;142). IFN-α plus cytarabine then became 
the standard therapy for those CML patients who were unsuitable for transplantation 
(142;143). 
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Response Criteria 
Complete haematologic 
response (CHR) 
Complete normalization of peripheral blood count: 
● Leukocyte count <10 x 109 cells/L 
● Platelet count <450 x 109 cells/L 
● No immature cells in the peripheral blood  
● No sings or symptoms of disease including  
splenomegaly 
Partial haematologic 
response (PHR) 
Same as those for CHR, except 
● Persistence of immature cells, or 
● Platelet count <50% of the pre-treatment count but 
>450 x 109 cells/L, or  
● persistent splenomegaly but >50% of the pre-
treatment extent 
Complete cytogenetic 
response (CCgR) 
No Ph+ cells detectable by cytogenetics in the bone 
marrow 
Partial cytogenetic 
response (PCgR) 1-34% Ph
+
 cells detectable in the bone marrow 
Major cytogenetic 
response (MCgR) 
<35% Ph+ cells detectable in the bone marrow 
(includes CCgR and PCgR) 
Minor cytogenetic 
response (mCgR) 35-90% Ph
+
 cells detectable in the bone marrow 
Complete molecular 
response (CMR) 
● Undetectable Bcr-Abl transcript by qRT-PCR, or  
● ≥4.5 log reduction compared to starting level 
Major molecular 
response (MMR) 
● ≥3 log reduction of Bcr-Abl transcript, or 
● <0.1% Bcr-Abl transcript by qRT-PCR 
 
Table  1-3: Criteria of treatment responses in CML.  
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1.4.2 Tyrosine kinase inhibitors (TKI) – imatinib  
As the understanding of the molecular biology of CML progressed further, Bcr-Abl 
became an attractive therapeutic target for CML. Imatinib mesylate (IM; Glivec® or 
Gleevec®, Novartis, Basel, Switzerland. Figure  1-7) is an Abl TKI, and it inhibits the 
kinase activity of Abl, c-Kit and platelet-derived growth factor receptors (PDGF-R) 
(44;144). IM competes with adenosine triphosphate (ATP) for the enzymatic binding 
site of Abl, and blocks Abl tyrosine kinase activity (44) (Figure  1-8). IM was developed 
by random screen of a large number of synthesized ATP-competitive 2-
phenylaminopyrimidine compounds for TKI activity, and CGP57148 (later known as 
STI571 and IM) emerged as a potent inhibitor of Abl tyrosine kinase (145). The 
activation loop in the enzymatic site of Abl controls its kinase activity by switching 
between active and inactive conformations. IM binds to Abl only when it is in the 
inactive state and prevents it from changing into the active conformation (146).   
 
 
    
 
 
Figure  1-7: Structure of IM (147).  
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Figure  1-8: Mechanism of action of IM on Bcr-Abl.  
ATP binding is essential for Bcr-Abl to phosphorylate substrates and subsequently 
activate downstream pathways that promote cell survival, proliferation and regulation. 
IM can bind to the inactive state of Bcr-Abl at its ATP binding site, and inhibit the 
phosphorylation of substrates that would activate downstream signalling and lead to 
CML. 
 
IM inhibits proliferation and causes apoptosis in Bcr-Abl+ cell lines and CML 
progenitors in vitro and in vivo, with very low toxicity to Bcr-Abl negative cell lines and 
normal progenitors, demonstrating the specificity of this drug against Bcr-Abl+ cells 
(145;148). In June 1998 IM was taken into a phase I clinical trial with CP CML 
patients who failed IFN-α treatment, and 98% of these patients achieved CHR within 
four weeks at 300mg or more IM once daily (149). Side effects with IM treatment were 
mild, including nausea, myalgias, oedema, and diarrhoea (149). A daily dose of 
400mg IM or more was recommended for future studies. A peak plasma 
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concentration of 4.6µM and a tough concentration of 1.46µM were achieved with this 
dose at steady-state (149). At the phase II clinical trial, IM was administered orally at 
400mg daily to CP CML patients who had failed IFN-α treatment (150). About 95% 
patients achieved CHR and 60% achieved major cytogenetic response (MCgR) (150). 
AP and BC CML patients were treated with 400mg or 600mg IM daily, and achieved 
higher response rates and longer survival time than conventional treatments 
(151;152).  
 
In June 2000, the phase III International Randomized Study of Interferon and STI571 
(IRIS) study was initiated with newly diagnosed CP CML patients and compared IM 
treatment with IFN-α plus cytarabine (153;154). After a median of 18 months follow-
up, 76.2% patients treated with IM achieved CCgR, while only 14.5% patients treated 
with IFN-α plus cytarabine achieved CCgR (153;154). IM was shown to be superior to 
IFN-α plus cytarabine in treating newly diagnosed CP CML, and subsequently most 
patients in the IFN-α plus cytarabine treatment arm crossed over to the IM arm 
(153;154). In May 2001, IM was rapidly approved by the United States Food and Drug 
Administration (FDA) for treatment of Ph+ CML (153). After six years follow-up of the 
IM arm in the IRIS study, the estimated total survival rate was 88%, or 95% when 
counting CML-related deaths only, and the cumulative best rate of CCgR was 83% 
(155). Owing to the efficacy and low toxicity of IM, it is now considered as the first-line 
treatment for newly diagnosed CP CML (153-155).  
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However, resistance developed against IM. It was shown that the approximate 
relapse rate was 17% after 60 months of IM treatment, and about 7% of all patients 
treated with IM entered AP or BC (143). About 20-25% of patients treated with IM 
never achieved CCgR (156). Resistance to IM can be described as primary or 
acquired. Primary resistance is where there is no initial response to IM, and it is 
defined as a failure to achieve CHR within 3 months, cytogenetic response within 6 
months, PCgR within 12 months or CCgR within 18 months of treatment (157;158). 
Acquired resistance is loss of established CHR, or CCgR, or progression to AP or BC 
(157). Acquired resistance to IM is often mediated by point mutations in the kinase 
domain of Bcr-Abl (159). 
1.4.2.1  p-CrkL as a surrogate marker of Bcr-Abl kinase inhibition by TKI   
Phosphorylated CrkL (p-CrkL) is commonly used as a surrogate marker for Bcr-Abl 
tyrosine kinase activity (160-163). It was firstly identified in 1994 that a 39 kDa protein 
was consistently tyrosine phosphorylated in peripheral blood neutrophils from all 18 
chronic phase CML patients screened, but not in normal controls (93). It was also 
found that the same protein was tyrosine phosphorylated in Bcr-Abl+ cell lines, such 
as K562 and BV173 (93). Later this 39 kDa protein was identified as CrkL after 
protein purification (93). The CrkL gene had been discovered in 1993; it is located on 
chromosome 22 and centromeric to the Bcr gene (164). Its protein product is very 
similar to the product of a viral oncogene v-Crk which is from avian sarcoma virus 
CT10, and CrkL is 60% homologous to Crk that is the human homolog of v-Crk (164). 
CrkL protein contains a SH2 domain and two tandem SH3 domains without having 
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any catalytic domain (164). It was revealed that CrkL interacted with Abl directly (93). 
It was also found that CrkL was tyrosine phosphorylated by Abl and Bcr-Abl in 
transfected COS-1 cells and complexed with both of them in K562 and transfected 
COS-1 cells (165;166). Subsequently, it was identified that Bcr-Abl phosphorylated 
CrkL on tyrosine 207 (167).  
 
p-CrkL has been used as a marker to assess the effect of IM on inhibition of Abl 
kinase activity in patient samples by Western blotting (149;160). A method was 
developed to detect the level of p-CrkL in CD34+ CML progenitor cells using 
intracellular flow cytometry (161). This method takes much less time than Western 
blotting, but more importantly requires as few as 104 cells for each test, while Western 
blotting requires more than 105 cells, making the flow cytometry method a preferred 
choice with rare stem cell populations (161). A further validation of the flow cytometry 
method was reported in 2009, it showed that p-CrkL and total tyrosine 
phosphorylation are reduced to the same levels in K562 cells with 48 hours of IM 
treatment (162). However, a direct comparison of p-CrkL and Bcr-Abl tyrosine kinase 
activity has not been made, especially at short time-points (≤24h).   
1.4.3 Second generation TKI – nilotinib and dasatinib 
Second generation TKI drugs have emerged to target Bcr-Abl in order to overcome 
IM resistance. Nilotinib (Tasigna®; formerly AMN107, Novartis, Basel, Switzerland) 
(Figure  1-9) is a rationally designed and orally available specific inhibitor of Abl 
tyrosine kinase (168). Apart from Abl kinase, nilotinib also inhibits the activity of c-kit 
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and PDGF-R (169). Nilotinib was designed to have higher binding affinity than IM to 
the ATP binding site on the kinase domain of Abl (168). Nilotinib binds to the inactive 
conformation of Abl kinase, and blocks its tyrosine kinase activity (170;171). 
 
Nilotinib inhibits 32 out of 33 IM-resistant Bcr-Abl mutants except the T315I mutation 
(168). Nilotinib exhibits ≥20-time more potency than IM in IM sensitive and insensitive 
Bcr-Abl+ cell lines (170;172;173). Although nilotinib is much more effective than IM in 
Bcr-Abl+ cell lines, nilotinib and IM are equally potent in human primary CD34+ CML 
cells, and only have anti-proliferative effect instead of eradicating these cells (172). 
Nonetheless, clinical studies have demonstrated the effectiveness and safety of 
nilotinib in IM resistant or intolerant CML patients (174;175), leading to the approval of 
nilotinib by FDA for treating adult Ph+ CP and AP CML patients who are resistant to or 
intolerant of prior therapy including IM, and subsequently newly diagnosed adult Ph+ 
CP CML patients (176).  
 
 
 
 
 
Figure  1-9: Structure of nilotinib (147). 
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Dasatinib (Sprycel®; formerly BMS-354825, Bristol-Myers Squibb, Princeton, USA) 
(Figure  1-10) is a dual Src/Abl tyrosine kinase inhibitor (177). It also targets c-kit and 
PDGF-R (177). Dasatinib is an orally administrated drug and is 325-fold more potent 
than IM in cells expressing wild-type Bcr-Abl protein (173). Almost all Bcr-Abl kinase 
domain mutations can be inhibited by dasatinib except the T315I mutation (159;173). 
Dasatinib binds to both active and inactive conformations of Abl kinase, rendering it 
much higher binding affinity than IM (159).  
 
Clinical trials demonstrated the efficacy of dasatinib in all phases of IM resistant or 
intolerant CML patients, and it is well tolerated (178-180). Dasatinib was approved by 
FDA for treatment of adult Ph+ CML and ALL patients who are resistant to or 
intolerant of prior therapy (such as IM), as well as newly diagnosed adult Ph+ CP CML 
patients (181). However, dasatinib is not able to eliminate the primitive quiescent 
CML stem cell population (163). For this reason, although both nilotinib and dasatinib 
have improved effects in suppressing CML than IM, they are still not able to cure 
CML. 
 
 
 
 
Figure  1-10: Structure of dasatinib (147). 
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1.5 Mechanisms of TKI resistance and CML stem cell persistence  
Although most CML patients treated with IM are able to achieve CCgR, many of them 
still have detectable level of Bcr-Abl transcripts, and only 4% of patients treated with 
standard-dose IM have achieved complete molecular response (CMR) (143;156). 
After withdrawal of IM, about half of CML patients with durable CMR have disease 
relapse, whilst the other half remain in CMR for at least seven years (182). However, 
Bcr-Abl DNA is still detectable by highly sensitive PCR in the vast majority of these 
patients with stable CMR after IM is withdrawn (182). The disease relapse and 
minimal residual disease indicate that CML is not cured by IM. Resistance of CML to 
TKI can be described as Bcr-Abl independent or dependent (e.g. point mutations) 
(157).  
1.5.1 Bcr-Abl independent resistance 
Bcr-Abl independent resistance can be due to acquisition of additional oncogenic 
mutations, at which point Bcr-Abl becomes an irrelevant target (157). Aberrant growth 
factor secretion is another possible mechanism of resistance to TKI. Adaptive 
autocrine and paracrine secretion of granulocyte macrophage colony-stimulating 
factor (GM-CSF) activates anti-apoptotic JAK2/STAT5 pathway in a Bcr-Abl 
independent way in primary CML progenitors, and contributes to the resistance of 
CML cells to TKI treatment in vivo (183). Inhibition of JAK2 by AG490 abolishes the 
resistance mediated by GM-CSF (183), indicating the combination of TKI and JAK2 
inhibitor is a potential method to eradicate CML. In addition, the frequency and level 
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of expression of type 1 insulin-like growth factor receptor (IGF-IR) is much higher in 
BC CML patients than in CP and AP, and inhibition of IGF-IR partially overcomes 
CML resistance to IM (184). Thus, targeting IGF-IR may facilitate TKI in treating CML 
in advanced stages (184).  
 
Autophagy is another possible mechanism for CML cells to survive under TKI 
treatment. Autophagy is a pathway which degrades proteins or organelles to maintain 
cellular homeostasis, and also generates energy under starvation or other cellular 
stress (185). IM induces autophagy in CML cell lines and primary CML cells (186). 
Blockage of autophagy increases IM induced apoptosis in CML cells (185). 
Importantly, combination of autophagy inhibitor chloroquine and TKIs significantly 
induces apoptosis in CML progenitor and stem cells (186). This indicates that 
autophagy serves as a survival mechanism in CML cells with TKI treatment, and 
autophagy inhibition potentiates apoptosis induced by TKI in primitive CML cells 
(186).      
1.5.2 Bcr-Abl dependent resistance 
The possible mechanisms of Bcr-Abl dependent resistance are Bcr-Abl kinase 
domain point-mutations, Bcr-Abl gene amplification, Bcr-Abl protein over-expression 
and drug efflux (157). The major cause of resistance to IM is point-mutations in the 
kinase domain of Bcr-Abl protein (187). Almost all Bcr-Abl kinase domain mutants can 
be inhibited by second-generation TKIs, except the T315I mutant (188). Threonine 
315, located at the Abl kinase domain, forms a pivotal hydrogen bond with TKI (187). 
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Mutation at this site disrupts the binding of TKI with Bcr-Abl. CML patients harbouring 
T351I Bcr-Abl mutant are associated with poor clinical prognosis (189).  
1.5.2.1 Drug Efflux 
One possible mechanism of TKI resistance is drug efflux, which pumps out 
intracellular drugs typically by ATP binding cassette (ABC) transporters. ABC 
transporters are involved in multi-drug resistance in cancer chemotherapy (190). Drug 
efflux may lead to sub-optimal intracellular TKI concentration and insufficient inhibition 
of Bcr-Abl kinase activity.  
 
It was shown that overexpression of an ABC transporter ABCB1 (MDR1, p-
glycoprotein) in Bcr-Abl+ cell lines conferred partial resistance to IM (191). However, 
the activity of ABCB1 in primary CML CD34+ cells is very low, and inhibition of 
ABCB1 was not able to increase intracellular IM level (192). In addition, it was 
suggested that another ABC transporter ABCG2 (BCRP) was involved in the efflux of 
intracellular IM in ABCG2-overexpressing cell lines (193). ABCG2 transduced human 
BC CML cell line K562 cells become insensitive to IM and nilotinib treatments, and 
both TKIs associate with ABCG2 at its substrate binding sites (194). Although 
functional ABCG2 is overexpressed in CML CD34+ cells, IM inhibits ABCG2 activity in 
this primitive CML population and is not a substrate of ABCG2 (195). This indicates 
that ABCG2 is not a regulator of intracellular IM concentration in primitive CML cells 
(195). Furthermore, nilotinib inhibits the activity of a range of transporters, including 
ABCB1, ABCG2 and the influx transporter human organic cation transporter 1 
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(hOCT1) in CML cell lines and CML CD34+ cells (196;197). The uptake and efflux of 
nilotinib is not modulated by these transporters in CML cells (197). Taken together, 
drug efflux is unlikely a mechanism of CML stem cell resistance to IM and nilotinib.    
1.5.2.2 Cytoplasmic retention of Bcr-Abl 
The NLS and NES-containing protein c-Abl may be present both in the nucleus and 
cytoplasm (49;72). Although there are three NLSs present in the Bcr-Abl protein, Bcr-
Abl is located in the cytoplasm of transformed fibroblasts (73;198). In addition, it was 
demonstrated that Bcr-Abl was localised to the cytoplasm of CML cell lines and 
primary cells (74). Export of NES-containing proteins from the nucleus is facilitated by 
the NES receptor CRM1/exportin-1 (199). CRM1/exportin-1 can be inactivated by a 
cytotoxin called leptomycin B (LMB), resulting in the inhibition of NES dependent 
protein export from the nucleus (72;199). In Bcr-Abl transfected fibroblasts, LMB 
treatment could not trap Bcr-Abl in the nucleus, showing that Bcr-Abl was not 
imported into the cell nucleus despite its NLS domains (198). However, in fibroblasts 
transfected with kinase–defective Bcr-Abl, about 30-35% kinase–defective Bcr-Abl 
was accumulated in the cell nucleus by LMB (198). In addition, IM could induce Bcr-
Abl nuclear localisation  and result in Bcr-Abl nuclear entrapment with LMB (198). The 
nuclear fraction of Bcr-Abl was demonstrated to correlate with increased IM 
concentration and incubation time, reaching a plateau with 10µM IM at about 25-35% 
(198). This indicates that inhibition of Bcr-Abl tyrosine kinase can induce nuclear 
transportation of Bcr-Abl protein, and the kinase activity of Bcr-Abl plays a role in its 
cytoplasmic retention.   
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Nuclear Abl kinase can be activated by DNA damage, subsequently inducing 
activation of protein p73 which is functionally homologous to the tumour suppressor 
protein p53. The activation of Abl and p73 is involved in DNA damage-induced 
apoptosis (200). It was demonstrated that nuclear Bcr-Abl kinase could induce cell 
apoptosis in transformed fibroblasts and K562 cells. Bcr-Abl expressing cells were 
treated with both IM and LMB to trap Bcr-Abl inside the nucleus, and then cells were 
washed extensively to get rid of IM to recover the tyrosine kinase activity of Bcr-Abl. 
After that cells were incubated with LMB alone. With this protocol, the apoptotic rate 
of Bcr-Abl expressing cells was about 70-80% higher than untransfected cells 
(198;200). These observations provided a new strategy for killing Bcr-Abl+ cells. 
Interestingly, only about 20-25% of total Bcr-Abl accumulated in the nucleus of K562 
cells treated with both IM and LMB, indicating that there were other mechanisms 
besides tyrosine kinase activity holding Bcr-Abl in the cytoplasm (198). 
1.5.2.3 Quiescent CML stem cells 
The quiescent (viable and non-dividing) CML stem cell population is insensitive to TKI 
treatment (201). IM and nilotinib have an anti-proliferative effect in the CML stem cell 
population, resulting in an accumulation of quiescent CML stem cells (172;201). 
Although dasatinib can target the committed CML stem cells, the quiescent CML stem 
cell population is still insensitive to this drug (163). In addition, the quiescent CML 
CD34+ cells are resistant/persistent to a range of cytotoxic agents, including Ara-C, 
arsenic, PI-3K inhibitor LY294002 and et al. (202;203). Thus, eradication of this 
primitive Ph+ stem cell population becomes an interesting research focus (157).  
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In addition, primitive CML CD34+38– cells (approximating the in vivo quiescent stem 
cell pool) had significantly higher levels of Bcr-Abl mRNA transcript and Bcr-Abl 
protein compared to mature mononuclear cells (MNC) (163). Additionally, total 
phosphotyrosine and p-CrkL levels are increased in CML CD34+38– cells with respect 
to MNC population. The level of p-CrkL is significantly elevated in CML CD34+38– 
cells compared to bulk CML CD34+ cells, indicating higher Bcr-Abl tyrosine kinase 
activity in CD34+38– cells than CML MNC and bulk CD34+ cells (163). Therefore, 
sufficient inhibition of Bcr-Abl tyrosine kinase in quiescent CML stem cells is required 
to eradicate them.  
 
Type of Resistance  Possible Mechanisms 
Bcr-Abl Dependent Bcr-Abl kinase domain mutations 
Bcr-Abl gene amplification  
Bcr-Abl protein over-expression  
Drug efflux 
Cytoplasmic retention of Bcr-Abl 
CML stem cell persistence 
Bcr-Abl Independent Additional oncogenic mutations 
Aberrant growth factor secretion 
Autophagy 
 
Table  1-4: Possible mechanisms of TKI resistance.  
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1.6 Novel treatment approaches 
1.6.1 Farnesyltransferase inhibitors and CML 
Ras (also known as p21Ras) is a G or guanosine-nucleotide-binding protein. Ras is 
active when bound with guanosine triphosphate (GTP) and inactive with guanosine 
diphosphate (GDP). The Ras family contains H-Ras, K-Ras and N-Ras genes, the 
molecular weight of their protein products are 21 kDa (204). Ras proteins regulate 
several signalling pathways, among which the Ras-Raf-MEK-ERK signalling cascade 
is the pivotal one. In normal cellular context, this cascade is activated by binding of 
external stimuli to receptor tyrosine kinases (RTKs), leading to the dimerization of the 
RTKs and phosphorylation of an adaptor protein Grb2 (105). Subsequently, 
phosphorylated Grb2 brings a guanosine nucleotide exchange factor SOS (Son of 
Sevenless) to the membrane bound inactive Ras-GDP, and converts it into active 
Ras-GTP, leading to the sequential activation of Raf, MEK and ERK (105). Activated 
ERK then translocates into the cell nucleus resulting in phosphorylation of many 
transcription factors and transcription of genes involved in cell proliferation, 
differentiation and survival (105). Ras activity is regulated by opposite effects of GEFs 
and GAPs (205). GAPs enhance the intrinsic GTPase activity of Ras, resulting in 
increased GTP hydrolysis rate. Thus, GAPs negatively regulate Ras activity. On the 
other hand, GEFs facilitate exchange of Ras-GDP to Ras-GTP, making more active 
form of Ras protein. Therefore, GEFs are activators of Ras signalling (205).   
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Ras signalling is a critical pathway activated by Bcr-Abl protein. Experiments have 
demonstrated that inactivation of Ras signalling impaired the leukaemic 
transformation ability of Bcr-Abl protein (106). It was reported that the proliferation of 
a Bcr-Abl+ CML cell line BV173 was blocked by knock down of Ras. It was shown that 
inactivation of Ras dramatically reduced the number of colonies formed in soft agar 
assays with Bcr-Abl expressing Rat-1 fibroblasts (106). In addition, the transformation 
ability of Bcr-Abl in mouse bone marrow cells was completely inhibited by co-
expression of inactive Ras (106). These observations show that Ras plays an 
essential role in the Bcr-Abl transformation, which makes Ras a potential therapeutic 
target in treating CML.   
 
Cytosolic Ras protein is post-translationally modified to enable its membrane 
association, which is critical for the signalling functions of Ras (206). The post-
translational modifications of Ras include farnesylation, proteolysis and carboxyl 
methylation (207). The first step in this process is addition of a 15-carbon farnesyl 
group to the cysteine residue of Ras C-terminal CAAX consensus sequence (C is 
cysteine, A is any aliphatic amino acid and X is any amino acid). Subsequently, the C-
terminal tripeptide AAX is removed by proteolysis. Finally, the new C-terminal 
farnesylcysteine residue is carboxyl methylated (208;209). Among these three steps, 
farnesylation of the C-terminal cysteine residue of Ras by farnesyltransferase is the 
key step of this process (208). Therefore, inhibition of the farnesyltransferase activity 
prevents membrane association of cytosolic Ras and its signalling function.  
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Based on this, a range of farnesyltransferase inhibitors (FTI) were developed to inhibit 
the farnesyltransferase activity and intended to block the Ras signalling pathway. 
These FTIs have potential applications in a wide range of tumours, since mutant 
forms of Ras with constitutive activity are involved in about 90% of pancreatic 
adenocarcinoma, 50% of colon adenocarcinoma, 30% of myeloid leukemia and many 
other types of human tumours (210). More importantly, our previous study revealed 
that lonafarnib, a FTI, sensitized primitive quiescent CML cells to IM treatment in vitro 
(202).   
1.6.2 BMS-214662  
BMS-214662 is a potent FTI, which was developed as an inhibitor of Ras signalling 
pathway (Figure  1-11)(206). BMS-214662 has slightly lower FTI activity than another 
FTI, BMS-225975, as measured by in vitro kinase assay and in cell lines with mutant 
Ras (211). However, BMS-214662 exhibits potent apoptotic effects in tumour cells in 
vivo, whereas BMS-225975 only has cytostatic effects in the same context (211). This 
indicates BMS-214662 may induce apoptosis in tumour cells by a novel mechanism 
of action apart from its FTI activity. In addition, previous research demonstrated that 
BMS-214662, but not BMS-225975, selectively induced apoptosis in quiescent CML 
stem and progenitor cells in respect to their normal counterparts, making BMS-
214662 a potential drug to eradicate CML (212). BMS-214662 induces apoptosis in 
primary CML stem and progenitor cells via the activation of protein kinase C β (PKCβ) 
and the intrinsic apoptotic pathway including generation of reactive oxygen species 
(ROS) and release of cytochrome c from the mitochondria (213). However, the exact 
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mechanism of how BMS-214662 activates the intrinsic apoptotic pathway is still not 
clear. 
 
Figure  1-11: The structure of BMS-214662 and BMS-225975.  
Adopted from Manne et al., 2004 (211).  
1.6.3 Protein tyrosine phosphatases  
Protein tyrosine phosphatases (PTPs) modulate signalling pathways mediated by 
protein tyrosine kinases (PTKs) and cytokines (214). Most of PTPs negatively 
regulate these signalling pathways, apart from a few PTPs like SHP2 and CD45, 
which increase immune response and cytokine signalling (214). SHP1 and SHP2 are 
SH2 domain-containing, non-receptor PTPs (215). They both have two tandem SH2 
domains at the N-terminus, then a catalytic domain and an inhibitory C-terminus 
(215). Although SHP1 and SHP2 are structurally similar, they have different functions 
and expression patterns. SHP1 is highly expressed in haemopoietic cells, and 
negatively regulates cell signalling mediated by a range of cytokine receptors (215). 
However, SHP2 is widely expressed and promotes cell signalling pathways leading to 
differentiation, proliferation, and migration (215). 
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Phosphorylation of Bcr-Abl is regulated by PTPs. Bcr-Abl enhances expression of 
SET via JAK2 kinase (216;217). SET is an inhibitor of tumour suppressor protein 
phosphatase 2A (PP2A) (218), and PP2A is a serine/threonine phosphatase which 
activates SHP1 (217). The tyrosine phosphatase SHP1 associates with and 
dephosphorylates Bcr-Abl (217). Thus, Bcr-Abl maintains its tyrosine phosphorylated 
status by inhibiting SHP1 through SET-PP2A-SHP1 pathway. Inhibition of SHP1 by 
Bcr-Abl renders proliferative advantage to Bcr-Abl+ cells, as it was shown that defect 
of SHP1 gene was associated with hyperproliferation of haemopoietic cells in mice 
(219). In addition, expression of SHP1 is decreased in primary CML cells along with 
disease progression, which may explain resistance of advanced CML to TKI 
treatment (214). 
 
Activation of PP2A and SHP1 becomes a potential therapeutic strategy in TKI-
insensitive CML. PP2A activation leads to Bcr-Abl tyrosine dephosphorylation and its 
proteasomal degradation via SHP1 (217). Besides Bcr-Abl, SHP1 also associates 
with and dephosphorylates JAK2 kinase (220), and triggers proteasomal degradation 
of JAK kinases (221). JAK2 plays a critical role in Bcr-Abl mediated cell signalling 
(222;223). In addition, the substrates of PP2A include MAPK, STAT5, Akt, Myc and 
Bad. Down-regulation of SET and overexpression of PP2A in a Bcr-Abl+ cell line 
inhibited phosphorylation of MAPK, STAT5 and Akt, reduced Myc expression and 
elevated the level of pro-apoptotic Bad (217). Activation of PP2A inhibits proliferation 
and clonogenic potential of Bcr-Abl+ cells, and induces apoptosis greatly in these cells 
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(217). Overall, activation of PP2A and SHP1 inhibits Bcr-Abl and JAK2 kinase activity, 
as well as their downstream signalling, and impairs the leukaemogenic potential of 
Bcr-Abl.  
 
Protein tyrosine phosphatase 1B (PTP1B) is another PTP which can dephosphorylate 
Bcr-Abl. Similar as SHP1, PTP1B is an intracellular PTP and a negative modulator of 
tyrosine kinases (224). PTP1B is able to associate with and dephosphorylate Bcr-Abl 
in vivo (225). PTP1B negatively regulates signalling and transformation mediated by 
Bcr-Abl in vitro and in vivo (225;226).  
1.6.4 Disruption of association of Bcr-Abl and its binding partners 
Since there are other mechanisms besides tyrosine kinase retaining Bcr-Abl in the 
cytoplasm (198), impairment of these mechanisms may induce nuclear localisation of 
Bcr-Abl and enhance apoptosis of CML cells. Cytoplasmic binding partners of Bcr-Abl 
may be involved in its cytoplasmic retention, and disruption of their association could 
potentially induce nuclear translocation of Bcr-Abl protein.   
1.6.4.1  Bcr-Abl and actin 
In the Bcr-Abl fusion protein, Bcr not only activates the tyrosine kinase activity of Abl, 
but also enhance the F-actin binding ability of Abl (82). The F-actin binding domain of 
Abl and Bcr-Abl protein is located in their C-terminal end (73). It was shown that Bcr-
Abl with defective F-actin binding ability had decreased transforming potential, but 
was not able to abolish dependence of Ba/F3 cells on IL-3 (73). In transfected COS 
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cells, wild type Bcr-Abl co-localises with F-actin, but F-actin binding domain (FABD) 
deleted Bcr-Abl mutant does not (227). The FABD-deleted Bcr-Abl is located in the 
cytoplasm diffusely with punctation (227). Treatment with IM does not induce nuclear 
localisation of FABD-deleted Bcr-Abl (227). However, it is not clear whether FABD-
deleted Bcr-Abl translocates to the nucleus with IM treatment, as Bcr-Abl may shuttle 
back to the cytoplasm very quickly in the absence of LMB.  
1.6.4.2  Bcr-Abl and 14-3-3 
14-3-3 proteins are highly conserved and ubiquitously expressed 28-33 kDa proteins 
involved in a wide variety of cellular processes in eukaryotes (228;229). There are 
seven major members in the mammalian 14-3-3 family (β, γ, ε, σ, ζ, τ and η), and 
these members form homodimers and heterodimers. 14-3-3 proteins have phospho-
serine and phospho-threonine binding activities (229). By interacting with a wide 
range of proteins, 14-3-3 proteins are involved in cellular processes including signal 
transduction, apoptosis, metabolism, protein trafficking, cell cycle regulation and DNA 
damage/oxidative stress responses (228;229). 14-3-3 dimers function as adaptor 
molecules in signalling to allow un-complexed proteins to associate with each other 
indirectly (230).  
 
14-3-3 proteins are involved in regulating nucleocytoplasmic shuttling of c-Abl. There 
is a consensus 14-3-3 binding site between the second and third NLSs of c-Abl 
protein (231). It was revealed that 14-3-3 proteins (β, γ, σ, ε, ζ and η) interacted with 
c-Abl at this site and sequestered c-Abl in the cytoplasm, as binding with 14-3-3 
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masks the NLSs of c-Abl (231). In addition, it was found that upon exposure to 
oxidative stress and DNA damage, activated JNK phosphorylated 14-3-3 (on Serine 
184) and resulted in the release of c-Abl from 14-3-3, hence nuclear translocation of 
c-Abl (231). Phosphorylation of c-Abl at Thr735 is crucial for its binding with 14-3-3 
proteins (231), and Thr735 phosphorylation is independent of DNA damage and 
subcellular localisation of c-Abl, and has no effect on the tyrosine kinase activity of c-
Abl (231).  
 
Furthermore, the N-terminal region of Bcr protein encoded by the first exon is 
associated with a member of 14-3-3 family, Bcr-associated protein 1 (Bap-1) (61). 
Bcr-Abl protein also interacts with Bap-1 (61). In addition, 14-3-3 β binds to the 
serine/threonine kinase domain of Bcr (232), and other 14-3-3 isoforms were found to 
interact with Bcr as well, including 14-3-3 γ, ε, ζ, τ, and η (233). 14-3-3 ζ, 80% of 
amino acid sequence identical to Bap-1, was revealed to be associated with both Bcr 
and Bcr-Abl proteins (61).  
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Figure  1-12: Nuclear translocation of c-Abl and Bcr-Abl in response to DNA damage.  
Following genotoxic stress, activated JNK phosphorylates 14-3-3 and disrupts 14-3-
3/c-Abl complex, leading to nuclear translocation of c-Abl. Then DNA damage activates 
the tyrosine kinase activity of c-Abl and results in apoptosis. Bcr-Abl can also be 
induced into the nucleus in response to genotoxic stress, which may enhance 
genomic instability in Bcr-Abl+ cells. NLSs are indicated as little blue ovals on Abl. 
Adapted from Yoshida et al., 2005 (231) and Pendergast 2005 (234).  
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1.6.5 Novel stem cell targeted drug delivery 
Stem cell targeted TKI delivery may be used in order to overcome the elevated 
expression and activity of Bcr-Abl kinase in CML stem cells (163). Low density 
lipoprotein (LDL), the major transporter of cholesterol in human plasma (235), could 
be an interesting drug delivery vector to primary haemopoietic stem cells. LDL 
particles are spherical and have a diameter of 22 nanometres (236). A LDL particle 
contains a core of about 1500 esterified cholesterol molecules surrounded by a shell 
of phospholipids, unesterified cholesterol and apoprotein B (237;238). Circulating LDL 
is taken up by cell surface receptors, then internalized and degraded to release 
cholesterol (Figure  1-13). Uptake of LDL is elevated in gynaecological cancer cells 
compared to normal cells (239). LDL receptor (LDLR) activity and cellular LDL uptake 
is markedly increased in primary peripheral blood and bone marrow AML and BC 
CML cells with respect to their healthy counterparts (237). Thus, LDL may be used as 
a selective drug delivery vehicle targeting CML stem cells.  
 
However, as natural LDL is extracted from serum, it has limited availability, as well as 
issues of genetic and batch-to-batch variation. Synthetic LDL (sLDL) is 
physicochemically and biologically equivalent to natural LDL (240;241). It can be 
routinely produced (242), and does not have the issues associated with natural LDL. 
Furthermore, sLDL has been shown to incorporate drugs (243;244), demonstrating 
the competence of sLDL as a drug delivery vector. The effectiveness of sLDL as a 
drug delivery vehicle in CML stem cells had not been investigated yet. 
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Figure  1-13: Internalization of LDL particles via receptor mediated endocytosis.  
LDL particles circulating in the blood are taken up by LDL receptors in clathrin-coated 
pits on cell surface. These pits are internalized and form coated vesicles which fuse 
and form endosomes. In the acidic environment of endosomes, LDL particles are 
separated from their receptors and delivered to lysosomes, where they are degraded 
to release free cholesterol. LDL receptors are then recycled to the plasma membrane 
by transport vesicles. Adapted from Brown and Goldstein 1986 (236). 
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1.7 Aims 
The following aims are addressed in this thesis:  
1. To investigate the efficacy of nuclear entrapment of Bcr-Abl to induce apoptosis in 
CML cells; 
2. To visualize the subcellular localisation of Bcr-Abl protein in CML progenitors 
which survive long-term TKI treatment, and to assess with which proteins Bcr-Abl 
is co-localised; 
3. To determine if p-CrkL is an accurate surrogate marker of Bcr-Abl tyrosine kinase 
activity especially at short time points; 
4. To investigate the mechanism of action of the putative farnesyltransferase 
inhibitor, BMS-214662 in CML cells; 
5. To assess the efficacy of sLDL as a drug delivery vehicle to target primitive CML 
cells. 
Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
75 
2 Methods and Materials 
2.1 Methods 
2.1.1 Cell Culture  
2.1.1.1 Culture of cell lines 
CML blast crisis cell lines K562 and KCL22, AML cell line HL60, murine cell lines 
Ba/F3 wild type and Ba/F3 Bcr-Abl were cultured in RPMI++ ( 2.3.7.1). Cells were 
grown at 37°C with 5% CO2 in tissue culture flasks. Cells were fed every one or two 
days to maintain a density of 2-10 x 105 cells/mL. 10ng/mL IL-3 was added to Ba/F3 
wild type cell culture medium as these cells are IL-3 dependent.  
2.1.1.2 Cell counting and trypan blue dye exclusion 
The number of cells was counted with a haemocytometer. 10µL of cells were loaded 
into one side of the chamber in the haemocytometer, and at least 100 cells were 
counted to give a statistically significant count. For assessment of cell viability, trypan 
blue dye exclusion method was used. Trypan blue is a vital dye which can penetrate 
through the membrane of dead cells but not viable cells. Thus, dead cells can be 
distinguished with their blue colour under a microscope. At first, trypan blue solution 
was diluted 1 in 10 in PBS, and 90µL of such dilution was mixed with 10µL cells 
giving a dilution factor of 10. Then 10µL of the mixture was loaded into the 
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haemocytometer and at least 100 cells were counted. Cells without blue staining were 
counted as viable cells.  
2.1.1.3 CML sample collection and enrichment           
The research was approved by the Greater Glasgow and Clyde Health Board Local 
Research Ethics Committee (LREC) and all human participants gave written informed 
consent. Leukapheresis samples from newly diagnosed untreated patients with 
chronic phase CML were enriched to more than 90% CD34+ progenitors by positive 
selection with CliniMACS and cryopreserved routinely in the lab. Enriched CD34+ 
samples were validated by Ms Elaine Allan to be Ph+ by D-FISH.  
2.1.1.4 Cell sorting 
Cell sorting was performed by technicians. Briefly, CD34+ enriched cells were stained 
with anti-human anti-CD34-APC and anti-CD38-PE antibodies for 15 minutes in the 
dark. Then stained cells were sorted by using a BD FACS Aria into two populations: 
CD34+38hi/+ and CD34+38low/−. The CD34+38low/− fraction approximates the most 
primitive quiescent stem cell pool (less than 5% total CD34+ cells).  
2.1.1.5 Cryopreservation of cells 
Primary CML CD34+ cells and cell lines were cryopreserved in liquid nitrogen for long-
term storage. Newly selected CML CD34+ cells were suspended in 4.5% human 
albumin (ALBA®) and aliquoted in cryotubes, then an equal volume of 20% dimethyl 
sulphoxide (DMSO) in 4.5% ALBA® was added to give a final DMSO concentration of 
10%. Cell lines in exponential growth phase were collected and resuspended with 
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10% DMSO in foetal calf serum (FCS) (5-10 x 106 cells/mL), and were aliquoted into 
cryotubes. The cryotubes were then transferred into a Mr. Frosty freezing container 
and kept in a -80°C freezer overnight to achieve a -1°C per minute cooling rate then 
transferred to liquid nitrogen for long-term storage. 
 
2.1.1.6 Recovery of frozen cells 
Primary CD34+ cells were removed from liquid nitrogen and immediately thawed at 
37°C in a water bath until the ice crystals had disappeared. The cells were transferred 
to a 15mL sterile tube and recovered by slowly adding 10mL of warm DAMP solution 
( 2.3.7.2) drop-wise over a 20-minute period with a pastette. This step was performed 
at room temperature to enhance the activity of the DNase I, with gentle shaking to 
prevent clumping of the cells. After centrifugation at 120 x g for 10 minutes, the 
supernatant was carefully removed without disturbing the pellet, and then the pellet 
was loosened by flicking the tube. The pellet was washed twice more in DAMP to get 
rid of all DMSO. The CML cells were resuspended in SFM + 5GFs medium ( 2.3.7.4) 
and plated in a 25cm3 non-adherent tissue culture flask at 5 x 105 cells/mL for 
overnight recovery. Then the recovered cells were plated in SFM + PGFs medium 
( 2.3.7.5) when the experiment required.  
 
Cell lines were thawed in a 37°C water bath and recovered slowly as above but in 
RPMI++ instead of DAMP. The cells were then washed twice with RPMI++ and 
resuspended in 20mL of RPMI++. Finally cells were plated in a 75cm3 tissue culture 
flask (2 x 105 cells/mL unless otherwise stated). 
Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
78 
2.1.2 Flow Cytometry 
Flow cytometry is able to characterize individual cells with fluorochrome-labelled 
antibodies. It supplies excitation energy with lasers and detects fluorescent emissions 
with a range of filters and detectors. It can also measure the size of a cell using 
forward scatter (FSC), and the granularity of a cell using side scatter (SSC).    
2.1.2.1 Surface antibody staining 
1 x 105 primary cells were collected and washed in PBS/2% FCS (2mL FCS with 
98mL PBS; 120 x g for 10 minutes). The washed cells were resuspended in 100µL 
PBS/2% FCS with appropriate antibody solution. Then the cells were incubated in the 
dark for 15 minutes. After incubation, the cells were washed twice in PBS/2% FCS 
(120 x g for 10 minutes), and analysed by FACS immediately, or kept at 4°C until 
analysis. Appropriate isotype controls were used as negative controls.   
2.1.2.2 Intracellular antibody staining 
1 x 105 cells were washed with PBS and resuspended in 100µL of fixing reagent 
(Reagent A of Fix & Perm® kit) and incubated for 15 minutes. The fixed cells were 
then washed with PBS/1% BSA (1g BSA in 100mL PBS), and supernatant was 
completely removed. Appropriate volume of primary antibody was diluted (e.g. anti-p-
CrkL; 1:10 dilution) in the permeabilising reagent (Reagent B of Fix & Perm® kit), and 
the cell pellet was resuspended in the primary antibody dilution. The cells were then 
incubated for 45 minutes at room temperature in the dark. After incubation, cells were 
washed twice in PBS/1% BSA (120 x g for 10 minutes) to get rid of excessive primary 
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antibody. Then the cells were resuspended with 100µL appropriate secondary 
antibody (e.g. anti-rabbit IgG FITC-conjugate; 1:50 dilution in PBS/1% BSA) and 
incubated at room temperature for 30 minutes in the dark. Finally cells were washed 
twice in PBS and analysed by flow cytometry. A matched isotype control was used 
instead of primary antibody in a separate sample as a negative control.   
2.1.2.3 Viability analysis with Annexin V and Via-Probe 
Cell viability was assessed by flow cytometry with Annexin V and Via-Probe staining. 
One of the features of early apoptosis is the translocation of phosphatidylserine from 
the inner layer of plasma membrane to the outer layer, where the cell surface 
phosphatidylserine is available for binding by Annexin V before the integrity of plasma 
membrane has been lost. In addition, cells continue to bind Annexin V after loss of 
plasma membrane integrity in late apoptosis. Via-ProbeTM (7-Amino-actinomycin D; 7-
AAD) is a dye of nucleic acid. Late apoptotic cells are stained with 7-AAD as the 
integrity of plasma membrane is lost. Staining cells simultaneously with Annexin V-
FITC (green fluorescence) and 7-AAD (far red fluorescence) enables distinguishing of 
viable, early apoptotic and late apoptotic (or necrotic cells) by flow cytometry (Annexin 
V– 7AAD–, Annexin V+ 7AAD– and Annexin V+ 7AAD+, respectively) (Figure  2-1).    
 
 
 
 
 
Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
80 
 
 
 
 
 
 
 
 
Figure  2-1: Assessment of cell viability by flow cytometry with Annexin V and Via-
Probe staining.  
 
For detection of viability, cells were collected at the stated times of drug exposure and 
pelleted by centrifugation (120 x g for 10 minutes). After that, pellets were 
resuspended in 85µL Annexin V Binding Buffer (1X) with 5µL Annexin V and 10µL 
Via-ProbeTM (100µL in total per 1 x 105 cells). Cells were then incubated in the dark 
for 15 minutes at room temperature. After incubation, 400µL 1X Annexin V Binding 
Buffer was added to each sample, and analysed immediately by flow cytometry.  
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2.1.3 Western blotting 
2.1.3.1 Protein lysate preparation 
Western blotting was used to separate, detect and quantify specific proteins from cell 
lysate. NP-40 lysis buffer ( 2.3.7.6) was prepared prior to use and kept on ice. Cells 
were taken from culture and washed twice with ice-cold PBS (120 x g for 5 minutes) 
in 1.5mL eppendorf tubes. Alternatively, cells taken from culture were pelleted rapidly 
at 21,000 x g for 30 seconds at 4°C. After removal of supernatant, the NP-40 lysis 
buffer was added to the cell pellets (2 x 105 cells/50µL) and mixed up by pipetting up 
and down at least five times and incubated on ice for 15 minutes. Subsequently, the 
cell lysates were centrifuged at 21,000 x g for 10 minutes at 4°C to pellet chromatins 
and debris. Finally, the supernatants were transferred to new eppendorf tubes and 
kept at -20°C until use.  
2.1.3.2 Protein quantification 
Bicinchoninic acid (BCA) protein assay was used to quantify protein lysate 
concentrations according to the manufacturer’s instructions. This assay reduces Cu2+ 
to Cu1+ by protein in an alkaline medium and detects Cu1+ by a reagent containing 
BCA in a colorimetric way. Chelation of one Cu1+ ion with two BCA molecules forms 
purple-coloured reaction product. This product is water soluble and absorbs strongly 
at 562 nm and its absorbance almost linearly correlates with increasing 
concentrations from 20 to 2000µg/mL. 
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Bovine serum albumin (BSA) standards were prepared by serially diluting 2000µg/mL 
BSA in distilled water. The following BSA concentrations were prepared: 2000, 1500, 
1000, 750, 500, 250, 125, 50, 25 and 5µg/mL. These BSA standards were kept at -
20°C and used in multiple times. BCA working solution was prepared by mixing 
reagents A and B (50:1) thoroughly, and then 200µL of BCA working solution was 
added to each well of a 96-well plate. 10µL of each BSA standards were added to 
each well in triplicate, and 10µL of protein samples were added in duplicate. Then the 
plate was incubated at 37°C for 30 minutes and read by an ELISA plate reader for 
absorbance at 562 nm. Although the colour development continues, following 
incubation at 37°C the colour development rate is slow enough for the samples to be 
read. Finally, protein concentrations were calculated according to the BSA standards 
and equal amounts of protein lysates were loaded for Western blotting.  
2.1.3.3 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
employed to separate proteins based on their size. After protein quantification, protein 
lysates were mixed with same volumes of Laemmli 2X sample buffer (supplemented 
with 5% 2-mercaptoethanol) in a 1.5mL eppendorf tube and heated to 95°C for 10 
minutes. SDS, contained within the sample buffer, is a negatively charged anionic 
detergent. It binds to hydrophobic regions of protein and denatures protein into its 
primary structure as soluble polypeptide chains. It also applies negative charge to 
protein molecules in proportion to its mass, leading to migration of protein towards the 
positive electrode if an electric field is applied.   
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After short centrifugation, the samples were loaded into a Nupage® Novex® Bis-Tris 
4-12% gradient gel. 10µL of Novex® SharpTM Pre-stained protein standard marker 
was loaded into a lane for protein size measurement. The gel was run in 1X 
NuPAGE® MOPS SDS Running Buffer (20X Running Buffer diluted in dH2O) at 200V 
for 60 minutes with Invitrogen XCell SureLockTM Mini-Cell electrophoresis system. 
During the electrophoresis, proteins run through a polyacrylamide gel, a polymer 
meshwork of acrylamide monomers. With electric field applied, proteins with different 
sizes move at different rates. Smaller proteins run faster that larger ones, leading to 
separation of proteins according to their size.   
2.1.3.4 Transfer to PVDF membrane 
After gel electrophoresis, separated proteins on the gel were transferred to a 
Polyvinylidene fluoride (PVDF) membrane with the XCell IITM Blot Module. The PVDF 
membrane was soaked in methanol briefly for its activation, and then the membrane 
was soaked in transfer buffer for several minutes until it is completely wet. The 
sponges and filter papers were all pre-wet in transfer buffer ( 2.3.7.7) before use. Then 
the transfer sandwich was assembled as shown in Figure  2-2. Proteins were 
transferred at 30V for 60 minutes.  
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Figure  2-2. Assemble of sandwich for transfer of proteins to PVDF membrane. 
 
10% methanol was included in the transfer buffer, and it has two important functions 
during the protein transfer. Firstly, methanol can maintain dimensional stability of 
gels. Polyacrylamide gel is able to absorb water. Thus the gel size increases a lot in 
water, resulting in loss of protein resolution in transfer. The presence of methanol in 
transfer buffer can minimize gel swelling. Secondly, methanol is capable of removing 
SDS from proteins and increase protein binding to the membrane. Since SDS adds a 
large amount of negative charges to proteins, protein molecules move very fast 
through the membrane and their interactions with PVDF decrease. Thus, removal of 
SDS by methanol retains proteins in the membrane.  
Sponge 
Sponge 
Filter paper 
Filter paper 
Sponge 
Sponge 
Gel 
PVDF membrane 
+ 
─ 
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2.1.3.5 Antibody labelling 
After transfer, the PVDF membrane was stained with 0.1% Ponceau S for a minute to 
visualize protein bands and to examine transfer efficiency. Then the membrane was 
washed with distilled water several times to de-stain Ponceau S. Following that, the 
membrane was blocked in the 5% BSA/TBST blocking buffer (5g BSA in 100mL 
TBST) at room temperature for 1 hour with constant agitation. After blocking, the 
membrane was incubated with primary antibody solution diluted in the blocking buffer 
overnight at 4°C with gentle rotation. The next morning, the membrane was washed in 
the 1X TBST buffer ( 2.3.7.9) four times (10 minutes each time) to get rid of unbound 
primary antibody and reduce background. After washes, the membrane was 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibody dilution 
for 1 hour at room temperate with agitation. Then the membrane was washed in the 
1X TBST buffer four times (10 minutes each time) to remove unbound secondary 
antibody. Finally, the membrane was developed with the Immuno-StarTM WesternCTM 
Kit according to the manufacturer’s instruction. Briefly, equal amounts of 
luminol/enhancer solution and peroxide solutions were mixed just prior to use. The 
membrane was incubated with the mixture for about three minutes. HRP oxidises 
luminol in the presence of hydrogen peroxide. Then the oxidized luminol goes back to 
its initial state, and light is emitted. The enhancer increases signal intensity and 
length. At last, digital pictures of protein bands were taken by the Molecular Imager® 
ChemiDocTM XRS machine.  
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2.1.3.6 Stripping  
In order to incubate the PVDF membrane with a different primary antibody, the 
membrane was incubated in 1X Re-BlotTM Plus Strong Antibody Stripping Solution 
(diluted with distilled water) for about 15 minutes with constant shaking at room 
temperature. Then the membrane was washed briefly in TBST and re-blocked in 5% 
BSA/TBST for 1 hour before incubation with another primary antibody. The stripping 
solution removes antibodies bound in the membrane without removing proteins.  
2.1.4 Immunoprecipitation 
Immunoprecipitation is used to concentrate and separate a specific protein from a 
lysate with lots of different proteins. In the beginning, 1 x 107 cells were collected and 
washed twice with ice-cold PBS, and then the cell pellet was resuspended and lysed 
with 1mL ice-cold NP-40 lysis buffer, then incubated on ice for 30 minutes with 
occasional agitation for complete cell lysis. After incubation, the lysate was 
centrifuged at 21,000 x g for 15 minutes at 4°C to pellet insoluble materials. The 
supernatant was then transferred to a new eppendorf tube and 1µg of appropriate 
primary antibody was added followed by overnight incubation at 4°C with constant 
agitation. In this stage, the primary antibody specifically bound to a particular protein 
and indirectly to other proteins complexed with that particular protein. After that, 40µL 
of Protein A-Sepharose beads (50% slurry, pre-washed with NP-40 lysis buffer) was 
added to the lysate and incubated at 4°C for 2 hours with constant agitation. The 
primary antibody sticks to the beads during this incubation. Beads complexed with the 
antibody and proteins were then washed three times with the NP-40 lysis buffer to get 
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rid of non-specifically bound proteins (1000 x g for 2 minutes). Finally, 40µL of 
Laemmli 2X sample buffer was added to the beads, and boiled at 95°C for 10 
minutes. In this step, proteins were denatured, separated from the beads and were 
then dissolved in the sample buffer. Finally, the beads were pelleted and the 
supernatant was subject to analysis by Western blotting.  
2.1.5 Immunofluorescence microscopy 
Poly-L-lysine coated multi-spot microscope slides were prepared in advance. Briefly, 
poly-L-lysine solution was diluted 1:10 in distilled water, and multi-spot microscope 
slides were immersed in the dilution in a coplin jar for 10 minutes. After that, 
excessive poly-L-lysine dilution was removed from slides, and these slides were air-
dried and kept in a box for future use. Poly-L-lysine is adhesive and it facilitates 
suspension cells binding to glass microscope slides.  
 
CML cells were pipetted onto poly-L-lysine coated multi-spot microscope slides (2 x 
104 cells/spot) and left for 90 minutes. Then the suspension CML cells should be 
attached to microscope slides facilitated by poly-L-lysine. Subsequently, culture 
medium on the cells was removed by blotting with tissue paper without touching the 
cells. After that cells were fixed by 3.65% formaldehyde in PBS for 15 minutes at 
room temperature and then permeabilized by 0.5% Triton-X100 in PBS (5µL Triton-
X100 in 95µL PBS) for 10 minutes. Formaldehyde fixes cells by cross-linking protein 
molecules. Triton-X100 is a detergent which can dissolve cellular lipid membranes to 
allow antibody access of internal proteins.   
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After permeabilization, cells were incubated with 5% BSA/PBS (5g BSA in 100mL 
PBS) for one hour at room temperature to block non-specific binding of antibodies. 
After blocking, cells were incubated with 0.5 µg/mL primary antibodies in 5% 
BSA/PBS for one hour at room temperature. Isotype control antibodies (class 
matched with primary antibodies) were used as negative controls. Then the cells were 
washed four times (5 minutes each time) with PBS to get rid of unbound primary 
antibodies in a coplin jar, isotype controls were washed in a separate coplin jar to 
avoid any antibody cross-contamination. After washing, cells were incubated with 
fluorochrome conjugated secondary antibodies for one hour at room temperature in 
the dark. After four washes (5 minutes each time) in PBS in a coplin jar, cells were 
air-dried and mounted in VECTASHIELD® mounting medium containing 4,6-
diamidino-2-phenylindole (DAPI) and visualized by a Zeiss Imager M1 fluorescence 
microscope at 10x100 times magnification using oil immersion. Images were captured 
with multiple layers from the top to the bottom of cells and with the optimal distance 
(0.25µM) between adjacent layers. Captured images were subjected to deconvolution 
to remove non-specific fluorescence and sharpen images. Deconvolution was 
performed by the deconvolution module of the AxioVision software, the iterative 
algorithm and clip normalisation method was used.  
 
Alexa Fluor® 488 phalloidin was added (1:250 dilution) into the primary antibody 
dilution to co-stain F-actin. Phalloidin is a mushroom toxin which binds with F-actin 
specifically. Alexa Fluor® 488 cholera toxin subunit B (CTxB) conjugate was 
employed to stain lipid rafts. CTxB is commonly used as a marker for lipid rafts. 
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Briefly, cells were incubated with the CTxB conjugate (1:500 dilution) at 4°C for 30 
minutes before fixation. Then cells were washed with PBS once (5 minutes at 4°C) to 
get rid of excessive CTxB conjugate and fixed by formaldehyde. The following 
procedures are as above.  
 
Fluorescence was measured as grey values by ImageJ software. The region of 
nucleus was selected manually according to the DAPI staining in order to quantify the 
red fluorescence within the nucleus. In the red channel, mean grey values and area 
sizes of the nuclear and whole cell were then measured. Mean grey value is the sum 
of all grey values in the selected area divided by the size of the area. The percentage 
of nuclear fluorescence was calculated using the equation Fn% = 100% An (Mn − 
Mb)/Aw (Mw − Mb). In this equation, Mn, Mb, and Mw represent the nuclear, 
background, and whole cell mean grey values, respectively. An and Aw represent 
nuclear and whole cell areas, respectively. Three background areas were randomly 
selected around each cell, and the mean of these background mean grey values was 
calculated as Mb. 
2.1.6 Uptake of sLDL by cell lines and primary cells 
Synthesis of sLDL particles was performed by our collaborators in Cancer Research 
UK Formulation Unit, University of Strathclyde. CML cell line K562 (2.5 x 105 
cells/mL) and primary CML patient cells (5 x 105 cells/mL) were incubated in the 
presence or absence of sLDL particles. At the end of incubation, 5 x 104 cells were 
sampled from each condition and washed with PBS.  Mean fluorescence intensity of 
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the cells was then measured by flow cytometry in the FITC channel. For fluorescence 
microscopy, 2 x 104 cells from each condition were left on a poly-L-lysine coated 
multi-spot microscope slide for 90 minutes to allow cell attachment. Then cells were 
fixed with 3.65% formaldehyde in PBS for 15 minutes at room temperature, and air-
dried. Finally, fixed cells were mounted in VECTASHIELD® mounting medium 
containing DAPI, and examined by the fluorescence microscope.  
2.1.7 Polymerise chain reaction (PCR) 
PCR is a powerful technique to amplify a single or a few DNA copies to billions of 
copies. It contains 20-40 thermal cycles, with each cycle consisting of three steps 
including denaturation of double-stranded DNA into single strands, annealing of 
primers to the single-stranded DNA and extension of primers by the Taq polymerase. 
2.1.7.1 Primer design 
Primers were designed with NCBI/Primer-Blast. The cDNA sequences were identified 
by searches on the Pubmed website, and then the sequences were used to design 
appropriate primers. The primers were about 20 base pairs with similar melting 
temperatures between forward and reverse primers, and no internal loops or primer 
dimers.       
2.1.7.2 RNA extraction and cDNA synthesis by reverse transcription 
Total cellular RNA was extracted using the RNeasy Mini Kit according to the 
manufacturer’s instructions. The concentration and quality of extracted RNA was 
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measured with a NanoDrop ND-1000 spectrophotometer. An absorbance at 260nm 
quantified nucleic acid concentration, and RNA purity was determined by the ratio of 
260/280 (1.8 to 2.0) and 260/230 (1.8 or greater). This is because nucleic acid is 
detected at 260nm, while solvents, salts and protein are detected at 230nm and 
280nm.  
 
RNA was reverse transcribed into cDNA by the High Capacity cDNA Reverse 
Transcription Kit according to the manufacturer’s instruction. Briefly, 10µL of the 
extracted RNA was mixed with 10µL of 2X Reverse Transcription Master Mix 
( 2.3.7.10) in a PCR tube. Then the 20µL mixture was run in a PCR Thermo Cycler. 
The program was 25°C for 10 minutes, 37°C for 120 minutes and 85°C for 5 seconds. 
Synthesised cDNA was kept at 4°C for short-term storage or at -20°C for long-term 
storage.  
2.1.7.3 PCR 
PCR Mix ( 2.3.7.11) was prepared in a PCR tube with GeneAmp® RNA PCR Core Kit 
according to the manufacturer’s instruction. The PCR tube was heated to 94°C for 5 
minutes at first to denature all the double-stranded cDNA, and then the PCR Thermo 
Cycler was set up to run 35 cycles of 94°C for 30 seconds, 52°C for 1 minute and 
72°C for 1 minute. After all cycles finished, the tubes were heated to 72°C for 5 
minutes for final extension, and then held at 4°C.   
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2.1.7.4 Gel electrophoresis 
The PCR products were electrophoresed in gels in order to visualize individual DNA 
bands. Basically, a 1% agarose gel was prepared with 0.5g agarose powder in 50mL 
of 1X TBE buffer ( 2.3.7.12; 10X TBE buffer diluted in dH2O). It was melted in a 
conical flask in a microwave until the agarose powder had completely dissolved. 
When the gel cooled down to about 60°C, 1µL ethidium bromide (10mg/mL) was 
added and mixed well. Then the gel was poured into a casting tray with a comb 
inserted to create loading wells. The gel was left to set for about 30 minutes. The 
comb was removed and the gel was placed in a gel tank with 1X TBE buffer. The TBE 
buffer should cover the gel and be 2-5 mm higher). 10µL of PCR product mixed with 
2µL loading dye (6X) was loaded into each well of the gel (2µL of 100bp DNA ladder 
was loaded in a separate lane), and then the gel was run at 50V constant voltage. 
After running, the gel was viewed by a UV transilluminator (ChemiDoc) and 
photographed.   
2.1.8 ROS measurement 
Intracellular reactive oxygen species (ROS) was measured with 2'-7'-
dichlorofluorescin diacetate (DCFDA). The non-fluorescent DCFDA can be cleaved 
into green fluorescent 2',7'-dichlorofluorescein (DCF) by intracellular esterases and 
oxidation. DCFDA is commonly used to detect the generation of ROS in cells. To 
measure intracellular ROS level with drug treatments, fresh cells were washed with 
PBS and incubated with 5µM DCFDA / PBS at 37°C in the dark for 30 minutes. Cells 
were loaded with DCFDA at this stage as DCFDA was cell-permeable. After that, 
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cells were washed with PBS and plated in fresh medium, and then cells were left to 
recover in a cell culture incubator for 2 hours. Subsequently, appropriate drugs were 
added to the cell culture, and at the end of the treatment the level of fluorescent DCF 
was measured by flow cytometry in the FITC channel. Cells without drug treatment 
(either unloaded or loaded with DCFDA) were used as negative controls.        
2.2 Statistics 
The results are shown as the mean ± standard error of the mean (mean ± SEM). 
Unless otherwise stated, all statistical analyses were performed with the Microsoft 
Office Excel software using the two-sided unpaired Student’s t-test and the 
assumption of normality was checked. P-values less than 0.05 were considered 
statistically significant.  
2.3 Materials 
2.3.1 Small molecule inhibitors 
Imatinib Mesylate (IM) was provided as a white powder under a Materials Transfer 
Agreement from Novartis Pharma (Basel, Switzerland). It was dissolved in sterile 
water and stored as 100mM aliquots at 4°C. Dasatinib, BMS-214662 and BMS-
225975 were provided as white powder under Materials Transfer Agreements from 
Bristol-Myers Squibb (Princeton, USA). They were dissolved in sterile DMSO to give 
a stock concentration of 20mM, 100mM and 100mM respectively, and stored as 
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aliquots at −20°C. PP2 and sodium stibogluconate (SSG) were purchased from 
Calbiochem, Merck Biosciences (Nottingham, UK) as white powder. PP2 was 
dissolved in DMSO to give a stock concentration of 10mM and stored as aliquots at 
−20°C. SSG was dissolved in sterile water (10mg/mL) and heat to 75°C until 
completely dissolved immediately prior to use. All small molecule inhibitors were 
diluted to the appropriate concentrations prior to use. 
2.3.2 Tissue culture materials 
Chugai Pharma 
London, UK 
Recombinant human G-CSF 
Gilson  
Middleton, USA 
Yellow and Blue pipette tips 
Greiner Bio-One 
Gloucestershire, UK 
Cryo.sTM cryotubes  
Tissue culture flasks (25cm2, 75cm2 and 
175cm2) 
Tissue culture plates (6-well, 12-well, 24-
well and 96-well) 
Pipettes (5mL, 10mL and 25mL) 
Invitrogen 
Paisley, UK 
2-mercaptoethanol 
Foetal calf serum (FCS) 
L-glutamine 200mM 
IMDM medium 
Penicillin-streptomycin solution 5000u/mL 
RPMI 1640 medium 
Dulbecco’s PBS  
Nalgene Labware 
Roskilde, Denmark 
25 and 75cm3 non-adherent tissue culture 
flasks 
Cryo freezing container “Mr. Frosty” 
Vacubottles 
Startorius 
Hannover, Germany 
Minisart 0.2µM Sterile filters 
Minisart 0.45µM sterile filters 
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Scottish National Blood Transfusion 
Glasgow, UK 
20% Human Serum Albumin 
4.5% human albumin solution (ALBA®) 
Sigma-Aldrich 
Dorset, UK 
Bovine serum albumin (BSA) 
Dimethyl sulphoxide (DMSO) 
Hydrochloric acid (HCl) 
Magnesium chloride (MgCl2) 
PBS tablets 
Poly-L-lysine 
Potassium Chloride (KCl) 
Trypan Blue Solution (0.4%) 
Trisodium citrate 
Stem Cell Technologies 
British Columbia, Canada 
Bovine pancreatic deoxyribonuclease 
(DNase 1) 1mg/mL 
Bovine serum albumin/insulin/transferrin 
(BIT) serum substitute 
Flt-3 ligand 
Interleukin-3 (IL-3) 
Interleukin-6 (IL-6) 
Stem Cell Factor (SCF) 
Sterilin Ltd 
Hounslow, UK 
Pastettes 
5mL, 10mL and 25mL disposable 
pipettes 
15 and 50mL sterile plastic falcon tubes 
Weber Scientific International 
West Sussex, UK 
Hawksley Neubauer counting chamber 
 
2.3.3 Flow cytometry materials 
Becton Dickinson 
Oxford, UK 
Annexin V Binding Buffer (10X) 
FACS flow 
FACS clean 
Mouse anti-human-annexin-V-FITC  
Mouse anti-human-CD34-APC 
Mouse anti-human-CD34-PE 
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Mouse anti-human-CD38-PE 
Mouse anti-human-CD45-PE  
Mouse anti-human-CD133-APC  
Mouse IgG-APC isotype control 
Mouse IgG-FITC isotype control 
Mouse IgG-PE isotype control 
Via-ProbeTM   
Caltag Laboratories 
Silverstone, UK 
Fix and Perm® A and B 
Cell Signaling, New England Biolabs  
Hitchin, UK 
Rabbit anti-p-CrkL antibody 
 
Greiner Bio-One 
Gloucestershire, UK  
FACS tubes 
Sigma-Aldrich 
Dorest, UK 
Goat anti-rabbit IgG FITC-linked 
secondary antibody 
 
2.3.4 Fluorescence microscopy supplies 
Abcam 
Cambridge, UK 
Mouse IgG2a isotype control 
Rabbit IgG isotype control 
Carl Zeiss 
Jena, Germany 
AxioVision software 
Imager 1 fluorescence microscope 
Cell Signalling, New England Biolabs 
Hitchin, UK 
Mouse anti-Bcr-Abl (b2a2 junction 
specific) antibody 
Hendley 
Essex, UK 
Multi-spot microscope slides 
 
Invitrogen 
Paisley, UK 
Alexa Fluor® 488 cholera toxin subunit B 
conjugate 
Alexa Fluor® 488 goat anti-rabbit IgG  
Alexa Fluor® 594 goat anti-mouse IgG 
Alexa Fluor® 488 phalloidin 
Santa Cruz 
Santa Cruz, USA 
Rabbit anti-Pan-14-3-3 antibody 
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Sigma-Aldrich 
Dorest, UK 
Poly-L-lysine solution  0.1 % (w/v) in H2O 
Triton-X100 
Vector Laboratories 
Burlingame, CA, USA 
VECTASHIELD® mounting medium with 
DAPI 
 
2.3.5 Molecular biology materials 
Lonza 
Basel, Switzerland 
Nucleofector® II Device  
Amaxa® Cell Line Nucleofector® Kit V 
Applied Biosystem 
Foster City, CA, USA 
GeneAmp® RNA PCR Core Kit 
High Capacity cDNA Reverse 
Transcription Kit 
Nuclease free water 
Bio-Rad  
Hercules, CA, USA 
Combs for gel casting 
Gel casting trays 
Immuno-BlotTM PVDF membrane 
Immuno-StarTM WesternCTM Kit 
Laemmli 2X sample buffer  
Molecular Imager® ChemiDocTM XRS 
PVDF membrane 
Becton Dickinson 
Oxford, UK 
Anti-PTP1B antibody  
Anti-SHP1 antibody 
Anti-SHP2 antibody 
Cell Signalling, New England Biolabs 
Hitchin, UK 
Goat anti-mouse IgG HRP-linked 
secondary antibody 
Goat anti-rabbit IgG HRP-linked 
secondary antibody 
Mouse anti-Bcr-Abl (b2a2 junction 
specific) antibody  
Rabbit anti-c-Abl antibody  
Rabbit anti-GAPDH antibody 
Rabbit anti-p-CrkL antibody  
Rabbit anti-Ubiquitin antibody  
Chemicon International  Re-BlotTM Plus Strong Antibody Stripping 
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Temecula, CA, USA Solution 
Chemical Store, University of Glasgow 
Glasgow, UK 
Ethanol 
Methanol 
Eurofins MWG Operon 
Wolverhampton, UK 
PCR Primers 
Helena Biosciences 
Gateshead, UK 
Agarose Powder 
Invitrogen 
Paisley, UK 
Novex® SharpTM Pre-stained Protein 
Standard  
NuPage® MOPS SDS Running Buffer 
(20X) 
Nupage® Novex® Bis-Tris 4-12% gel 
NuPage® Transfer Buffer (20X) 
XCell IITM Blot Module  
XCell SureLockTM Mini-Cell 
electrophoresis system 
Labtech International  
East Sussex, UK 
NanoDrop ND-1000 spectrophotometer  
Lonza  
Basel, Switzerland 
Amaxa® Cell Line Nucleofector® Kit V 
Nucleofector® Device 
Qiagen 
West Sussex, UK 
RNeasy Mini Kit 
QIAshredder Kit 
Sigma-Aldrich 
Dorset, UK 
0.1% Ponceau S solution 
2-glycerophosphate  
Aprotinin 
Boric acid 
Dichlorofluorescin diacetate (DCFDA) 
Ethylenediaminetetraacetic acid (EDTA) 
Formaldehyde solution (36.5%) 
Leupeptin  
NP-40 
PMSF 
Protein A-Sepharose® 4B 
Sodium chloride  
Sodium fluoride 
Sodium orthovanadate 
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Sodium pyrophosphate  
Tris base 
TWEEN 20 for electrophoresis 
Thermo-Scientific 
Hertfordshire, UK 
Albumin standard  
BCATM Protein Assay Kit 
SG Wasseraufbereitung und  
Regenerierstation GmbH  
Barsbuttel, Germany 
Ultra Pure Water system (sterile water) 
Upstate (Millipore) 
Watford, UK 
Anti-Phosphotyrosine (4G10®) antibody 
Promega, 
Southampton, UK 
100bp DNA ladder  
PCR loading dye (6X)  
 
2.3.6 PCR primer sequences 
Actin Forward GTGCGTGACATTAAGGAGAA 
Actin Reverse GGAGGGGCCGGACTCGTCA 
Bcr-Abl Forward GATGCTGACCAACTCGTGTG 
Bcr-Abl Reverse AGCAGATACTCAGCGGCATT 
 
 
2.3.7 Media and solutions 
2.3.7.1 RPMI++ 
RPMI 1640 440mL 
FCS 50mL 
L-glutamine (200mM) 5mL 
Penicillin/streptomycin solution  
(10,000 UmL-1/ 10,000 gmL-1) 
5mL 
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2.3.7.2 ‘DAMP’ solution 
DNase I (2 vials at ~2500 U/vial (1mL) 2mL 
Magnesium chloride (400X, 1.0 M stock) 1.25mL 
Trisodium citrate (0.155M) 53mL 
Human Serum Albumin (20%, SNBTS) 25mL 
Dulbecco’s PBS (magnesium/calcium free) 418.75mL 
 
2.3.7.3 Serum free medium (SFM) 
BIT 25mL 
L-glutamine (200mM) 1.25mL 
Penicillin/streptomycin solution 
(10,000 UmL-1/ 10,000 gmL-1) 
1.25mL 
2-mercaptoethanol (50mM) 250µL 
Low density lipoprotein (10 mg/mL)  500µL 
IMDM 97.25mL 
Make up in a sterile bottle then filter sterilise using a Vacubottle. 
2.3.7.4 SFM supplemented with five growth factors (SFM + 5GFs) 
Serum free medium 10mL 
IL-3 (50µg/mL) 4µL 
IL-6 (50µg/mL) 4µL 
G-CSF (20µg/mL) 10µL 
Flt3L (50µg/mL) 20µL 
SCF (50µg/mL) 20µL 
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2.3.7.5 SFM supplemented with physiological growth factors (SFM + PGFs) 
Serum free medium 10mL 
SCF (0.5µg/mL) 4µL 
G-SCF (2µg/mL) 5µL 
GM-CSF (0.1µg/mL) 20µL 
IL6 (5µg/mL) 2µL 
LIF (0.1µg/mL) 5µL 
MIP-a (0.1µg/mL) 20µL 
Filter through 0.22µM filter  
 
2.3.7.6 NP-40 Protein lysis buffer 
dH2O 8.7mL 
NaCl  (5M) 300µL 
Hepes-NaOH (1M, pH 7.5) 200µL 
EDTA (100mM) 200µL 
NP-40  50µL 
PMSF (100mM) 100µL 
Sodium fluoride (500mM) 40µL 
Sodium orthovanadate (500mM) 20µL 
Sodium pyrophosphate (100mM) 100µL 
2-glycerophosphate (1M) 200µL 
Leupeptin (1mg/mL) 50µL 
Aprotinin (1mg/mL) 22µL 
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2.3.7.7 Transfer buffer 
NuPAGE® Transfer Buffer (20X) 30mL 
dH2O 510mL 
Methanol 60mL 
 
2.3.7.8 10X TBS buffer 
NaCl 876.6g 
Tris  121.1g 
dH2O 10L 
Adjust pH to 8.0 
 
2.3.7.9 1X TBST buffer 
10X TBS buffer 1L 
TWEEN 20 10mL 
dH2O 8.99L 
 
2.3.7.10 2X Reverse Transcription Master Mix (10µL) 
10X RT Buffer  2µL 
25X dNTP Mix 0.8µL 
10X RT Random Primers 2µL 
Reverse Transcriptase 1µL 
Nuclease free H2O 4.2µL 
 
Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
103 
2.3.7.11 PCR Mix (50µL)  
10X PCR Buffer  5µL 
dNTP Mix (1000µM) 10µL 
Taq polymerase 0.25µL 
Forward primer (100µM) 0.25µL 
Reverse primer (100µM) 0.25µL 
MgCl2 (25mM) 5µL 
cDNA 1µL 
Nuclease free H2O 28.25µL 
 
 
2.3.7.12 10X TBE buffer 
Boric Acid 55g 
EDTA (0.5M, pH8.0) 40mL 
Tris Base 108g 
dH2O 1L 
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3 Results 1: Treatment of CML cells with IM and LMB  
3.1 Introduction 
Despite the success of TKI in treating CML, Bcr-Abl mRNA and DNA are still 
detectable in CML patients who have achieved CCgR and even CMR (143;182). In 
addition, the primitive CML stem cell population is insensitive to TKI treatment (201), 
and may lead to disease relapse. Therefore, new strategies must be developed to 
eradicate this TKI-insensitive CML stem cell population in order to cure CML. 
 
There are three NLSs and one NES in the Abl protein, and Abl constantly shuttles 
between the cytoplasm and the nucleus (72;245), and these localisation signals are 
intact in the Abl portion of the Bcr-Abl fusion protein. However, Bcr-Abl protein is 
exclusively located in the cytoplasm of expressing fibroblasts and K562 cells (198), 
but Vigneri and Wang have reported that inhibition of phosphorylation of Bcr-Abl by 
IM could induce nuclear import of Bcr-Abl protein (198). In their study, nuclear 
entrapment of Bcr-Abl by LMB resulted in apoptosis of transfected fibroblasts and 
K562 cells induced by reactivation of Bcr-Abl tyrosine kinase activity in the nucleus 
(198). In addition, they treated K562 cells with IM and LMB for 72 hours followed by 
drug washout, and K562 cells were eliminated six days after drug removal, but not 
with IM or LMB alone treatment (198). These findings suggest that long term drug 
exposure was not required. However, they did not test this combination in human 
primary CML cells. 
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Furthermore, Aloisi et al reported that sequential treatment of CML myeloid 
progenitors with IM then LMB effectively reduced the number of Bcr-Abl+ colonies 
with limited effects on normal CD34+ cells (246). Their rational was that the initial 12-
hour IM treatment inhibited Bcr-Abl tyrosine kinase activity, and induced nuclear 
localisation of Bcr-Abl protein. The addition of LMB for another 12 hours trapped Bcr-
Abl inside the nucleus. Finally, drug washout at the end of the treatment reactivated 
Bcr-Abl tyrosine kinase in the nucleus, and induced apoptosis via the p73 pathway 
(198;246). In that report Aloisi et al demonstrated a cytostatic effect of the sequential 
IM and LMB treatment on CML myeloid progenitors by colony-forming assay. 
However, the cytotoxicity of the sequential regimen on CML cells has not been 
investigated.  
 
Thus, the aims of this chapter were to investigate the cytotoxic efficacy of 72-hour 
continuous IM and LMB combined treatment in human primary CML progenitors, and 
evaluate the cytotoxic effect of the sequential IM and LMB treatment on CML cells.  
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3.2 IC50 of LMB in K562, KCL22 and HL60 cells 
In order to assess the cytotoxicity of LMB, the 50% proliferation inhibitory 
concentrations (IC50) of LMB were investigated in Bcr-Abl+ CML cell lines K562 and 
KCL22, and in Bcr-Abl– AML cell line HL60. Cells were treated with LMB with 
concentrations from 0.625 to 40nM for 24 and 72 hours. The number of viable cells 
was counted with trypan blue (Figure  3-1), and the IC50 values are shown in Table 
 3-1.  
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KCL22 Cells
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Figure  3-1: Determination of IC50 for LMB in K562, KCL22 and HL60 cells.  
Viable cells were counted by trypan blue at 24 and 72 hours. The percentage of cells in 
each treatment compared with no drug control (NDC, 100%, the untreated at each 
corresponding time-point) were calculated and is presented as mean ± SEM (n=3). LMB 
concentrations are plotted in Log2 scale.  
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 Leptomycin B (LMB) IC50 (nM) 
Time (hours) K562 KCL22 HL60 
24 26 7 5 
72 7 3 2 
 
Table  3-1: IC50 for LMB in K562, KCL22 and HL60 cells at 24 and 72 hours.  
Estimated from mean values in the above figure.  
 
Vigneri and Wang used 10µM IM and 10nM LMB in their cell survival assays (198), as 
did Aloisi et al in their colony-forming assays (246). Since the experiments in this 
chapter were designed as follow-up of their investigations and the observed IC50 
values for LMB were also in the low nM range, 10µM IM and 10nM LMB were used in 
the subsequent experiments.   
3.3 Continuous treatment of IM and LMB in CML cells  
To investigate the cytotoxicity of IM and LMB combined treatment in human primary 
CML CD34+ progenitors, cells were treated with 10µM IM, 10nM LMB or both drugs 
continuously for 72 hours. Then drugs were washed out and cells were plated into 
fresh medium. The number of cells in each treatment was counted with trypan blue 
every 2 or 3 days. Fresh medium was added after cell counting and cell density was 
adjusted to the original seeding density if necessary. Dilution factors were calculated 
every time when fresh media was added, and the total number of counted viable cells 
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multiplied by the corresponding dilution factors. Non-CML (Lymphoma) CD34+ cells 
were used as a Bcr-Abl– control. 
 
As shown in Figure  3-2A, the 72-hour IM and LMB continuous treatment regimen did 
not eliminate CML CD34+ cells. Although it caused a one-log reduction of cell counts 
compared with input three days after drug washout, these cells then recovered and 
continue to grow. An alternative scheduling regimen of the two drugs, such as 
sequential treatment, might be effective in killing primary CML CD34+ cells. In 
addition, the LMB alone arm showed very similar effect as the combined treatment 
arm in CML CD34+ cells (Figure  3-2A), indicating the combined treatment does not 
improve cytotoxic effect with respect to LMB alone. Furthermore, LMB inhibited 
proliferation of non-CML CD34+ cells (Figure  3-2B), demonstrating the non-specific 
cytotoxicity of this compound. However, CML CD34+ cells did appear to be more 
sensitive to LMB than non-CML CD34+ cells.  
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Figure  3-2: IM and LMB 72-hour continuous treatment.  
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CML CD34+ (A) and non-CML CD34+ (B) cells were treated with 10µM IM, 10nM LMB or 
both drugs for 72 hours. Drugs were washed out with PBS at the end of 72-hour 
treatment, and cells were plated in fresh medium. The number of viable cells in each 
treatment was counted with trypan blue at Day 3, 6, 8, 11, 13 and 16. Cell counts were 
plotted in log10 scale and presented as mean ± SEM (n=3, CML samples 223, 236 and 
255. Non-CML samples 006, 007 and 011). CD34+ cells were plated at 5 X 105 cells/mL in 
2 mL cultures in SFM + 5GFs medium.  
3.4 Sequential treatment of IM and LMB in CML cell lines 
After the failure of IM and LMB continuous treatment to eliminate CML progenitors, 
the effects of IM and LMB sequential treatment were investigated in CML cells, 
initially in CML cell lines. K562 and KCL22 cells were treated with 10µM IM for 12 
hours, and then 10nM LMB was added in without change of culture medium. The 
cells were incubated with both IM and LMB for another 12 hours, after that, drugs 
were washed out with PBS and the cells were plated into fresh medium (as illustrated 
in Figure  3-3A). This sequential regimen was adopted from the report by Aloisi et al 
(246).  
 
The adjusted total cell counts in each treatment are shown in Figure  3-3B and C. It 
was shown that 10µM IM significantly inhibited proliferation of both K562 and KCL22 
cell lines (p<0.05 since Day 3 and p<0.05 since Day 6, respectively; Figure  3-3B and 
C). In addition, K562 cells, but not KCL22 cells, were eliminated by IM at the end of 
the experiments, indicating that K562 is more sensitive to IM than KCL22. Although 
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the IM+LMB treatment arm had lower cell counts than the IM alone arm, the 
difference was not statistically significant in either K562 or KCL22 cells (p>0.07 at all 
time-points). This suggested that the sequential IM and LMB treatment did not 
significantly reduce the proliferation of CML cell line cells compared to IM alone. 
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C 
 
Figure  3-3: IM and LMB scheduling treatment in K562 and KCL22 cells.  
Diagram illustrating the scheduling treatment strategy with IM and LMB in CML cells. 
Drugs were washed out at the end of 24-hour treatment, and cells were plated in fresh 
medium. The number of viable cells in each treatment was counted with trypan blue at 
Day 1, 3, 6, 8 and 10. Cell counts were plotted in log10 scale in graph B (K562 cells) 
and C (KCL22 cells), and presented as mean ± SEM (n=4). Cells were plated at 2 X 105 
cells/mL in 2 mL cultures.   
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3.5 Sequential treatment of IM and LMB in BaF3 wild type and Bcr-
Abl expressing cells 
In order to assess whether sequential IM and LMB treatment differentially affect Bcr-
Abl positive and negative cells, the sequential treatment was applied to Ba/F3 wild 
type and Ba/F3 Bcr-Abl expressing cells (Ba/F3 p210). LMB (10nM) inhibited 
proliferation of both Ba/F3 wild type and p210 cells by about one log compared to the 
untreated arm, again showing the non-specific cytotoxicity of this drug. As expected, 
10µM IM eliminated Ba/F3 p210 cells at Day 8 (Figure  3-4B), but had mild though 
significant inhibition of proliferation of Ba/F3 wild type cells compared to the untreated 
(p<0.05 at every time-point; Figure  3-4A).  
 
However, there was no statistical significant difference between IM+LMB and IM 
treatment arms in Ba/F3 p210 cells (p>0.07 at every time-point; Figure 3-3B). This 
result confirms that sequential IM and LMB treatment did not induce more cell death 
compared to IM only in the Bcr-Abl transduced cell line in a similar way to the Ph+ 
CML cell lines. 
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Figure  3-4: IM and LMB scheduling treatment in Ba/F3 cells.  
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Ba/F3 wild type (A) and Ba/F3 Bcr-Abl expressing cells (B) were treated with IM and 
LMB in the schedules shown in Figure  3-3A. The number of viable cells in each 
treatment was counted with trypan blue. Cell counts were plotted in log10 scale, and 
presented as mean ± SEM (n=4).  Cells were plated at 2 X 105 cells/mL in 2 mL cultures.  
10ng/mL IL-3 was added as a supplement to parental Ba/F3 cell culture medium. 
3.6 Sequential treatment of IM and LMB in CML primary cells 
In order to test the effect of the sequential treatment on CML progenitors, primary 
CML CD34+ cells were treated with the same scheduling regimen as in CML cell lines, 
and it was found that both IM and IM+LMB treatment arms significantly inhibited cell 
proliferation compared to the untreated arm at Day 3 (p=0.002 and p=0.014, 
respectively), Day 6 (p=0.004 and p=0.009, respectively) and Day 10 (p=0.05 and 
p=0.01, respectively). Unlike in CML cell lines, IM and IM+LMB treatment arms did 
not reduce cell counts of primary CD34+ cells to lower than input at later time-points, 
showing just a mild cytostatic effect (Figure  3-5A).  
 
On the other hand, there was no statistical significant difference between IM and 
IM+LMB treatment arms at each time-point (p>0.35 at every time-point; Figure  3-5A), 
suggesting that sequential IM and LMB treatment did not preferentially inhibit 
proliferation of primary CML CD34+ cells compared to IM alone.  
 
In addition, the percentage of viable cells in each treatment was measured by flow 
cytometry of staining cells with Annexin V and Via-Probe (Figure  3-5B). Cells 
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negative for both Annexin V and Via-Probe staining were considered viable. It 
showed that the difference between IM+LMB and LMB treatments was not statistically 
significant (p>0.32 at every time-point), although significant difference was observed 
between IM+LMB and IM treatments on Day 1 and Day 3 (p=0.028 and p=0.022, 
respectively). These data suggested that sequential IM and LMB treatment did not 
further induce apoptosis of primary CML CD34+ cells compared to LMB alone.   
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Figure  3-5: IM and LMB scheduling treatment in primary CML CD34+ cells.  
(A) Viable cell counts with trypan blue were plotted in log10 scale  (B) Percentage of 
viable cells in each treatment compared with untreated as analyzed by flow cytometry 
with Annexin V and Via-Probe (mean ± SEM, n=2, CML235 and CML255, each sample 
was plated in duplicates). Cells were plated at 5 X 105 cells/mL in 2 mL cultures in SFM 
+ 5GFs medium. (*p<0.05)  
3.7 Nuclear localisation of Bcr-Abl in IM and LMB treated CML cells 
To determine whether the Bcr-Abl protein was translocated into cell nucleus after IM 
and LMB exposure as per the hypothesis, KCL22 cells were treated with 10µM IM 
and 10nM LMB for 4 hours. Subsequently, cells were stained with a Bcr-Abl b2a2 
junction specific antibody and prepared for immunofluorescence microscopy. It was 
observed that the vast majority of the Bcr-Abl protein was located in the cytoplasm of 
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untreated KCL22 cells (Figure  3-6). However, after treatment with IM and LMB a 
significant proportion of Bcr-Abl protein was observed in the nucleus of KCL22 cells.  
 
 
 
 
Figure  3-6: Nuclear localisation of Bcr-Abl in KCL22 cells treated with IM and LMB.  
KCL22 cells were treated with 10µM IM and 10nM LMB for 4 hours and then stained 
with Bcr-Abl b2a2 junction specific antibody (Red) for examination by 
immunofluorescence microscopy. DNA was stained with DAPI (Blue).  
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3.8 Summary and Discussion 
Overall, these findings demonstrated that neither continuous nor sequential regimens 
with IM and LMB in CML cell lines or primary CD34+ cells significantly increased 
inhibition of cell proliferation more than IM alone. It was also shown that the 
sequential treatment did not significantly induce more apoptosis than LMB alone in 
primary CML CD34+ cells.  
 
Previously researchers showed that 72-hour continuous IM and LMB treatment 
regimen could preferentially induce apoptosis and eliminate K562 cells (198). 
However, it is observed in this chapter that the combination strategy does not kill 
primary CML CD34+ cells more effectively than LMB alone (247). In addition, Aloisi et 
al  showed that sequential IM and LMB treatment (as illustrated in Figure  3-3A) had 
greater reduction in the colony-forming ability of CML myeloid progenitors compared 
with IM or LMB alone, and the sequential treatment preferentially targeted CML 
myeloid progenitors compared to their healthy counterparts in terms of clonogenicity 
(246). Here in this chapter, the cytotoxic effect of the sequential IM and LMB 
treatment was investigated in CML cell lines and progenitors, and it was determined 
that the sequential regimen did not improve the cytotoxic effect of IM in Bcr-Abl+ cell 
lines and primary CML CD34+ cells, although this regimen demonstrated cytostatic 
effect by colony-forming assays in CML myeloid progenitors (246).  
 
Patel et al showed the presence of Bcr-Abl protein in the nucleus of primary CML 
CD34+ cells, but not in the nucleus of CML cell line BV173 (248), implying that CML 
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progenitors are able to tolerate nuclear Bcr-Abl tyrosine kinase to a certain extent. 
This might explain the ineffectiveness of continuous and sequential IM and LMB 
treatment in this chapter. Another explanation is the de novo synthesis of CRM1 after 
drug washout, leading to the impairment of LMB effect with subsequent transportation 
of Bcr-Abl protein back out of the cell nucleus.   
  
In the sequential regimen, cell counts of Bcr-Abl+ cells were reduced to less than 
input by exposure to IM, and IM eliminated K562 and Ba/F3 p210 cells (Figure  3-3B 
and C; Figure  3-4B), demonstrating the cytotoxic effect of IM on these cell lines. 
However, IM showed mild cytostatic effect on CML CD34+ cells in both regimens 
(Figure  3-2A and Figure  3-5A), demonstrating the persistence/resistance of these 
progenitor cells to IM. In addition, 72-hour continuous LMB treatment led to a one-log 
reduction of cell counts three days after drug washout, showing the cytotoxicity of 
LMB  in CML CD34+ cells (Figure  3-2A), while no reduction was observed in the LMB 
alone treatment arm after drug washout in the sequential treatment (Figure  3-5A). 
This may be because cells were only treated with LMB for 12 hours in the sequential 
regimen. Furthermore, since the sequential IM and LMB treatment did not enhance 
kill of primary CML bulk CD34+ cells compared with IM and LMB alone, the rare, more 
primitive CD34+CD38– stem cell subset or normal primary CD34+ cells were not 
tested with the sequential regimen.  
 
Nuclear accumulation of Bcr-Abl protein was observed in IM and LMB treated KCL22 
cells (Figure  3-6), but the majority of Bcr-Abl was still retained in the cytoplasm. This 
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is consistent with our previous observation (247). We reported increase of nuclear 
Bcr-Abl protein in K562 cells after 4-hour IM and LMB exposure as measured by 
Western blotting with nuclear extraction, but the cytoplasmic Bcr-Abl level was 
maintained as high as the untreated (247). In addition, Vigneri and Wang made 
similar observations. They demonstrated that only 25-35% Bcr-Abl was trapped in the 
nucleus of the Bcr-Abl expressing fibroblasts treated with IM and LMB (198).  
 
Copland et al reported the resistance of primary CML CD34+ cells to IM treatment, 
and showed the second generation TKI dasatinib was much more effective in 
inhibiting Bcr-Abl tyrosine kinase activity in the primitive CML population (163). This 
led to the speculation that the IM used in the continuous and sequential regimens did 
not sufficiently block Bcr-Abl tyrosine kinase, and dasatinib may be a better TKI to 
use in these regimens. However, Vigneri and Wang observed the nuclear fraction of 
Bcr-Abl was around the same level in kinase-defective Bcr-Abl expressing fibroblasts 
treated with LMB only, or NES-inactivated Bcr-Abl expressing fibroblasts treated with 
IM for 24 hours (198), eliminating the possibilities of incomplete inhibition of Bcr-Abl 
tyrosine kinase activity by IM or nuclear exportation by LMB. These observations 
indicate other mechanisms apart from Bcr-Abl tyrosine kinase activity retaining Bcr-
Abl protein in the cytoplasm of CML cells.  
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4 Results 2: Subcellular localisation of Bcr-Abl protein in 
CML progenitor cells  
4.1 Introduction 
In the previous chapter, it was observed that most of the Bcr-Abl protein was in the 
cytoplasm of KCL22 cells after IM and LMB exposure, although a fraction of Bcr-Abl 
was accumulated in the nucleus (Figure  3-6). Retention of Bcr-Abl protein in the 
cytoplasm of IM and LMB treated K562 cells (247) and Bcr-Abl expressing fibroblasts 
(198) has also been reported. The mechanism of cytoplasmic retention of Bcr-Abl in 
CML cells when Bcr-Abl tyrosine kinase activity is inhibited is still not clear. However, 
cytoplasmic Bcr-Abl is known to promote cell proliferation and survival (44;68), while 
nuclear Bcr-Abl tyrosine kinase activity induces apoptosis (198). Thus, cytoplasmic 
retention of Bcr-Abl is a possible survival mechanism in CML cells against TKI 
treatment, and impairment of Bcr-Abl cytoplasmic retention may provide a novel 
therapeutic approach to cure CML.  
 
It was hypothesised that the Bcr-Abl protein was retained in the cytoplasm of TKI 
insensitive primary CML CD34+ cells, and that this retention was caused by its 
cytoplasmic binding partners. Therefore, the aims of the study in this section were to 
examine the subcellular localisation of Bcr-Abl protein in human primary CML CD34+ 
cells with or without TKI treatment, and investigate its cytoplasmic binding partners 
which potentially retain Bcr-Abl protein in the cytoplasm.        
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4.2 Validation of the Bcr-Abl b2a2 junction specific antibody  
In order to visualize subcellular localisation of Bcr-Abl protein in CML cells, 
immunofluorescence microscopy was employed with a specific Bcr-Abl antibody. 
Since the only commercially available Bcr-Abl antibody is b2a2 junction specific and 
was released onto the market relatively recently, the specificity of this novel antibody 
was initially tested. Figure  4-1A shows the examination of the specificity of the Bcr-
Abl b2a2 junction specific antibody by Western blotting. It is known that KCL22 cells 
express Bcr-Abl protein with b2a2 junction and K562 cells with b3a2 junction. HL60 
cells are Bcr-Abl negative. It was shown that Bcr-Abl protein was detected in KCL22 
cell lysate, but not in K562 or HL60 cell lysate (Figure  4-1A), demonstrating the 
specificity of the Bcr-Abl b2a2 junction specific antibody.   
 
However, the background of the Western blot was high and the Bcr-Abl protein band 
was quite weak and not very sharp. Thus, immunoprecipitation (IP) was used to 
concentrate Bcr-Abl protein. As shown in Figure  4-1B, the b2a2 Bcr-Abl protein in 
KCL22 cell lysate was immunoprecipitated by the b2a2 junction specific Bcr-Abl 
antibody, but not by its corresponding mouse IgG2a isotype control. In addition, no 
b3a2 Bcr-Abl protein was pulled down from the K562 cell lysate. These results 
demonstrated that the Bcr-Abl antibody specifically detected Bcr-Abl protein with 
b2a2 junction. 
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Figure  4-1: Validation of the Bcr-Abl b2a2 junction specific antibody by (A) Western 
blotting and (B) immunoprecipitation.  
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(A) Western blotting with K562, KCL22 and HL60 cell lysates, and the blot was probed 
with the Bcr-Abl b2a2 junction specific antibody.  Actin was used as a loading control. 
(B) Immunoprecipitation with the Bcr-Abl b2a2 junction specific antibody in KCL22 and 
K562 lysates, as well as mouse IgG2a isotype in KCL22 lysate. The 
immunoprecipitates were analysed by Western blotting and probed with c-Abl 
antibody.         
 
Moreover, to investigate subcellular localisation of Bcr-Abl protein, CML cells need to 
be stained with the Bcr-Abl b2a2 junction specific antibody and observed with a 
fluorescence microscope. Thus, the specificity of this antibody was examined with 
fluorescence microscopy as well. KCL22, K562 and HL60 cells were stained with the 
antibody, and only KCL22 cells showed positive staining (Figure  4-2D, red 
fluorescence). KCL22 cells stained with mouse IgG2a isotype was negative (Figure 
 4-2A). This result concludes that the Bcr-Abl antibody is b2a2 junction specific, and it 
is compatible with fluorescence microscopy.   
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Figure  4-2: Validation of Bcr-Abl b2a2 specific antibody with fluorescence microscopy.  
(A) KCL22 cells stained with IgG2a isotype control. (B) HL60 cells, (C) K562 cells and 
(D) KCL22 cells stained with the Bcr-Abl b2a2 junction specific antibody (Red). Cell 
nuclei were stained with DAPI (blue).  
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4.3 Identification of CML CD34+ samples expressing b2a2 Bcr-Abl   
In order to stain primary CML CD34+ samples using this Bcr-Abl b2a2 junction specific 
antibody, CML samples expressing b2a2 Bcr-Abl protein rather than b3a2 need to be 
identified. A pair of Bcr-Abl primers were designed which spanned the junction region 
of the Bcr-Abl gene (as illustrated in Figure  4-3A). Total mRNA was extracted from 
primary CML CD34+ cells and reversed transcribed into complementary DNA (cDNA). 
Polymerase chain reaction (PCR) was performed with the Bcr-Abl primers and the 
cDNA. In theory, the PCR products are 486 base pairs (bp) with b3a2 Bcr-Abl 
templates, and 411bp with b2a2 Bcr-Abl templates. Thus, b3a2 and b2a2 CML 
samples are able to be distinguished by the size of their PCR products after 
separation by gel electrophoresis. As shown in Figure  4-3B, primary CML CD34+ 
samples 250, 273, 274 and 281 were identified as b2a2 Bcr-Abl samples. K562 and 
KCL22 cells were used as controls, as they were known as b3a2 and b2a2 Bcr-Abl 
expressing cells respectively.   
 
In addition, the specificity of the Bcr-Abl b2a2 junction specific antibody in these 
primary b2a2 CML cells was validated by immunoprecipitation. It was demonstrated 
that Bcr-Abl protein was pulled down by the antibody, as well as c-Abl protein (Figure 
 4-4). The presence of c-Abl in the pull-down lysate was probably due to the binding of 
Bcr-Abl with c-Abl in these cells. It was reported that there is a SH2 binding domain in 
the Bcr part of Bcr-Abl, and the SH2 domain of c-Abl can associate with Bcr-Abl in a 
phosphotyrosine independent manner (63).      
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A 
 
 
B 
        1 gcgaacaagg gcagcaaagc tacggagagg ctgaagaaga agctgtcgga gcaggagtca 
       61 ctgctgctgc ttatgtctcc cagcatggcc ttcagggtgc acagccgcaa cggcaagagt 
      121 tacacgttcc tgatctcctc tgactatgag cgtgcagagt ggagggagaa catccgggag 
      181 cagcagaaga agtgtttcag aagcttctcc ctgacatccg tggagctgca gatgctgacc 
      241 aactcgtgtg tgaaactcca gactgtccac agcattccgc tgaccatcaa taaggaagat 
      301 gatgagtctc cggggctcta tgggtttctg aatgtcatcg tccactcagc cactggattt 
      361 aagcagagtt caaaagccct tcagcggcca gtagcatctg actttgagcc tcagggtctg 
      421 agtgaagccg ctcgttggaa ctccaaggaa aaccttctcg ctggacccag tgaaaatgac 
      481 cccaaccttt tcgttgcact gtatgatttt gtggccagtg gagataacac tctaagcata 
      541 actaaaggtg aaaagctccg ggtcttaggc tataatcaca atggggaatg gtgtgaagcc 
      601 caaaccaaaa atggccaagg ctgggtccca agcaactaca tcacgccagt caacagtctg 
      661 gagaaacact cctggtacca tgggcctgtg tcccgcaatg ccgctgagta tctgctgagc 
      721 agcgggatca atggcagctt cttggtgcgt gagagtgaga gcagtcctgg ccagaggtcc 
      781 atctcgctga gatacgaagg gagggtgtac cattacagga tcaacactgc ttctgatggc 
      841 aagctctacg tctcctccga gagccgcttc aacaccctgg ccgagttggt tcatcatcat 
      901 tcaacggtgg ccgacgggct catcaccacg ctccattatc cagccccaaa gcgcaacaag 
      961 cccactgtct atggtgtgtc ccctaactac gacaagt 
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C 
  
Figure  4-3: Identification of primary CML CD34+ samples with b2a2 Bcr-Abl by PCR.  
(A) Diagram illustrating the annealing of the primers on b2a2 and b3a3 Bcr-Abl 
templates. (B) Partial mRNA sequence of b3a2 Bcr-Abl, showing annealing sites of 
forward (blue) and reverse (pink) primers. The sequence was obtained from NCBI 
GenBank with Accession No. AJ131466. (C) Gel electrophoresis of PCR products to 
identify b2a2 Bcr-Abl samples. Actin was used as a positive control.  
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Figure  4-4: Validation of Bcr-Abl b2a2 specific antibody by immunoprecipitation.  
The specificity of the Bcr-Abl b2a2 junction specific antibody was validated in the 
lysates of primary CML CD34+ cells expressing b2a2 Bcr-Abl protein. Mouse IgG2a 
isotype was used as a negative control. The immunoprecipitates were analysed by 
Western blotting and probed with c-Abl antibody.               
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c-Abl 
 Bcr-Abl  IgG2a  IP: 
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4.4 12-Day Dasatinib Treatment of CML CD34+ cells 
After identification, b2a2 positive CML samples 250, 273 and 281 were used to 
investigate the subcellular localisation of Bcr-Abl protein in primary CML CD34+ cells 
by immunofluorescence microscopy. Hamilton et al treated CML CD34+ cells with 
150nM dasatinib continuously for 12 days in vitro, and found about 10% of CML cells 
survived (249). This method of drug selection was adopted here in order to get TKI 
resistant/persistent cells. CML CD34+ cells were thawed and cultured in serum free 
medium with five growth factors overnight to recover. Then the cells were washed 
and replated in serum free medium with physiological growth factors, with the addition 
of 150nM dasatinib (Day 0). Cells were replated with fresh medium and dasatinib 
every two or three days for 12 days. Physiological growth factors were used to mimic 
in vivo conditions. Cells without dasatinib treatment were also cultured in similar 
conditions for 12 days as a control.  
 
At the end of treatment, the untreated cells and cells surviving dasatinib treatment 
were stained with the Bcr-Abl b2a2 junction specific antibody and the subcellular 
localisation of Bcr-Abl protein was visualized by fluorescence microscopy (Figure 
 4-5A). The percentages of nuclear Bcr-Abl protein relative to the whole cell were 
measured by ImageJ software based on the red fluorescence (Figure  4-5B). It was 
shown that the percentages of nuclear Bcr-Abl protein in the untreated and dasatinib 
treated CML cells at the end of the 12-day treatment were 41.8 ± 2.2% and 50.5 ± 
3.0% respectively (n=18, 6 cells from each CML sample, mean ± SEM), and the 
difference between them is statistically significant (p=0.024). This indicates that 
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dasatinib treatment induced a fraction of Bcr-Abl protein to translocate into the cell 
nucleus from the cytoplasm, but a large proportion (almost half) of Bcr-Abl protein 
was still located in the cytoplasm of these treated cells.  
 
A 
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NDC 
150nM  
Dasatinib 
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Figure  4-5: Subcellular localisation of Bcr-Abl protein.  
(A) Localisation of Bcr-Abl protein in the untreated cells (NDC) and 150nM dasatinib 
treated primary CML CD34+ cells at Day 12. Bcr-Abl protein was stained with the Bcr-
Abl b2a2 junction specific antibody (red) and cell nuclei were stained with DAPI (blue). 
(B) A scatter plot demonstrating the percentage of nuclear Bcr-Abl protein in NDC and 
150nM dasatinib treated primary CML CD34+ cells at Day 12. The nuclear and whole cell 
red fluorescence intensities were measured with the ImageJ software (n=18, 6 cells 
from each CML sample), and the percentages of red fluorescence in the nuclei relative 
to in the whole cells were shown in the scatter plot.  
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In the mean time, the effectiveness of dasatinib as a TKI in this experiment was 
examined by measuring p-CrkL level in these cells. p-CrkL is a downstream effector 
of Bcr-Abl, and has been used as a convenient surrogate marker to measure Bcr-Abl 
tyrosine kinase activity (161). As shown in Figure  4-6A, p-CrkL completely 
disappeared in the 150nM dasatinib treated CML CD34+ cells at Day 4 and Day 12, 
with or without physiological growth factors. This indicates that the tyrosine kinase 
activity of Bcr-Abl protein was completely inhibited by dasatinib in this experiment.  
 
 
Figure  4-6: A representative Western blot showing the inhibition of CrkL 
phosphorylation with 150nM dasatinib in primary CML CD34+ cells.  
 
Although the subcellular localisation of Bcr-Abl has been revealed in the surviving 
cells, it is not clear whether they are still CD34+ and at what stages of maturation they 
are at. In order to determine the phenotype of cells visualized in Figure  4-5A, the 
expression of the cell surface markers CD34, CD45 and CD133 were analysed by 
flow cytometry. CD45 is a common marker of leucocytes (250), CD34 is a marker of 
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haemopoietic progenitor cells and CD133 is a marker of primitive haemopoietic 
progenitor cells (251). At Day 0, all the CML cells are CD34+ and CD45+ (Figure 
 4-7A), indicating all the cells are haemopoietic progenitors at this stage. At the end of 
12-day dasatinib treatment, the percentage of CD34+ cells decreased to 7.2 ± 3.5% 
(n=3, mean ± SEM), while the vast majority of cells are still CD45+. On the other 
hand, the primitive CD133+ cells decreased from 14.1 ± 1.1% at Day 0 to 3.1 ± 0.21% 
at Day 12 of dasatinib treatment (Figure  4-7D). These data shows that the surviving 
cells from 12-day dasatinib treatment are mainly CD45+, CD34low/– and CD133low/–. In 
addition, there is no statistical significant difference between NDC and dasatinib 
treatment arms regarding percentage of CD34+ cells or CD133+ cells at Day 4 and 
Day 12 (p≥0.082, Figure  4-7D). 
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Figure  4-7:  Representative flow cytometry plots.  
CML281 cells were stained with surface-markers and analyzed at Day 0 (A), Day 4 (B) 
and Day 12 (C) of 150nM dasatinib treatment. (D) Average percentages of CD34+ cells 
and CD133+ cells with CML samples 250, 273 and 281 in different treatment conditions.  
4.5 Bcr-Abl binding partners  
Previously it was shown that 50.5 ± 3.0% of Bcr-Abl protein was in the nucleus of 
dasatinib treated cells (Figure  4-5), suggesting that about 50% of Bcr-Abl protein was 
still retained in the cytoplasm of these cells. The cytoplasmic retention of Bcr-Abl may 
be due to its cytoplasmic binding partners. If these binding partners were identified, 
disruption of their binding with Bcr-Abl may induce nuclear translocation of the rest of 
cytoplasmic Bcr-Abl protein. Thus, the co-localisation of Bcr-Abl and its binding 
partners was investigated in the Day 12 dasatinib treated primary CML CD34+ cells. 
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F-actin is a known Bcr-Abl binding partner and there is an F-actin binding domain in 
the C-terminus of Bcr-Abl protein (73). Impairment of F-actin binding has been 
reported to decrease the transforming ability of Bcr-Abl protein (73). However, the 
role of F-actin retaining Bcr-Abl in the cytoplasm of TKI-insensitive primary CML cells 
is not clear. Thus, co-localisation of Bcr-Abl and F-actin was investigated in Day 12 
dasatinib treated primary CML CD34+ cells by immunofluorescence microscopy 
(Figure  4-8). Another possible group of binding partner is the 14-3-3 family it has 
been reported that nucleocytoplasmic shuttling of c-Abl protein was regulated by 14-
3-3 proteins whereby 14-3-3 sequestered c-Abl protein in the cytoplasm by binding to 
its phosphorylated Thr735 residue (231). Upon DNA damage or oxidative stress, JNK 
is phosphorylated which in turn phosphorylates 14-3-3, resulting in the release and 
nuclear translocation of c-Abl (231). Since the Abl part of Bcr-Abl protein contains the 
14-3-3 binding site (i.e. Thr735 residue), it could be hypothesized that 14-3-3 
associate with Bcr-Abl and sequester it in the cytoplasm. Therefore, Bcr-Abl and 14-
3-3 proteins were stained and visualized by immunofluorescence microscopy (Figure 
 4-9), in order to examine if they co-localised in the Day 12 dasatinib treated primary 
CML CD34+ cells. It was observed that a small proportion of Bcr-Abl protein co-
localised with F-actin or 14-3-3 proteins in both NDC and dasatinib treated cells. 
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Figure  4-8: Co-staining of Bcr-Abl and F-Actin in 12-Day 150nM dasatinib treated 
primary CML CD34+ cells, as well as the 12-Day untreated cells (NDC).  
Bcr-Abl protein was stained with the Bcr-Abl b2a2 junction specific antibody (red), F-
Actin was stained with Alexa Fluor 488® phalloidin (green), and overlay shows the 
merge of red and green channels. Cell nuclei were stained with DAPI (blue). White 
arrows indicate some of the co-localised pixels.  
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Figure  4-9: Co-staining of Bcr-Abl and 14-3-3 in 12-Day 150nM dasatinib treated 
primary CML CD34+ cells, as well as the 12-Day untreated cells (NDC).  
Bcr-Abl protein was stained with the Bcr-Abl b2a2 junction specific antibody (red), 14-
3-3 proteins were stained with a Pan-14-3-3 antibody (green), and overlay shows the 
merge of red and green channels. Cell nuclei were stained with DAPI (blue). White 
arrows indicate some of the co-localised pixels.  
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In order to confirm the association of Bcr-Abl and 14-3-3 proteins in CML cells, and 
investigate if IM can disrupt their association, Bcr-Abl and 14-3-3 proteins were 
immunoprecipitated by Bcr-Abl b2a2 junction specific antibody and pan 14-3-3 
antibody respectively in KCL22 cells with or without 1µM IM treatment for 2 hours. It 
was observed that 14-3-3 proteins were detected in the Bcr-Abl immunoprecipitates, 
and that Bcr-Abl was also detected in the 14-3-3 immunoprecipitates as well (Figure 
 4-10). This demonstrates the binding of Bcr-Abl and 14-3-3 proteins in KCL22 cells. In 
addition, Bcr-Abl and 14-3-3 are still associated with each other in the presence of IM 
(Figure  4-10), indicating that IM treatment in KCL22 cells did not disrupt Bcr-Abl/14-3-
3 complex and their association was independent of Bcr-Abl tyrosine kinase activity.  
 
Figure  4-10: Immunoprecipitation showing Bcr-Abl/14-3-3 association in KCL22 cells.  
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KCL22 cells were treated with or without 1µM IM for 2 hours. Bcr-Abl and 14-3-3 
proteins were pulled down by the Bcr-Abl b2a2 junction specific and pan 14-3-3 
antibodies respectively. c-Abl and 14-3-3 antibodies were used on Western blotting. 
WCL: Whole Cell Lysate.  
 
It was observed that some Bcr-Abl protein was located in close proximity to the 
plasma membrane in CML cells (Figure  4-8 and Figure  4-9). Lipid rafts are 
glycolipoprotein microdomains in the cytoplasmic membrane, which serve as 
integrating centres for the assembly of signalling molecules (252). Therefore, it was 
interesting to investigate if Bcr-Abl associated with lipid rafts as they are both 
integrators of signalling molecules.  
  
Monosialotetrahexosylganglioside (GM1) is a component of the cytoplasmic 
membrane and is enriched in lipid rafts, and clustering of GM1 can be used to 
indicate the presence of lipid rafts (253). Cholera toxin subunit B (CTxB) binds 
specifically to GM1 and fluorophore-conjugated CTxB is commonly used to detect 
GM1, and therefore lipid rafts (253). A fraction of Bcr-Abl was found co-localised with 
GM1 clusters in KCL22 cells and primary CML cells (Figure  4-11, as indicated by 
white arrows). With 12-day dasatinib treatment, some GM1 aggregates are still co-
localised with Bcr-Abl (Figure  4-11B). This indicates that lipid rafts might be involved 
in the cytoplasmic retention of Bcr-Abl in CML cells.  
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Figure  4-11: Co-staining of Bcr-Abl and GM1. 
Bcr-Abl (red) and GM1 (green) were stained in KCL22 cells (A) and CML281 primary 
cells (B). Bcr-Abl protein was detected by the Bcr-Abl b2a2 junction specific antibody 
and GM1 was visualized by Alexa Fluor 488 conjugated CTxB. CML281 cells were 
sampled from the end of 12-Day 150nM dasatinib treatment experiment. White arrows 
indicate some of the co-localised pixels. 
150nM Dasatinib NDC 
Bcr-Abl Merge GM1 
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4.6 Summary and discussion 
In summary, the specificity of the Bcr-Abl b2a2 junction specific antibody was 
validated by Western blotting, immunoprecipitation and immunofluorescence 
microscopy. Then the subcellular localisation of Bcr-Abl protein in TKI 
resistant/persistent primary CML CD34+ cells was measured by immunofluorescence 
microscopy. It was shown that there was a significant increase in nuclear Bcr-Abl in 
12-Day 150nM dasatinib treated cells with respect to NDC, while about 50% of Bcr-
Abl was stilled retained in the cytoplasm of treated cells. Cell surface marker staining 
showed the surviving cells had greatly reduced CD34 and CD133 surface expression, 
implying that these cells were losing ‘stemness’. In addition, a small proportion of Bcr-
Abl protein was found co-localised with F-actin or 14-3-3 proteins in the surviving 
cells, indicating the cytoplasmic retention of Bcr-Abl might be due to its binding with 
F-actin or 14-3-3 proteins. The association of Bcr-Abl and 14-3-3 proteins was 
confirmed by immunoprecipitation in KCL22 cells, while IM treatment did not disrupt 
their association. Furthermore, the molecular signalling organizing centres, lipid rafts, 
might be involved in the cytoplasmic retention of Bcr-Abl. 
 
Bcr-Abl protein had been previously found located in the cytoplasm of Bcr-Abl 
expressing fibroblasts, K562, and BV173 cells (198;248), while nuclear Bcr-Abl was 
visualized in 12-Day cultured primary CML CD34+ cells which showed a significant 
increase in nuclear Bcr-Abl on dasatinib treatment (Figure  4-5). This is consistent with 
report by Patel et al where they showed the presence of nuclear Bcr-Abl protein in 
CML CD34+ cells, and an increase in nuclear Bcr-Abl after IM treatment (248). 
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However, it is not clear why nuclear Bcr-Abl is absent in Bcr-Abl+ cells lines and 
fibroblasts, but present in primary CML CD34+ cells. These observations 
demonstrated that primary CML CD34+ cells are able to tolerate the presence of 
nuclear Bcr-Abl protein, which could potentially induce apoptosis in these cells. 
Another consistent finding was the focal distribution of Bcr-Abl protein observed in 
KCL22 (Figure  3-6) and primary CML CD34+ cells (Figure  4-5A), which was also 
demonstrated by Patel et al (248). They argued that Bcr-Abl foci might be sites for 
signalling protein assembly, since a proportion of Bcr-Abl foci are co-localised with 
other proteins such as p-CrkL, Grb2 and Cbl (248).        
  
There is a possibility that at the end of 12-Day dasatinib treatment, point-mutation 
may occur in the kinase domain of Bcr-Abl protein, conferring resistance to dasatinib 
treatment and preventing nuclear translocation of Bcr-Abl. However, Figure  4-6A 
demonstrated complete inhibition of p-CrkL by dasatinib, indicating the Bcr-Abl 
tyrosine kinase activity was blocked. In addition, Hamilton et al showed that at the 
end of 12-Day 150nM dasatinib treatment there was no Bcr-Abl gene mutation (254), 
and they also observed maximal inhibition of p-CrkL, which is a downstream effector 
of Bcr-Abl. Thus, it is unlikely that there is TKI resistance induced by Bcr-Abl kinase 
domain mutation.  
 
It is also possible that the Day 12 surviving cells are Ph– cells, which could explain 
their insensitivity to dasatinib treatment. However, immunofluorescence microscopy 
demonstrated positive Bcr-Abl protein staining in those surviving cells (Figure  4-5A). 
Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
 
 
147 
In addition, Hamilton et al confirmed the presence of Bcr-Abl exclusively within the 
surviving cells by FISH (249;254), eliminating the possibility of presence of non-CML 
cells in the Day 12 surviving population. Furthermore, they showed the surviving cells 
from 12-Day 150nM dasatinib treatment were able to form colonies in LTC-IC 
(249;254). Since LTC-IC is the most stringent in vitro assay to assess stem cell 
function, it indicated the presence of stem cells in the survived population. However, 
cell surface staining demonstrated the survived cells are CD45+, CD34low/– and 
CD133low/– (Figure  4-7), indicating most of these cells might not be haematopoietic 
stem/progenitor cells. One possible explanation, however, is that the human HSCs 
can be CD34– (255;256). Another explanation is that only a small proportion of the 
surviving cells are stem cells which form colonies in LTC-IC.  
 
Since there was no LMB to trap Bcr-Abl in the nucleus in this experiment, Bcr-Abl 
could shuttle freely out of the nucleus via its NES. Wang et al demonstrated IM alone 
did not induce nuclear accumulation of Bcr-Abl protein in the Bcr-Abl expressing 
fibroblasts, while IM and LMB combination led to accumulation of Bcr-Abl in the 
nucleus (198). This indicates that although inhibition of tyrosine kinase targeted Bcr-
Abl into the nucleus, Bcr-Abl shuttles out of nucleus very quickly in the absence of 
LMB. In the case of 12-Day dasatinib treated CML cells, nuclear translocated Bcr-Abl 
protein is quite possible to shuttle back into the cytoplasm quickly. This shuttling 
potentially explains why only about 50% Bcr-Abl was observed in the nucleus of 
surviving CML cells as it is a single point in a dynamic system.           
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Interestingly, ectopically expressed Bcr-Abl protein with four additional NLSs was 
shown to be able to translocate into the nucleus and induced apoptosis in K562 cells, 
but not wild type Bcr-Abl or Bcr-Abl with only one additional NLS (257). This indicates 
that the NLSs of wild type Bcr-Abl may be masked to prevent its nuclear 
translocation. 14-3-3 proteins sequester proteins in the cytoplasm by blocking their 
NLSs (258). It was shown that Bcr-Abl and 14-3-3 interacted with each other in CML 
cells (Figure  4-9 and Figure  4-10). Dong et al also demonstrated 14-3-3/Bcr-Abl 
association by immunoprecipitation (259). Thus, it is quite possible that 14-3-3/Bcr-
Abl association masks NLSs of Bcr-Abl, and holds it in the cytoplasm.   
 
Hamilton et al showed that, in the surviving CML cells of 12-Day dasatinib treatment 
in the absence of growth factors, there was maximal inhibition of Bcr-Abl tyrosine 
kinase as measured by p-CrkL and no Bcr-Abl kinase domain mutation (249;254). 
This suggests that the survival of CML cells is independent of Bcr-Abl tyrosine kinase 
activity. The survival mechanisms of CML cells fall into two broad categories, Bcr-Abl 
dependent and independent mechanisms (157). It was shown that normal human 
quiescent haemopoietic progenitors could not survive in the absence of IL-3 or GM-
CSF in culture (18), while 10% of Bcr-Abl+ primary CML CD34+ cells survived 12-Day 
dasatinib treatment in the absence of any growth factor (249;254). This suggests that 
the survival of CML cells is dependent on the presence of Bcr-Abl protein, but not on 
the tyrosine kinase activity of Bcr-Abl. The mechanism by which kinase-inhibited Bcr-
Abl protein enables CML cells survive in the absence of growth factors is not clear. 
Since the Bcr-Abl protein retained in the cytoplasm of surviving cells is in focal 
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formation (Figure  4-5), it is possible that the tyrosine kinase inhibited Bcr-Abl may 
serve as a scaffolding protein which integrate other signalling molecules in the 
cytoplasm, and provide a survival mechanism for dasatinib treated CML CD34+ cells.   
If this is the case, impairment of the cytoplasmic Bcr-Abl retention will lead to 
increased accumulation of nuclear Bcr-Abl, disruption of its scaffolding role in the 
cytoplasm, and elimination of resistant/persistent CML progenitor cells. One possible 
way of doing this is to dissociate Bcr-Abl from its cytoplasmic binding partners. It has 
been shown here that 14-3-3 proteins complexed with Bcr-Abl in the cytoplasm of 
Day 12 surviving CML cells (Figure  4-9). It was reported that 14-3-3 proteins were 
linked to diverse signalling molecules (229), and they interacted with Bcr-Abl (61). 
Thus, disruption of the association between 14-3-3 and Bcr-Abl may increase nuclear 
accumulation of Bcr-Abl, and impair cytoplasmic signalling of Bcr-Abl.  
 
BV02, a newly discovered inhibitor of 14-3-3, was reported to be able to dissociate c-
Abl from 14-3-3 and induce nuclear translocation of c-Abl (260). BV02 also induced 
apoptosis in Ba/F3 cells expressing wild type Bcr-Abl or T315I mutant Bcr-Abl. It also 
demonstrated anti-proliferative effect in CD34+ CML cells sampled from CML patients 
at BC stage that developed in vivo resistance to IM (147). However, it is not clear 
whether BV02 is able to disrupt 14-3-3/Bcr-Abl complex in CML cells, or if it can 
increase nuclear accumulation of Bcr-Abl. The combination effect of TKI and BV02 in 
resistant/persistent CML progenitors is worthy of further investigation.       
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5 Results 3: p-CrkL is not a surrogate of Bcr-Abl activity in 
vitro at short time-points 
5.1 Introduction 
In previous study, CML cells were treated with IM to induce nuclear localisation of 
Bcr-Abl protein through inhibition of its tyrosine kinase (Figure  3-6). Due to the rapid 
nature of kinase inhibition and nuclear transportation, an appropriate time-point 
should be chosen after IM treatment, at which time Bcr-Abl kinase activity is inhibited 
to allow its nuclear transportation, but cells should not be apoptotic. Thus, studies are 
required to measure the earliest time-point of inhibition of Bcr-Abl tyrosine kinase by 
IM. 
 
p-CrkL has been commonly used to assess Bcr-Abl tyrosine kinase activity (160-163), 
as p-CrkL is a downstream substrate of Bcr-Abl (166) and is the major tyrosine 
phosphorylated protein in CML cells, but not in normal cells (93). In addition, the level 
of CrkL phosphorylation correlates well with the level of Bcr-Abl protein in CML cells, 
while p-CrkL is not detected in Bcr-Abl negative samples (165). Recently, p-CrkL has 
begun to be used as a surrogate marker of Bcr-Abl tyrosine kinase activity due to its 
convenience to be detected and low cell number requirement by flow cytometry 
(161;162).   
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However, the accuracy of p-CrkL as a reflection of Bcr-Abl tyrosine kinase status at 
early time-points during in vitro TKI treatment has not been examined. Although Bcr-
Abl is the prominent driving force of tyrosine phosphorylation in CML cells, p-CrkL 
level does not necessarily equate to p-Tyr Bcr-Abl level. Therefore, the aims of this 
chapter were to reveal the kinetic of Bcr-Abl kinase inhibition by measuring p-CrkL 
and p-Tyr Bcr-Abl levels after TKI treatment, and investigate if p-CrkL is an accurate 
surrogate marker of Bcr-Abl tyrosine kinase activity in Ph+ cells at early time-points of 
TKI treatment.       
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5.2 Assessment of the accuracy of p-CrkL as a surrogate marker of 
Bcr-Abl kinase activity in K562 cells after IM treatment at early 
time-points 
IM is currently the first line drug for treating CP CML patients. Its IC50 in K562 cells is 
600nM as measured by 3H-thymidine uptake proliferation assay at 72 hours (172). In 
order to investigate if p-CrkL is an accurate surrogate marker of Bcr-Abl kinase 
activity after IM treatment at early time-points (≤48 hours), K562 cells were treated 
with 1µM IM. 1µM IM is higher than the IC50 concentration in K562 cells, and it was 
chosen to assure kinase inhibition. At each time-point of IM treatment (0, 0.5, 1, 2, 4, 
8, 24, 48 hours), cells were collected and prepared for Western blotting. p-CrkL 
(Tyrosine 207), tyrosine phosphorylated Bcr-Abl (p-Tyr Bcr-Abl) and Bcr-Abl protein 
levels were measured. GAPDH was used as a loading control as described in the 
Materials and Methods.  
 
After 1µM IM treatment, p-Tyr Bcr-Abl level dropped quickly to 24.9 ± 7.7% (n=3, 
mean ± SEM) of baseline (NDC at 0 time-point) by 1 hour time-point and then 
plateaued around this level out to the 48 hours time-point. Interestingly, p-CrkL level 
dropped to 59.3 ± 13.5% at 0.5 hour time-point, but then recovered to 94.4 ± 17.3% at 
4 hours time-point (p=0.012, paired t-test), and subsequently declined to 39.0 ± 
13.4% at 48 hours time-point. This phasic response of p-CrkL was unexpected and 
different to the response of Bcr-Abl after IM treatment. This strongly demonstrates 
that p-CrkL may not mirror the response of Bcr-Abl. The difference between protein 
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levels of p-CrkL and p-Tyr Bcr-Abl was statistically significant at several time-points 
(p<0.05 at 4 hours time-point; p<0.01 at 8 hours time-point; p<0.001 at 24 hours time-
point). 
A 
 
B 
0 2 4 6 8
0
20
40
60
80
100
120
p-Tyr Bcr-Abl
p-CrkL by Western
20 24 44 48
p-CrkL by FACS
Time (Hour)
%
 
to
 
B
as
el
in
e
 
 
 
 0   0.5   1     2    4     8     24   48 
p-Tyr Bcr-Abl 
Bcr-Abl 
p-CrkL 
GAPDH 
Hours of 
Treatment 
Replicate 1 
  0   0.5   1     2    4     8   24   48 
Replicate 2 Replicate 3 
 0   0.5   1    2      4     8   24   48 
Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
 
 
154 
C 
0.5 1.0 2.0 4.0 8.0 24.0 48.0
0
20
40
60
80
100
p-CrkL by Western
p-Tyr Bcr-Abl
*
**
***
P=0.012
Time (Hour)
%
 
to
 
B
a
s
el
in
e
 
 
Figure  5-1: Levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL in 1µM IM treated K562 cells.  
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL and GAPDH 
at different time-points (0, 0.5, 1, 2, 4, 8, 24, 48 hours) after IM treatment (n=3). (B) Plots 
showing normalized densitometry values of Western blot protein bands, as well as p-
CrkL levels measured by intracellular flow cytometry. Densitometry was performed on 
each Western blot protein band to measure pixel intensity. P-Tyr Bcr-Abl, Bcr-Abl and 
p-CrkL protein band densitometry values were normalised against their corresponding 
GAPDH values. Values are shown as percentage of baseline. (C) Histograms showing 
the same percentages as in plot B with p-values indicated (* p<0.05, ** p<0.01, *** 
p<0.001). Results are shown as mean ± SEM, n=3 
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These results show that p-CrkL is not an accurate indicator of p-Tyr Bcr-Abl level in 
K562 cells after 1µM IM treatment at early time-points (≤24 hours). Since Bcr-Abl 
protein is auto-phosphorylated, p-Tyr Bcr-Abl level is a direct measurement of Bcr-Abl 
tyrosine kinase activity. Thus, p-CrkL is not an accurate surrogate marker of Bcr-Abl 
tyrosine kinase activity in this case. In addition, it was observed that the p-Tyr Bcr-Abl 
level dropped sharply within 0.5 hour of IM treatment in K562 cells (Figure  5-1B), thus 
it was interesting to investigate further how rapidly p-Tyr Bcr-Abl levels could be 
reduced and if the p-CrkL response was a surrogate marker of Bcr-Abl tyrosine 
kinase activity within minutes of IM treatment. K562 cells were treated with 1µM IM, 
and cells were sampled at very short time-points (0, 1, 5, 10, 15 minutes). Western 
blotting was employed to measure p-CrkL and p-Tyr Bcr-Abl levels (Figure  5-2A). 
GAPDH was used as a loading control.  
 
It was observed that there was a rapid reduction of p-Tyr Bcr-Abl to less than 50% of 
baseline by 10 minutes of 1µM IM treatment in K562 cells, while p-CrkL remained 
around baseline level during this period (Figure  5-2B). The difference between p-CrkL 
and p-Tyr Bcr-Abl levels are statistically significant (p<0.05 at 5 and 10 minutes; 
p<0.01 at 15 minutes) (Figure  5-2C). These results demonstrate that p-CrkL is not an 
accurate surrogate marker of Bcr-Abl tyrosine kinase activity after IM treatment at 
very short time-points in K562 cells (≤ 15 minutes).    
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Figure  5-2: p-Tyr Bcr-Abl and p-CrkL levels in 1µM IM treated K562 cells (≤ 15 minutes). 
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, p-CrkL and GAPDH at 
different time-points (0, 1, 5, 10, 15 minutes) after IM treatment (n=3). (B) Plots showing 
normalized densitometry values of Western blot protein bands. Values are shown as 
percentage of no drug control. (C) Histograms showing the same percentages as in 
plot B with P-values indicated (*p<0.05, ** p<0.01). Results are shown as mean ± SEM, 
n=3. 
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In the first study (Figure  5-1), K562 cells were centrifuged at low speed (120 x g) and 
washed with PBS to prepare cell lysates. Since time-points as short as 1 minute were 
examined in the study above, the preparation of the cells had to be amended and 
cells were centrifuged at high speed (21,000 x g) without washing in PBS (Figure 
 5-2). As the responses seen at very short time-points were quite dramatic, it was 
possible that this change in methodology could have affected the phosphorylation 
status of CrkL and Bcr-Abl. Therefore, the full time course was repeated with the high 
speed centrifugation method, and the results are shown in Figure  5-3. Similar to low 
speed methodology (Figure  5-1), p-Tyr Bcr-Abl level dropped quickly within 1 hour of 
1µM IM treatment to 14.5 ± 1.3% (n=3, mean ± SEM) and then plateaued around this 
level to 24 hours. p-CrkL level dropped to 50.6 ± 3.6% at 0.5 hour time-point, and 
recovered to 99.3 ± 11.8% at 4 hours time-point (p=0.041), finally dropping slightly at 
24 hours time-point. The differences between p-CrkL and p-Tyr Bcr-Abl levels at all 
time-points are statistically significant (p<0.01 at 0.5, 1, 2, 4, 8 and 24 hours time-
points). Taken together, the low speed (Figure  5-1) and high speed (Figure  5-3) 
methods were very similar to each other. In general, the high speed centrifugation 
method produced results with smaller error bars, so this method was used in 
subsequent Western blotting experiments.  
 
 
 
Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
 
 
159 
A 
 
B 
 
 
Figure  5-3: p-Tyr Bcr-Abl and p-CrkL levels in 1µM IM treated K562 cells up to 24 hours.  
Cells were centrifuged at 21,000 x g for 30 seconds at each time-point and then subject 
to Western blotting analysis. Results are shown as mean ± SEM (n=3). 
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Based on these observations, a three-phase model was formed to illustrate the level 
of p-CrkL after 1µM IM treatment. As shown in Figure  5-4, there is a rapid reduction of 
p-CrkL after IM treatment in the first phase as p-CrkL levels drop to about half of the 
baseline level at 0.5 hour time-point. In phase two, the p-CrkL level recovers to 
around the baseline level by 4 hours. Finally, p-CrkL level declines slowly in the third 
phase.  
 
 
 
 
 
 
 
 
 
Figure  5-4: Model of p-CrkL level after IM treatment in K562 cells.  
(1) A sharp drop of p-CrkL immediately after IM treatment. (2) Re-phosphorylation of 
CrkL from 0.5 hour to a peak at 4 hours time-point. (3) Gradual decrease of p-CrkL level 
from 4 hours time-point.    
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5.3 Investigation of the role of protein tyrosine phosphatases in 
Bcr-Abl dephosphorylation after IM treatment in K562 cells 
5.3.1 Effect of SSG and IM co-treatment on p-Tyr Bcr-Abl in K562 cells 
The initial rapid reduction of p-Tyr Bcr-Abl within minutes of TKI treatment suggests 
there may be an active dephosphorylation of Bcr-Abl protein after TKI treatment, and 
it was hypothesized the initial sharp drop of p-Tyr Bcr-Abl level after TKI treatment 
may be due to protein tyrosine phosphatase (PTP) activity. Therefore, K562 cells 
were treated with both IM and PTP inhibitor, sodium stibogluconate (SSG), which 
inhibits activity of PTPs including SHP-1, SHP-2 and PTP1B (261). SSG inhibits 99% 
of SHP-1 activity at 10µg/mL, and inhibits 99% of SHP-2 and PTP1B activities at 
100µg/mL with in vitro PTP assays (261). Thus, K562 cells were treated with 1µg/mL, 
10µg/mL or 100µg/mL SSG with 1µM IM for 1 hour, and it was observed that the 
combination of IM with 10µg/mL or 100µg/mL SSG resulted in significantly higher 
levels of p-Tyr Bcr-Abl than IM alone (p=0.007 and p=0.046, respectively), but not as 
high as the baseline level (Figure  5-5). These results suggest that SSG can partially 
inhibit the initial drop of p-Tyr Bcr-Abl level caused by IM, indicating PTPs play a role 
in Bcr-Abl dephosphorylation.  
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Figure  5-5: Combination treatment of 1µM IM and SSG in K562 cells for 1h.  
(A) A representative Western blot showing p-Tyr Bcr-Abl and GAPDH protein levels in 
these treatments including untreated, SSG alone, 1µM IM alone, IM with 1µg/mL, 
10µg/mL and 100µg/mL SSG, and (B) Histograms showing normalized densitometry 
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values of Western blot protein bands. Values are shown as percentage of no drug 
control. Results are shown as mean ± SEM (n=3). 
 
5.3.2 Expression of protein tyrosine phoshpatases in K562 cells 
Since PTPs are involved in the dephosphorylation of Bcr-Abl protein and SSG targets 
SHP1, SHP2 and PTP1B, the next aim was to specify which one(s) of the three 
possible PTPs were relevant in K562 cells. At first, expression of the three PTPs were 
examined by Western blotting with K562 cell lysate, and it was found that SHP1 was 
almost absent in K562 cells, while SHP2 and PTP1B proteins were highly expressed 
(Figure  5-6). This result is consistent with previous reports that K562 cells did not 
express SHP1 mRNA and protein (214;262). In addition, it has been reported that 
differentiated K562 cells express SHP1, while expression of both SHP2 and PTP1B is 
not changed upon differentiation of K562 cells (262).    
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Figure  5-6: Expression of PTPs in K562 cells.  
Protein expression of three PTPs, including SHP1, SHP2 and PTP1B, was assessed in 
K562 cells by Western blotting. K562 whole cell lysates were resolved by SDS-PAGE 
and incubated with anti-SHP1, anti-SHP2 or anti-PTP1B antibodies individually. GAPDH 
was used as the loading control.  
5.4 Assessment of the accuracy of p-CrkL as a surrogate marker of 
Bcr-Abl kinase activity in K562 cells after dasatinib treatment at 
early time-points 
Dasatinib is a second line TKI for treating CML. It is a dual Abl/Src inhibitor and 325 
times more potent than IM in inhibiting wild type Bcr-Abl activity (173). Thus, it is 
interesting to study if p-CrkL is a surrogate marker of Bcr-Abl tyrosine kinase activity 
after dasatinib treatment in K562 cells. Similar to the previous experiments in Chapter 
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 5.2, K562 cells were treated with 10nM dasatinib, and cells were sampled at several 
time-points (0, 0.5, 1, 2, 4, 8 hours).  
 
It was observed that, with 10nM dasatinib, the p-Tyr Bcr-Abl response was similar to 
that seen with IM, which dropped rapidly to 14.3 ± 2.0% at 1 hour and then remained 
around this level. However, unlike IM, dasatinib caused a strong reduction in p-CrkL 
to 18.8 ± 4.7% by 1 hour, although this reduction slightly recovered to 28.8 ± 6.3% at 
4 hours time-point (p=0.035, paired t-test). The difference between p-CrkL and p-Tyr 
Bcr-Abl are not statistically significant at each time-point (p≥0.070). These results 
indicate that p-CrkL accurately reflects Bcr-Abl tyrosine kinase activity after 10nM 
dasatinib treatment in K562 cells, which is quite different from IM treatment. This 
could be due to the additional inhibition of Src kinases by dasatinib. 
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Figure  5-7: Protein levels of p-Tyr Bcr-Abl, Bcr-Abl and p-CrkL in 10nM Dasatinib 
treated K562 cells up to 8 hours by Western blotting, and p-CrkL level by FACS.  
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL and GAPDH 
at different time-points (0, 0.5, 1, 2, 4, 8 hours) after IM treatment (n=3). (B) Plots 
showing normalized densitometry values of Western blot protein bands, as well as p-
CrkL levels measured by FACS (n=3). Values are shown as percentage of no drug 
control. Results are shown as mean ± SEM, n=3. 
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5.5 Effect of PP2 and IM co-treatment on p-Tyr Bcr-Abl and p-CrkL 
As shown above, the dual Abl/Src kinase inhibitor dasatinib significantly reduced p-
CrkL level in K562 cells, while p-CrkL maintained at high level with IM treatment. 
Thus, Src kinases could be involved in CrkL phosphorylation. In order to test if Src 
kinases phosphorylate CrkL, the effects of Src inhibitor PP2 on p-CrkL level with or 
without IM was assessed in K562 cells.  
5.5.1 Measurement of IC50 for the Src inhibitor PP2 in K562 cells 
PP2 is a potent inhibitor of the Src tyrosine kinase family (263), and it was reported 
that the IC50 of PP2 was 10µM in K562 cells at 72 hours (264). Since the CrkL re-
phosphorylation occurred within 24 hours, IC50 of PP2 at 24 hours in K562 cells was 
measured by viable cell count with trypan blue. It was shown that PP2 had an IC50 of 
approximately 30µM (Figure  5-8), which was used in subsequent experiments.  
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Figure  5-8: Determination of IC50 for PP2 in K562 cells at 24 hours.  
50% inhibition of K562 cell proliferation was achieved by 30µM PP2 at 24 hours. Viable 
cells were counted by trypan blue and are shown as percentage to NDC (mean ± SEM, 
n=3). 
 
5.5.2 PP2 and IM co-treatment in K562 cells 
In order to examine the effect of Src inhibition on p-CrkL, K562 cells were treated with 
30µM PP2 and 1µM IM. It was observed that (Figure  5-9) p-CrkL level was 
significantly decreased within 0.5 hour of the IM and PP2 co-treatment, and reached 
the lowest level of 7.0 ± 0.6% of baseline at 1 hour time-point. The p-CrkL level then 
recovered to 31.1 ± 5.1% by 8 hours and slightly dropped to 27.8 ± 3.2% at 24 hour 
time-point. On the other hand, p-Tyr Bcr-Abl level decreased to 24.1 ± 1.8% and 
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remained around this level. p-CrkL level was significant lower than p-Tyr Bcr-Abl level 
at 0.5 hour and 1 hour time-points (p=0.006 and p=0.0009, respectively), while there 
was no significant difference between p-CrkL and p-Tyr Bcr-Abl levels at later time-
points. The increase of p-CrkL from 1 hour to 4 hour time-point is statistically 
significant (p=0.011, paired t-test). The pattern of p-CrkL response in the IM and PP2 
co-treatment (Figure  5-9) is similar to the response in dasatinib treatment (Figure 
 5-7), as they both have an initial strong reduction, followed by a slight but significant 
recovery of p-CrkL level, and p-CrkL reached similar levels as p-Tyr Bcr-Abl at later 
time-points.    
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Figure  5-9: Co-treatment of 1µM IM and 30µM PP2 in K562 cells for up to 24 hours.  
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, p-CrkL and GAPDH at 
different time-points (0, 0.5, 1, 2, 4, 8 and 24 hours) after IM and PP2 co-treatment. (B) 
Plots showing normalized densitometry values of Western blot protein bands as 
percentage to baseline. Results are shown as mean ± SEM (n=3).  
 
 
 
 
 
Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
 
 
171 
5.6 Effects of hydroxyurea treatment on p-Tyr Bcr-Abl and p-CrkL 
It was concerning that the observation of rapid reduction of p-CrkL and p-Tyr Bcr-Abl 
after TKI treatments, as well as recovery of p-CrkL (Figure  5-1 and Figure  5-3), might 
be a technical issue. In order to ensure that this was not a technical artefact, a non-
Bcr-Abl targeting drug need to be tested with K562 cells to make sure there was no 
such observation. Hydroxyurea, an inhibitor of DNA synthesis, was used to treat CML 
patients before the era of IM (135), and it is not known to target Bcr-Abl protein. 
Therefore, K562 cells were treated with 400µM hydroxyurea, a concentration which is 
around the proliferation inhibitory IC50 as shown in Figure  5-10A. It was found that p-
CrkL and p-Tyr Bcr-Abl levels were maintained (Figure  5-10B and C). Cell counts at 
24 hours showed hydroxyurea inhibited K562 cell proliferation by about 42% (Figure 
 5-10A), indicating the hydroxyurea used in this experiment is active. This result 
eliminates the possibility of technical artefact, such as lack of access of the antibodies 
to epitope target, in the previous experiments.  
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Figure  5-10: p-Tyr Bcr-Abl and p-CrkL levels in K562 cells with 400µM hydroxyurea.  
(A) Cell counts by trypan blue dye exclusion at 24-hour 400µM hydroxyurea treatment 
in K562 cells. (B) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-
CrkL and GAPDH at different time-points (0, 0.5, 1, 2, 4, 8 hours) after hydroxyurea 
treatment (n=3). (C) Histograms showing normalized densitometry values of Western 
blot protein bands. Values are shown as percentage of baseline. All results are shown 
as mean ± SEM (n=3). 
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5.7 Summary and Discussion 
These results demonstrate that p-CrkL is not a reliable indicator of Bcr-Abl kinase 
activity within 24 hours of IM treatment and indicate that the early responses to IM 
and dasatinib differ significantly. Importantly, these data also show that in addition to 
inhibition of the Bcr-Abl kinase activity there is a rapid and active dephosphorylation 
of Bcr-Abl within 1 hour of TKI treatment, driven at least in part, by PTP activity. This 
dephosphorylation is only revealed on switching off Bcr-Abl kinase activity with TKI. 
 
The initial aim was to examine the accuracy of p-CrkL as a surrogate marker of Bcr-
Abl tyrosine kinase activity. Thus, p-CrkL and p-Tyr Bcr-Abl levels were compared 
after IM treatment in K562 cells. It was observed that p-CrkL level dropped to about 
39% of baseline level at 48 hours (Figure  5-1), which is consistent with the literature 
(162), but it was clearly shown that p-CrkL level was significantly different from p-Tyr 
Bcr-Abl level within 24 hours (Figure  5-1, Figure  5-2 and Figure  5-3). The differences 
between p-CrkL and p-Tyr Bcr-Abl levels could be due to incomplete inhibition of Bcr-
Abl by IM, i.e. a small proportion of active Bcr-Abl protein is sufficient to 
phosphorylate CrkL. Since IM only targets Bcr-Abl protein in an inactive conformation 
(146), it is possible that a low level of active Bcr-Abl tyrosine kinase exists after IM 
treatment. In addition, it was shown by Khorashad et al that when CD34+ cells from 5 
newly diagnosed CML patients were treated with high concentration IM (5µM) that p-
CrkL level decreased dramatically at 2 hour time-point to about 20% of baseline and 
was maintained around this level out to 16 hours (265). This report indicated that the 
significant difference between p-CrkL and p-Tyr Bcr-Abl levels after low concentration 
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IM (1µM) treatment may be abolished by a higher IM dose. This could be due to 
inhibition of other tyrosine kinases, which might phosphorylate CrkL, by a high dose 
of IM.  
 
In addition, the differences could result from phosphorylation of CrkL by other kinases 
other than Bcr-Abl. It was reported that CrkL may be a substrate of Src kinases (266). 
If this is the case, the dual Abl/Src inhibitor dasatinib should have a better effect on p-
CrkL inhibition compared with IM. Indeed, it was observed that there was no 
significant difference between p-CrkL and p-Tyr Bcr-Abl levels in dasatinib treated 
K562 cells (Figure  5-7), suggesting Src kinases could be involved in phosphorylating 
CrkL. In was further demonstrated that treatment of K562 cells with IM and  PP2 (an 
inhibitor of Src kinases) induced rapid reduction of p-CrkL to levels which were 
significantly lower than p-Tyr Bcr-Abl at early time-points, then CrkL phosphorylation 
recovered to approximately the same levels as p-Tyr Bcr-Abl at later time-points 
(Figure  5-9). Co-treatment of K562 cells with IM and PP2 dramatically reduced p-CrkL 
compared with IM only treatment, indicating that Src kinases play a role in 
phosphorylating CrkL. 
 
Interestingly, p-CrkL level was significantly recovered after an initial drop with IM 
treated K562 cells (Figure  5-1 and Figure  5-3), suggesting that there were other 
kinases phosphorylating CrkL after inhibition of Bcr-Abl kinase activity. At first, this 
recovery was thought to be mediated by Src kinases, as it was known that CrkL could 
be a substrate for Src kinases (266). However, there was still a recovery of CrkL 
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phosphorylation after dasatinib treatment in K562 cells (Figure  5-7), while the degree 
of recovery is smaller than with IM treatment. Similarly, the recovery of p-CrkL was 
observed in IM and PP2 co-treatment in K562 cells. These results indicate that there 
are other kinases that phosphorylate CrkL in addition to Bcr-Abl and Src.   
 
Unexpectedly, it was observed that p-Tyr Bcr-Abl is reduced to a minimum within 1 
hour of TKI treatment (Figure  5-1, Figure  5-3 and Figure  5-7), and reduced to less 
than 50% of  baseline level within just 10 minutes of IM treatment (Figure  5-2). The 
rapid reduction of p-Tyr Bcr-Abl lead to the hypothesis that Bcr-Abl was actively 
dephosphorylated by PTPs after TKI treatment. It has been reported that Bcr-Abl is a 
substrate of PTP1B, and co-expression of PTP1B and Bcr-Abl proteins in COS cells 
resulted in significantly lower level of p-Tyr Bcr-Abl compared with expression of Bcr-
Abl only (225). In addition, it was shown that inhibition of PTP1B activity, by 
expression of a dominant-negative substrate-trapping PTP1B mutant (binding to 
substrates, but without catalyzing activity), confers resistance to IM treatment in K562 
cells (224;264). Therefore, the rapid drop of p-Tyr Bcr-Abl level within 1 hour of TKI 
treatment may be caused by PTP1B activity in K562 cells, and a future direction to 
confirm this is to knock down PTP1B in CML cells by siRNA to examine if there is any 
inhibition of Bcr-Abl dephosphorylation after IM treatment. 
 
Furthermore, since all experiments in this Chapter were performed in the human CML 
cell line K562 cells, a future perspective is to confirm these findings in human primary 
CML cells, as primary cells might be different to cell line cells in this regard. Finally, 
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based on the findings in this Chapter, one could say that high p-CrkL level does not 
necessarily indicate high Bcr-Abl tyrosine kinase activity in CML cells. Thus, using p-
CrkL as a surrogate marker of Bcr-Abl activity can generate false positive results in 
some cases, and it may be mistaken to conclude that there is high Bcr-Abl activity 
when high p-CrkL level is observed. 
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6 Results 4: Does BMS-214662 induce CML cell apoptosis 
by proteasome inhibition? 
6.1 Introduction 
BMS-214662 is a FTI, which was developed as an inhibitor of Ras signalling pathway 
(206). Cytosolic Ras protein is post-translationally modified to enable its membrane 
association, which is critical for the signalling functions of Ras (206), and 
farnesylation of the C-terminal cysteine residue of Ras by farnesyltransferase is the 
key step of this process (208). Therefore, inhibition of the farnesyltransferase activity 
by FTI prevents membrane association of cytosolic Ras and its signalling function. 
BMS-214662 has been shown to induce apoptosis potently in tumour cells, but 
another highly related FTI, BMS-225975, does not (211). Since BMS-214662 and 
BMS-225975 have very similar FTI activity (211), it is thought that BMS-214662 
induces apoptosis in tumour cells by a mechanism apart from its FTI activity. 
Additionally, BMS-214662 exhibits apoptotic effect in primary CML stem and 
progenitor cells, making it a potential drug to eradicate CML (212;213), but it is not 
clear how exactly BMS-214662 activates the intrinsic apoptotic pathway in CML cells. 
 
In the previous chapter, hydroxyurea was tested in K562 cells as a control showing 
that p-CrkL and p-Tyr Bcr-Abl levels were maintained. In the mean time, BMS-214662 
was tested for the same purpose in K562 cells, and surprisingly it was found that 
BMS-214662 elevated p-Tyr Bcr-Abl and total Bcr-Abl levels (Figure  6-1). It has been 
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reported that c-Abl and Bcr-Abl protein could be ubiquitinated and degraded by the 
proteasome pathway (267;268). Thus, inhibition of proteasome activity may lead to 
the accumulation Bcr-Abl protein, and BMS-214662 may therefore act as a 
proteasome inhibitor leading to the accumulation of Bcr-Abl protein as observed in 
Figure  6-1. 
 
 
Figure  6-1: Accumulation of p-Tyr Bcr-Abl and total Bcr-Abl protein in K562 cells after 
BMS-214662 treatment.  
 
It has been reported that Bcr-Abl+ cells had much higher proteasome activity than 
their normal counterparts (269), suggesting that Bcr-Abl protein increases 
proteasome activity. In addition, it was reported that intracellular ROS is up-regulated 
by Bcr-Abl tyrosine kinase (270). Furthermore, inhibition of proteasome elevates 
intracellular ROS level in leukaemic cells. Therefore, it was hypothesised that if BMS-
214662 inhibited proteasome activity, this could result in the accumulation of Bcr-Abl 
protein and further elevation of intracellular ROS level, which CML cells can not 
tolerate leading to apoptosis. The aim of study in this section was to examine if 
Bcr-Abl 
P-CrkL 
GAPDH 
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IM 
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inhibition of proteasome activity is a novel mechanism of action of BMS-214662 which 
preferentially induces apoptosis in CML cells compared with the related FTI BMS-
225975.  
6.2 Determination of IC50 values in K562 cells 
If proteasome inhibition is the novel mechanism of action of BMS-214662 which BMS-
225975 does not have, it should induce accumulation of ubiquitinated proteins in CML 
cells in a similar pattern as a known proteasome inhibitor bortezomib, and different 
from BMS-225975. Since Bcr-Abl increases proteasome activity (269), inhibition of 
Bcr-Abl kinase by IM should decrease proteasome activity and accumulate 
ubiquitinated proteins, which could be measured by Western blotting. Before doing 
that, the cytotoxicity of these drugs needed to be examined in CML cells and suitable 
drug concentrations should be chosen. Therefore, the IC50 values of BMS-214662, 
BMS-225975, bortezomib and IM were measured in the CML cell line K562. Cells 
were treated with various concentrations of each drug for 24 and 72 hours. The 
number of viable cells in each treatment was counted with trypan blue (Figure  6-2), 
and the IC50 values are shown in Table  6-1.  
 
BMS-214662 has an IC50 value about 47 times lower than BMS-225975 in K562 cells 
at 24 hours, demonstrating a much more potent cytotoxic effect of BMS-214662 and 
confirming the existence of a non-FTI related mechanism of action of BMS-214662 
(Table  6-1). Since the levels of ubiquitinated proteins were measured within 24 hours 
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of drug treatments, 40µM BMS-214662, which is slightly higher than the IC50 at 24 
hours, was chosen to be used in the subsequent experiments to make sure the 
effects of the drug could be seen but before the degree of apoptosis was too great to 
allow analysis of the cells. As BMS-214662 and BMS-225975 have very similar FTI 
activity, 40µM BMS-225975 was tested as a negative control. If BMS-214662 
treatment arm had a significant difference from BMS-225975 arm, it should be due to 
the additional mechanism of action of BMS-214662. In addition, the established 
proteosome inhibitor bortezomib (20nM) was also used as a positive control. 
Additionally, 1µM IM was used in the following experiments to examine if inhibition of 
Bcr-Abl tyrosine kinase leads to accumulation of ubiquitinated proteins and down-
regulation of intracellular ROS.  
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Figure  6-2: IC50 for BMS-214662, BMS-225975, bortezomib and IM in K562 cells.  
Viable cells were counted by trypan blue at 24 and 72 hours. The percentage of cells in 
each treatment compared with NDC (100%) were calculated and is presented as mean ± 
SEM (n=3). Drug concentrations are plotted in Log10 scales.     
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IC50 in 
K562 
BMS-214662 
(µM) 
BMS-225975 
(µM) 
Bortezomib 
(nM) IM (µM) 
24h 14.5 680 22 2.75 
72h 0.5 3.4 9.5 0.4 
 
Table  6-1: IC50 for BMS-214662, BMS-225975, bortezomib and IM in K562 cells.  
Estimated from mean values in the above figure.  
6.3 Accumulation of ubiquitinated proteins and Bcr-Abl  
To test if BMS-214662 is a proteasome inhibitor, K562 cells were treated with 40µM 
BMS-214662, 40µM BMS-225975, 20nM bortezomib or 1µM IM. Cells were sampled 
at various time-points up to 8 hours, and subjected to Western blotting analysis. At 
first, the total ubiquitinated proteins were examined in each treatment condition 
(Figure  6-3A). It was observed that BMS-214662 and BMS-225975 accumulated 
ubiquitinated proteins in a very similar manner, but quite different from bortezomib at 
later time-points (Figure  6-3B). All three drugs began to up-regulate the level of total 
ubiquitinated proteins from 0.5 hour time-point, and all reached about 2-fold of 
baseline level at 1 hour time-point. However, bortezomib accumulated more and more 
ubiquitinated proteins with increasing time, and reached 5-fold of baseline level at 8 
hour time-point. In contrast, the level of ubiquitinated proteins was maintained around 
or under 2-fold of baseline in BMS-214662 and BMS-225975 treatment arms. There 
was no statistical significant difference between BMS-214662 and BMS-225975 
treatment arms in terms of the level of ubiquitinated proteins at any time-point 
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(p>0.55). On the other hand, bortezomib treatment arm had a significantly higher level 
of ubiquitinated proteins than BMS-214662 and BMS-225975 treatment arms at later 
time-points (p<0.05 at 4 hours time-point, p<0.01 at 8 hours time-point).  
 
There is a gradual accumulation of ubiquitinated proteins in the IM treatment arm, and 
achieved statistical significance at 4 and 8 hours time-points with respect to baseline 
(p=0.033 and p=0.046, respectively. Paired t-test). There is also a significant increase 
of ubiquitinated proteins from 0.5 hour to 4 hours time-point (p=0.026, paired t-test) 
(Figure  6-3B). This is consistent with the idea that IM reduces proteasome activity by 
inhibiting Bcr-Abl tyrosine kinase. In addition, there is no statistically significant 
change in the levels of ubiquitinated proteins in NDC arm compared to baseline 
(p>0.12, paired t-test), suggesting that the untreated cells did not alter their 
ubiquitinated-protein levels within the 8 hour of cell culture.    
 
Furthermore, Bcr-Abl protein was accumulated in both BMS-214662 and BMS-
225975 treatment arms (Figure  6-3C and D), and there was no statistical significant 
difference between these treatment arms at any time-points (p>0.20). Since both 
BMS-214662 and BMS-225975 consistently accumulated total ubiquitinated proteins 
and Bcr-Abl protein in K562 cells, it is likely that the protein accumulation is due to 
their common, presumed FTI activity. In the bortezomib treatment arm, Bcr-Abl 
protein was accumulated in the early time-points, but returned to baseline level at 
later time-points (Figure  6-3D). 
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Figure  6-3: Ubiquitination and Bcr-Abl protein levels after BMS-214662, BMS-225975 or 
Bortezomib treatment in K562 cells.  
(A) Western blots showing total ubiquitin levels at each time-point of drug treatments. 
GAPDH was used as a loading control. (B) Normalized total ubiquitin levels against 
GAPDH, and plotted as percentage to baseline (NDC at 0 hour time-point). (C) Western 
blots showing Bcr-Abl protein levels. (D) Normalized Bcr-Abl levels against GAPDH, 
Bcr-Abl 
GAPDH 
40µM BMS-214662 40µM BMS-225975 20nM Bortezomib 
Hours of 
Treatment    0    0.5    1      2      4      8        0    0.5    1      2     4      8     0     0.5     1      2      4     8      
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and plotted as percentage to baseline. Graphs were plotted as mean ± SEM, n=3. Ub 
stands for ubiquitin.    
6.4 Measurement of ROS in K562 cells 
According to the hypothesis, BMS-214662 induced apoptosis of CML cells by 
elevating intracellular ROS level. In order to test if BMS-214662 increases 
intracellular ROS level, DCFDA was employed, and was loaded into K562 cells prior 
to drug treatments. In the presence of ROS, DCFDA is cleaved into DCF, which is a 
green fluorescent dye and can be detected by flow cytometry in the FITC channel. 
Thus, the level of DCF fluorescence indicates the level of intracellular ROS. It was 
shown in Figure  6-4 that the BMS-214662 treatment arm had significantly higher DCF 
levels with respect to BMS-225975 at 1 hour and 4 hours time-points (p=0.0037 and 
p=0.00025, respectively). Bortezomib arm had baseline level DCF from 0.5 hour to 4 
hour time-points, and had an increase to more than 2-fold of baseline at 8 hour time-
point. On the other hand, the DCF level in the IM treatment arm was always around 
the baseline level at any time-point. In addition, hydrogen peroxide (H2O2) was used 
as a positive control to mimic oxidative stress, and it was observed that the H2O2 
treatment arm had dramatic increase of DCF fluorescence from the earliest time-point 
(Figure  6-4).  
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Figure  6-4: Intracellular ROS level in K562 cells after drug treatments.  
K562 cells were pre-loaded with DCFDA, and then treated with each drug individually. 
Cells were sampled at each time-point and analyzed by flow cytometry to measure DCF 
fluorescence level with the FITC channel.  DCF fluorescence was shown as percentage 
to the NDC at each time-point. Results are shown as mean ± SEM, n=3 (**p<0.01, *** 
p<0.001). 
 
 
 
Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
 
 
190 
6.5  Determination of IC50 values in serum-starved K562 cells 
As shown above, BMS-214662 induced significantly higher level of intracellular ROS 
than BMS-225975 in proliferating K562 cells. It then raised the question if this was the 
case in quiescent K562 cells. In order to synchronise cell cycle and arrest cell 
division, K562 cells were starved in serum free medium for 16 hours. Cell counting 
showed that these serum-starved K562 cells did not proliferate. As shown in Figure 
 6-5, the serum-starved K562 cells were re-plated and cultured for another 24 hours in 
serum free medium, and the cell density did not increase compared with input 
(p=0.23, paired t-test). In contrast, the density of proliferating K562 cells increased 
about 3-fold when they were cultured in serum-containing medium for 24 hours, and it 
is significantly different from the density of serum-starved K562 cells (p=0.0012) This 
demonstrated that the 16-hour serum-starvation had made K562 cells exit the cell 
cycle and stop proliferating.    
 
Subsequently, IC50 values of BMS-214662, BMS-225975, bortezomib and IM were 
measured in the non-proliferating K562 cells, since they may have different IC50 
values from proliferating K562 cells.  As shown in Table  6-2, the IC50 of BMS-214662 
at 24 hours is more than 13 times less than BMS-225975, demonstrating the 
preferential apoptotic effect of BMS-214662 in non-proliferating CML cells. In addition, 
BMS-214662, BMS-225975 and bortezomib had similar IC50 values between 
proliferating and non-proliferating K562 cells at 24-hour treatment (Table  6-1 and 
Table  6-2). Thus, the same concentrations of these drugs as used with proliferating 
K562 cells were used in the subsequent experiment with serum-starved non-
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proliferating K562 cells. The IC50 of IM in non-proliferating K562 cells at 24 hours is 
about five times higher than in proliferating K562 cells (Table  6-1 and Table  6-2), 
demonstrating the resistance of quiescent CML cells to TKI treatment.   
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Figure  6-5: Serum-starved K562 cells stopped proliferation.  
Proliferating K562 cells were starved in serum free medium for 16 hours to induce cell 
cycle arrest, and then the cells were re-plated at 2 x 105 cells/mL in serum-free medium 
for another 24 hours. As a control, proliferating K562 cells were plated at 2 x 105 
cells/mL in serum-containing medium for 24 hours.  
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Figure  6-6: Determination of IC50 for BMS-214662, BMS-225975, Bortezomib and IM in 
serum-starved K562 cells by trypan blue viable cell counts at 24 hours.  
K562 cells were starved in serum free medium for 16 hours, and then the cells were re-
plated and treated with each drug for another 24 hours. The percentage of cells in each 
treatment compared with NDC were calculated and is presented as mean ± SEM (n=3). 
Drug concentrations are plotted in Log10 scales.  
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IC50 in serum-
starved K562 
BMS-214662 
(µM) 
BMS-225975 
(µM) 
Bortezomib 
(nM) IM (µM) 
24h 37.5 500 25 13 
 
Table  6-2: IC50 for BMS-214662, BMS-225975, Bortezomib and IM in starved K562 cells.  
Estimated from mean values in the above figure.  
6.6 Measurement of ROS in serum-starved K562 cells 
Intracellular ROS levels were measured in non-proliferating K562 cells to investigate 
if BMS-214662 preferentially induced generation of intracellular ROS compared with 
BMS-225975. It was observed that both BMS-214662 and BMS-225975 treatment 
arms had elevated DCF levels, while BMS-214662 treatment arm generally had 
higher DCF level than the BMS-225975 arm at each time-point that achieved 
statistical significance at 8 hours and 24 hours time-points (p=0.0012 and p=0.031, 
respectively). In contrast, bortezomib did not significantly increase DCF level over 
baseline (p>0.16, paired t-test) (Figure  6-7).  
 
The DCF level in IM arm is significantly decreased at 24 hours time-point with respect 
to baseline and 8 hours time-point (p=0.013 and p=0.031, respectively. Paired t-test) 
(Figure  6-7). H2O2 was used as a positive control, and it was observed that the H2O2 
treatment arm had gradual increase of DCF fluorescence and reached about 2-fold of 
baseline at 24 hours time-point (Figure  6-7).  
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Figure  6-7: Intracellular ROS level in serum-starved K562 cells with drug treatments.  
Proliferating K562 cells were cultured in serum free medium for 16 hours, then loaded 
with DCFDA and treated with each drug in serum free medium. DCF fluorescence was 
measured by flow cytometry, and shown as percentage to the NDC at each time-point. 
Results are shown as mean ± SEM, n=3 (*p<0.05, ** p<0.01). 
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6.7 Summary and Discussion  
In summary, these results demonstrated that BMS-214662 is not a proteasome 
inhibitor like bortezomib. Although BMS-214662 treatment induced accumulation of 
total ubiquitinated proteins and specifically Bcr-Abl protein in K562 cells, another FTI 
BMS-225975 had very similar effects. This indicates that accumulation of total 
ubiquitinated proteins and Bcr-Abl protein is not the novel mechanism of action of 
BMS-214662 which preferentially induces apoptosis in CML cells. It is likely that the 
observed protein accumulation results from the common mechanism of BMS-214662 
and BMS-225975, which is their FTI activity. On the other hand, BMS-214662 
induced significantly higher levels of intracellular ROS in both proliferating and non-
proliferating K562 cells than BMS-225975, demonstrating the involvement of 
significant ROS production in the novel mechanism of action of BMS-214662.  
 
It was shown that the IC50 values of BMS-214662 are much lower than BMS-225975 
in both proliferating and non-proliferating K562 cells (Table  6-1 and Table  6-2), which 
is consistent with previous reports that BMS-214662 has a much more potent 
cytotoxic effect against tumour cells compared with BMS-225975. Manne et al 
demonstrated BMS-214662 preferentially induced apoptosis in tumour cells in vitro 
other than BMS-225975 (211). In addition, BMS-214662 caused dramatic tumour 
regression in vivo, while BMS-225975 only had a mild inhibition of tumour growth 
(211). Copland et al showed that BMS-214662 significantly reduced the number of 
quiescent CML CD34+ cells, and increased the percentage of caspase-3 positive 
CML CD34+ cells, but the effects of BMS-225975 was not different from NDC (212). 
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Since BMS-214662 and BMS-225975 have very similar FTI activity, these reports and 
observations consolidate the notion that BMS-214662 has a novel mechanism of 
action against tumour cells, including CML cells.   
 
Pellicano et al showed that BMS-214662 increased intracellular ROS level compared 
with NDC in CML CD34+ cells, but the effect of BMS-225975 on ROS was not studied 
in their report (213). In this chapter, the induction of ROS by both BMS-214662 and 
BMS-225975 was studied, and was found that both drugs up-regulated intracellular 
ROS levels in proliferating and non-proliferating K562 cells, but the level of ROS 
induced by BMS-214662 was significantly higher than by BMS-225975. This indicates 
that the FTI activity of BMS-225975 is able to increase intracellular ROS to a certain 
level, and that the much greater increase of ROS induced by BMS-214662 was due in 
part to its FTI activity but also by its novel non-FTI related activity.      
 
Bcr-Abl can increase proteasome activity (269). Consistent with this, it was observed 
that inhibition of Bcr-Abl tyrosine kinase by IM accumulated ubiquitinated proteins in 
proliferating K562 cells (Figure  6-3A and B), indicating IM decreased proteasome 
activity by Bcr-Abl inhibition. In addition, Bcr-Abl can up-regulate intracellular ROS 
level (270), so inhibition of Bcr-Abl tyrosine kinase is supposed to down-regulate ROS 
level. However, 1µM IM did not significantly decrease ROS level with 8-hour 
treatment in proliferating K562 cells (Figure  6-4). This may be because the length of 
treatment or drug concentration is not sufficient. On the other hand, the intracellular 
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ROS level significantly decreased with 24-hour 10µM IM treatment in non-proliferating 
K562 cells (Figure  6-7),  
  
Previous reports have shown that BMS-214662 was able to activate JNK signalling 
pathway (211), and up-regulate PKCβ level (213), whereas BMS-225975 could not 
activate these signalling pathways. In addition, co-treatment of CML progenitor and 
stem cells with BMS-214662 and PKCβ inhibitor greatly reduced apoptosis compared 
to BMS-214662 single treatment (213). In this chapter, it was illustrated that BMS-
214662 induced significantly higher level of intracellular ROS compared with BMS-
225975 in both proliferating and non-proliferating CML cells. However, further studies 
are required to link these findings together in order to uncover the novel mechanism 
of action of BMS-214662 against CML cells, which will facilitate novel drug 
development to eliminate CML disease.  
 
One possible model to link these observations is that BMS-214662 treatment 
generated sufficient amount of intracellular ROS to activate JNK (Figure  6-4 and 
Figure  6-7). It is known that JNK is activated upon exposure to oxidative stress and 
DNA damage, and then activated JNK phosphorylates 14-3-3 and results in the 
release of c-Abl (and possibly Bcr-Abl as well in CML cells) from 14-3-3, hence 
nuclear translocation of c-Abl and induction of apoptosis by Abl tyrosine kinase 
(231;234). In addition, 14-3-3/PKC association inhibits PKC enzymatic activity, 
including PKCβ (271), and expression of functionally inactivated 14-3-3 in mice is 
accompanied with elevated expression of PKCβ2 (272). Additionally, phosphorylating 
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of 14-3-3 by activated JNK disrupts 14-3-3/ligands association (229). Thus, 
phosphorylating of 14-3-3 by JNK in response to oxidative stress may lead to 14-3-
3/PKCβ dissociation, recovery of PKCβ activity and enhanced expression of PKCβ, 
which could explain the observations made by Pellicano et al (213). Thus, the future 
perspective is to examine the subcellular localization of c-Abl and Bcr-Abl proteins in 
BMS-214662 treated CML cells, as well as 14-3-3/PKCβ interaction.  
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7 Results 5: Targeted drug delivery by sLDL particles 
7.1 Introduction 
With the failure of efforts so far to eliminate CML stem cells, a new approach was 
developed based upon one possible explanation of TKI insensitivity, which is that 
there may be insufficient intracellular drug concentration in insensitive CML stem 
cells. The expression level and kinase activity of Bcr-Abl is greatly elevated in 
primitive CML CD34+CD38– cells compared to mature MNC (163). In addition, the 
clinically achievable steady state peak plasma concentration of IM is about 4.6µM at 
the standard 400mg once daily dosing (149), and it was demonstrated that this 
concentration of IM did not significantly reduce CrkL phosphorylation in CML 
CD34+38– cells in vitro (163). Therefore, insufficient inhibition of Bcr-Abl tyrosine 
kinase activity in the primitive CML CD34+38– cells could be an explanation of IM 
insensitivity, and an increased intracellular IM concentration may overcome this drug 
resistance, and kill CML stem cells.  
 
However, simple escalation of IM oral dose may not be the best choice, as the 
therapeutic window could be lost and side effects become intolerable with high levels 
of IM. On the other hand, a CML stem cell targeted drug delivery approach may 
overcome this resistant mechanism with limited toxicity. Natural LDL particles are 
preferentially uptaken by leukaemic cells (237). sLDL particles are functionally 
equivalent to LDL and do not have issues associated with natural LDL (240;241). 
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Therefore, sLDL particles are suitable for targeted drug delivery in CML stem cells.      
The ultimate aim of this study was to determine if the drug loaded sLDL particles may 
overcome insufficient intracellular drug levels in CML stem cells. The first step of this 
investigation, however, was to examine the ability of CML stem cells to uptake 
unloaded sLDL particles in vitro. 
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7.2 Uptake of sLDL by CML cells 
Competent sLDL particles were prepared with a green fluorescence tracer dye 
dioctadecyloxacarbocyanine (DiO), and synthetic apoprotein B receptor peptide which 
is recognized by LDLR inducing active cellular uptake. Control particles lacking the 
Apo-B receptor peptide were also prepared (peptide free sLDL). Since the tracer dye 
DiO emits green fluorescence, the level of sLDL uptake by CML cells could be 
measured by flow cytometry in the FITC channel.  
 
In order to study if CML cells were able to uptake sLDL particles and determine an 
optimal sLDL concentration and incubation time for the subsequent experiments, 
K562 cells were treated with sLDL for various lengths of time and sLDL 
concentrations. It was demonstrated that sLDL treated K562 cells (equivalent to 5µg 
cholesterol/mL culture medium) accumulated sLDL particles with increased 
incubation time, and there was a one-log elevation of FITC mean fluorescence 
intensity (MFI)  at 24 hours of treatment compared to the untreated cells (Figure 
 7-1A). In addition, an increased uptake of sLDL by K562 cells with increasing sLDL 
concentrations at 24 hours of treatment was also observed (Figure  7-1B). Taken 
together, these data demonstrated firstly the uptake of sLDL particles by K562 cells, 
and that this uptake was in a time and concentration dependent manner. Treatment 
for 24 hours with 5µg cholesterol/mL was chosen for the subsequent experiments.  
 
In addition, uptake of sLDL particles by CML CD34+38low/− cells was also examined. 
Similarly to K562 cells, sLDL treated (equivalent to 5µg cholesterol/mL) CML 
Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
 
 
202 
CD34+38low/− cells had approximately one-log increase in FITC MFI compared to the 
untreated cells, demonstrating the uptake of sLDL particles by these cells (Figure 7-
2). Cells treated with peptide free sLDL also had a slightly increased FITC MFI, but 
not as high as the competent sLDL treated cells, indicating a low level of passive 
sLDL uptake.     
 
A 
%
 
M
ax
 
Ce
ll 
N
u
m
be
rs
sLDL-FITC
Untreated
2h
6h
24h
 
Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
 
 
203 
B 
%
 
M
ax
 
Ce
ll 
N
u
m
be
rs
sLDL-FITC
Untreated
0.5µg sLDL
5µg sLDL
50µg sLDL
     
Figure  7-1: Uptake of sLDL particles by K562 cells.  
(A) K562 cells were treated with sLDL (5µg cholesterol/mL), and analyzed by flow 
cytometry at 2, 4 and 24 hours of treatment. (B) K562 cells were treated with 0.5, 5 and 
50µg cholesterol/mL, and measured by flow cytometry at 24 hours of treatment. 
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Figure  7-2: Uptake of sLDL particles by CML CD34+38low/− cells.  
CD34+38low/− cells were incubated with sLDL or peptide free sLDL (equivalent to 5µg 
cholesterol/mL) for 24 hours, and then analyzed by flow cytometry.  
7.3 Internalization of sLDL by CML cells 
It was demonstrated by flow cytometry that sLDL particles were taken up by CML 
cells. However, a fluorescent signal by flow cytometry does not necessarily mean 
sLDL particles had been internalized by these cells, since cell surface associated 
fluorescent dye would be detected by flow cytometry as well. Therefore, 
deconvolution microscopy was employed to confirm the internalisation of the sLDL 
particles in CML cells. K562 and CML CD34+38low/− cells were treated with sLDL 
particles (equivalent to 5µg cholesterol/mL) for 24 hours, and Z-Stack images were 
taken with multiple slices and then deconvolved to remove non-specific fluorescence. 
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As shown in Figure  7-3, intracellular sLDL particles were visualized in the cytoplasm 
of K562 and CML CD34+38low/− cells. The internalised sLDL particles appeared to be 
associated with cellular organelles such as the endosomes (indicated by white arrows 
in Figure  7-3). When the cells were treated with apoprotein B peptide-free sLDL 
particles, very weak green fluorescence was observed in the cytoplasm by 
fluorescence microscopy, again indicating a low level of passive sLDL uptake. Green 
fluorescence was not detected in the untreated cells. This result confirmed that the 
majority of fluorescence signals detected by flow cytometry were intracellular. 
Furthermore, the internalisation of the sLDL particles was confirmed by transmission 
electron microscopy (Figure  7-4; pictures were taken by Ms Abraham in the Glasgow 
Caledonian University). 
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B 
 
Figure  7-3: Fluorescence microscopy of sLDL.   
K562 (A) and CML CD34+38low/− (B) cells were treated with sLDL to confirm the 
internalization of sLDL particles. Z-stacks were captured then subjected to 
deconvolution to remove non-specific fluorescence. FITC channel shows sLDL 
particles (Green), DAPI channel shows cell nucleus (Blue), differential interference 
contrast (DIC) channel is to show the phase contrast images of cells.   
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Figure  7-4: Electron microscopy of CML CD34+ cells after treatment with sLDL.                     
CML CD34+ progenitors were treated with sLDL particles for 24 hours, and then fixed 
for transmission electron microscopy to confirm the internalisation of sLDL particles. 
White arrows indicate engulfed sLDL particles within intracellular vesicles/endosomes. 
Cells were fixed with 2.5% glutaraldehyde and sent to Glasgow Caledonian University 
for electron microscopy. 
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7.4 Summary and Discussion 
In this study, the cell targeting potential of sLDL particles was assessed. These 
results demonstrate uptake and internalization of sLDL particles by CML cell line 
K562 and for the first time by CML stem cells.  
 
Tumour cells were considered to require more cholesterol for increased cell 
proliferation compared to their normal counterparts. It was reported that cancer 
patients had significantly decreased serum cholesterol levels than matched normal 
controls, except breast cancer in women. (273-275). Reports demonstrated elevated 
uptake of LDL in cancer cells than normal cells (237;239;276). We recently showed 
that tumour prostate cells uptake significantly more sLDL particles than normal cells 
in vitro (277). These observations support the notion that tumour cells require more 
cholesterol than normal cells. In addition, we also demonstrated that Ph+ myeloid cell 
lines and CD34+ cells uptake significantly more sLDL particles compared to Ph– 
myeloid cell lines and CD34+ cells respectively (277). Thus, sLDL particles can be 
preferentially uptaken by tumour cells and Ph+ cells, achieving some level of targeted 
drug delivery when sLDL particles are loaded with specific drug(s). 
 
It might be argued that CML quiescent stem cells do not uptake sLDL particles due to 
their quiescence, but our observations demonstrated that these cells do uptake sLDL 
particles. Primary CML CD34+38low/− cells were shown to take up and internalize sLDL 
particles in Figure  7-2 and Figure  7-3B. In addition, we demonstrated the primary 
CML CD34+38low/− cells took up sLDL particles at about the same level as bulk CML 
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CD34+ cells, which was significantly higher than non-CML CD34+ cells (277). 
Furthermore, we also showed CML quiescent stem cells, which were identified by 
maintenance of maximal CESE fluorescence, also were able to uptake sLDL particles 
(277). These results showed that sLDL particles could be used as a drug delivery 
vehicle targeting CML CD34+38low/− cells.     
 
However, studies revealed that the second generation TKI, dasatinib, was able to 
inhibit Bcr-Abl tyrosine kinase activities in CML cells, but did not eliminate CML stem 
cells (157;163). This indicates that there are other mechanisms keeping primitive 
CML stem cells alive against dasatinib treatment, such as autophagy (186). It was 
shown that combination of TKI with the autophagy inhibitor chloroquine significantly 
reduced the number of colonies formed by CML stem cells (186). Therefore, sLDL 
particles would be used to delivery other drugs together with TKI in order to 
completely eliminate CML stem cells.  
 
Another potential advantage of using sLDL particle as a drug delivery vehicle is 
reduction of side effects in vivo. TKI cause many side effects in patients and these 
side effects can lead to intolerance and patient drop-out from TKI treatment (149). In 
addition, IM was reported to be cardiotoxic and caused heart failure, and this 
cardiotoxicity was induced by c-Abl inhibition in cardiocytes (278). Nilotinib and 
dasatinib also exhibited some degree of cardiotoxicity (279). By employment of sLDL 
as a targeted drug delivery vehicle, these side effects might be reduced. It was 
reported that LDL-DOX (Doxorubicin) complex exhibited no toxicity to the heart in 
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nude mice bearing HepG2 cells, whereas DOX only treatment caused cardiotoxicity in 
the mice while LDL-DOX and DOX had similar anti-proliferative effects on tumour 
cells (280). 
 
The following step of this study is to incorporate TKI and /or other drugs into the sLDL 
particles and examine if there is any improvement in inducing apoptosis in leukaemic 
quiescent stem cells. Hydrophobic drugs can be incorporated into the hydrophobic 
core of LDL, while hydrophilic drugs can be chemically modified into hydrophobic pro-
drugs and then incorporated (244). LDL has been shown to be successfully coupled 
with several drugs (280-282), indicating the feasibility of coupling sLDL with TKI 
and/or other drugs. Furthermore, using sLDL as a targeted drug delivery vehicle could 
potentially benefit treatment of other cancers of stem cell origin besides CML.       
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8 Final discussion and future perspectives 
Overall, these studies provide further insight into how CML cells may be fully 
eradicated. Although TKIs revolutionized the treatment of CML in the last decade and 
successfully eliminate differentiated CML cells, primitive quiescent CML stem cells 
still survive even with maximal inhibition of Bcr-Abl tyrosine kinase activity. In this 
thesis, we studied alternative strategies to eliminate these TKI-insensitive CML stem 
cells by addressing the aims specific in the Introduction (Chapter  1.7). Firstly, the 
efficacy of nuclear entrapment of Bcr-Abl to induce apoptosis in CML cells was 
investigated, and it was found that neither continuous nor sequential IM and LMB 
treatment significantly increased the cytotoxic or cytostatic effect of IM in Bcr-Abl+ cell 
lines and primary CML CD34+ cells. Then the subcellular localisation of Bcr-Abl 
protein was visualized in TKI-insensitive CML progenitors which survived long-term 
dasatinib treatment, and it was observed that there was a significant increase in 
nuclear Bcr-Abl level in these survived cells compared to the NDC and about 50% of 
Bcr-Abl protein was still retained in the cytoplasm of these survived cells. It was also 
found that a proportion of Bcr-Abl protein was associated with 14-3-3 proteins in the 
cytoplasm of these surviving cells, indicating the cytoplasmic retention of Bcr-Abl 
might be due to its binding with 14-3-3 proteins. In addition, the accuracy of p-CrkL as 
a surrogate marker of Bcr-Abl tyrosine kinase activity was studied at short time points, 
and found that p-CrkL was not a reliable indicator of Bcr-Abl kinase activity within 24 
hours of IM treatment in vitro. It was also observed that there was a rapid and active 
dephosphorylation of Bcr-Abl within 1 hour of TKI treatment, driven at least in part by 
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protein tyrosine phosphatase activity. Furthermore, the mechanism of action of the 
BMS-214662 in inducing apoptosis of CML cells was investigated, and it was 
demonstrated that the non-FTI mechanism of BMS-214662 was not proteasome 
inhibition but involved generation of a significant amount of intracellular ROS. Finally, 
the efficacy of sLDL as a drug delivery vehicle to target primitive CML stem cells was 
assessed, and it was observed that unloaded sLDL particles were preferentially taken 
up and internalized by CML cell line K562 and for the first time by CML stem cells, 
demonstrating the targeting potential of sLDL particles in CML when they are loaded 
with drugs. Additionally, novel strategies besides TKI treatment have been developed 
in recent years to target primitive CML stem cells. Examples of these strategies are 
shown in Table  8-1. 
Strategy Drugs Reference 
Activation of PP2A FTY720 (283) 
Activation of quiescent CML stem cells G-CSF or IFN-α (284;285) 
Allosteric inhibitor of Bcr-Abl GNF-2 (286) 
Degradation of PML  AraC and As2O3 (287) 
Inhibition of Alox5 pathway Zileuton (288) 
Inhibition of anti-apoptotic Bcl2 family member – 
Mcl1 Omacetaxine  (289;290) 
Inhibition of autophagy Hydroxychloroquine (186) 
Inhibition of JAK2 kinase TG101209 (222) 
Inhibition of self-renewal Cyclopamine (291) 
Targeting of IL-1 receptor accessory protein 
(IL1RAP) 
Anti-IL1RAP 
antibody (292) 
Table  8-1: Novel therapies of CML. 
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Neviani et al demonstrated that FTY-720 significantly reduced the number of human 
quiescent CML stem cells in vitro and murine Bcr-Abl+ LT-HSCs in vivo compared to 
their normal counterparts (283). FTY-720 is an inhibitor of SET, and inhibition of SET 
restores serine/threonine phosphatase PP2A in CML cells. Activated PP2A then 
activates tyrosine phosphatase SHP1 which is capable of dephosphorylating Bcr-Abl 
and JAK2 (217;218). Since both Bcr-Abl and JAK2 are substrates of another tyrosine 
phosphatase PTP1B (225;293) and it was shown in Chapter 5 that PTP1B could be 
involved in rapid dephosphorylation of Bcr-Abl after TKI treatment in K562 cells, 
activation of PTP1B in primitive CML stem cells may dephosphorylate both Bcr-Abl 
and JAK2 kinases and leads to apoptosis, which is worthy of further investigation.  
 
In addition, Neviani et al also demonstrated that although the expression level of Bcr-
Abl protein was much higher in quiescent CML CD34+ cells than proliferating CML 
CD34+ cell, the activity of Bcr-Abl (as measured by p-Abl level) is much lower in the 
former population than the latter, suggesting Bcr-Abl may serve a scaffolding role for 
other proteins that maintain survival of quiescent CML stem cells (283). Furthermore, 
Copland et al also demonstrated higher expression level of Bcr-Abl protein in primitive 
CML CD34+CD38– cells than total CML CD34+ cells (163). However, Copland et al 
observed higher p-CrkL and total phosphorylated tyrosine levels in the former 
population than the latter (163). This may be explained by the findings in Chapter 5, 
which is that p-CrkL level does not accurately correlate with Bcr-Abl activity in CML 
cells.  
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Hamilton et al observed that 10% of primary Bcr-Abl+ CD34+ cells survived long-term 
dasatinib treatment in the absence of any growth factor (249;254), while normal 
haemopoietic progenitors were not able to survive in the absence of IL-3 or GM-CSF 
(18). These observations indicate that it is the presence of Bcr-Abl protein that 
sustains survival of TKI-insensitive CML cells, but not its tyrosine kinase activity. This 
further demonstrates that Bcr-Abl may serve as a scaffold in TKI-insensitive CML 
cells. A possible example of the scaffolding role of Bcr-Abl was shown by Agarwal et 
al that Bcr-Abl aberrantly induced localisation of p27 in the cytoplasm in a kinase-
independent manner (294). p27 normally resides in the nucleus and serves as an 
inhibitor of cyclin dependent kinase, while in the cytoplasm it promotes oncogenesis 
(294). Thus, cytoplasmic retention of p27 enables Bcr-Abl to promote cell cycle 
progression.  
 
Neviani et al also showed that kinase-deficient Bcr-Abl enhanced JAK2 expression 
and kinase activity (283). On the other hand, knockdown of Bcr-Abl in primitive CML 
stem cells significantly reduced JAK2 activity (283). This demonstrates that Bcr-Abl 
elevates JAK2 activity in a kinase-independent manner. This might be due to 
mislocalisation of JAK2 which is caused by a non-kinase activity of Bcr-Abl protein. 
Activated JAK2 upregulates the level of SET and then inhibits PP2A activity, 
preventing the dephosphorylation of JAK2 (216-218). In addition, JAK2 plays a pivotal 
role in Bcr-Abl mediated cell signalling (222;223). For example, it activates STAT5 
and upregulates anti-apoptotic protein Bcl-xL (114;117). Furthermore, Neviani et al 
observed that inhibition of JAK2 significantly reduced β-catenin expression and its 
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transcriptional activity (283), suggesting the role of JAK2 in Wnt/β-catenin pathway, 
which functions to promote self-renewal of CML stem cells (295). Overall, these 
observations may explain the inability of TKIs in eliminating primitive CML stem cells, 
as kinase-inhibited Bcr-Abl is still able to promote cell cycle progression, inhibit 
apoptosis, and induce self-renewal in these stem cells. 
 
Since the presence of Bcr-Abl protein, but not its tyrosine kinase activity, is a relevant 
therapeutic target in primitive CML stem cells, one strategy is to induce nuclear 
translocation of Bcr-Abl in these cells in order to kill them. It can be speculated that 
the pro-survival scaffolding role of Bcr-Abl in the cytoplasm is impaired by inducing 
nuclear translocation of Bcr-Abl protein in primitive CML stem cells, and then nuclear 
Bcr-Abl plays a pro-apoptotic role in these cells. It was shown in Chapter 4 that Bcr-
Abl associated with 14-3-3 proteins in primary CML progenitors, as well as in TKI-
insensitive CML progenitors. It was also shown that about 50% Bcr-Abl protein still 
retained in the cytoplasm of CML progenitors after long-term TKI treatment. In 
addition, other investigators demonstrated 14-3-3/Bcr-Abl association as well. For 
example, 14-3-3 ζ binds with both Bcr and Abl parts of Bcr-Abl (231). Since a 14-3-3 
dimer can interact with two molecules at the same time (230) and 14-3-3 ζ is highly 
dimerized (296), it is possible that a 14-3-3 ζ homodimer can interact with two sites of 
Bcr-Abl protein simultaneously, with one site at Bcr and another at Abl part of Bcr-Abl. 
Thus, it is thought that interaction with 14-3-3 is a mechanism of cytoplasmic retention 
of Bcr-Abl.  
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R18 is a specific competitive antagonist of 14-3-3 proteins without selectivity for 
isoforms, which is capable of disrupting 14-3-3/ligand interaction in a phosphorylation 
independent manner (259;297;298). However, presence of R18 was not able to 
accumulate Bcr-Abl into the nucleus (299). Dong et al also demonstrated that R18 
was insufficient to disrupt 14-3-3/Bcr-Abl association in Bcr-Abl expressing BaF/3 
cells, while R18 induced apoptosis in Bcr-Abl expressing BaF/3 and K562 cells by 
disrupting 14-3-3 association with forkhead box O3a (FOXO3a) protein (259). 
Recently a small molecule competitive antagonist of 14-3-3 proteins, BV02, was 
identified to be able to disrupt 14-3-3/c-Abl association and induce nuclear 
translocation of c-Abl (147). BV02 induced apoptosis in Bcr-Abl+ cell lines and CML 
progenitors (147). However, further study is required to investigate whether BV02 is 
able to dissociate 14-3-3/Bcr-Abl complex and induce nuclear translocation of Bcr-
Abl.  
 
Another strategy is to induce quiescent CML stem cells to cycle, which, once cycling, 
can then be targeted by TKIs. It was observed that intermittent G-CSF treatment 
activated quiescent CML cells and enhanced the kill of CML progenitors by IM in vitro 
(284). However, this strategy was not effective in a pilot clinical trial with IM treated 
CML patients who had achieved CCgR (300). In addition, mathematical modelling 
predicts that addition of G-CSF may not improve the therapeutic effect of IM in CML 
patients (301). Furthermore, IFN-α is capable of promoting murine quiescent HSCs 
into cell cycle and sensitized them to the anti-proliferative drug, 5-FU in vivo (302). 
Some CML patients who switched from IFN-α to IM treatment achieved higher rate of 
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stable CMR compared to those who were not previously treated with IFN-α (303). 
This suggests that priming quiescent CML stem cells with IFN-α may activate these 
cells and sensitize them to IM treatment (285). However, the effectiveness of this 
strategy with human quiescent CML stem cells requires further investigation.  
 
Overall, despite the success of TKIs in killing the majority of CML cells, primitive 
quiescent CML stem cells are still insensitive to TKI treatment, causing disease 
relapse and minimal residual disease. In recent years, studies have been carried out 
to investigate why primitive CML stem cells resist or persist to TKIs, and possible 
approaches have been searched to eliminate them. Since most CML cells are 
dependent on Bcr-Abl tyrosine kinase to survive, TKIs are able to get rid of leukaemic 
burden. Together with drug(s) targeting primitive CML stem cells, the possibility of 
eliminating all CML cells is greatly increased. Therefore, combination of TKIs with 
these approaches, which specifically target leukaemic stem cells, is likely to eradicate 
CP CML ultimately.  
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9 Appendix 
Characteristics of CML samples used: 
Patient 
number 
CML 
stage 
WCC at 
leucapheresis 
(x 106/mL) 
Pre-
selection 
% CD34+ 
Post 
selection 
% CD34+ 
Method of 
CD34 
selection 
% Ph+ 
in 
CD34+ 
(FISH) 
223 Chronic 344 1.01 96.06 CliniMacs 96 
235 Chronic 500 3.2 90 CliniMacs 99.2 
236 Chronic 323 1.44 98.22 CliniMacs 98 
250 Chronic 374 2.8 97.28 CliniMacs 100 
255 Chronic 326 22.2 98.4 CliniMacs 100 
273 Chronic 400 6.4 96 CliniMacs 98 
274 Chronic 200 0.2 100 CliniMacs 98.6 
280 Chronic 230 6.3 99.7 CliniMacs 87.5 
281 Chronic 357.9 26.2 100 CliniMacs 94 
284 Chronic 250 11.2 99.6 CliniMacs 100 
 
 
Characteristics of non-CML samples used: 
Sample 
number Disease 
WCC at 
leucapheresis  
(x 106/mL) 
Pre-
selection 
% CD34+ 
Post 
selection 
% CD34+ 
Method of 
CD34 
selection 
% Ph+ 
in 
CD34+ 
(FISH) 
006 T-Cell Lymphoma 150 7.31 99.19 CliniMacs 0 
007 Follicular NHL 189 2.73 99.04 CliniMacs 0 
011 Myeloma 194 3.52 99.7 CliniMacs 0 
 
 
WCC, white cell count 
NHL, non-Hodgkin's Lymphoma 
FISH, fluorescence in situ hybridization 
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